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Chapter I 
 
 
 
INTRODUCTION 
 
 
 
The M5 muscarinic acetylcholine receptor 
 
 
The cholinergic system and the neurotransmitter acetylcholine 
 The M5 muscarinic acetylcholine receptor (M5) is a component of the cholinergic 
nervous system. The cholinergic system is a collection of neurons that employ the 
neurotransmitter acetylcholine (ACh) to convey signals within both the central nervous 
system (CNS) and the peripheral nervous system (PNS). Within the PNS, the cholinergic 
system encompasses the preganglionic neurons of the sympathetic nervous system, the 
pre- and post-ganglionic neurons of the parasympathetic nervous system, and the somatic 
nervous system
1–3
. Within the CNS, cholinergic neurons are concentrated in cell groups 
located in the basal forebrain, midbrain, and hindbrain where they control and regulate a 
number of essential functions including cognition, sleep/wake cycles, reward-seeking 
behavior, motor control, and thermoregulation
1–3
. 
 The neurotransmitter ACh is a polyatomic organic cation derived from dietary 
choline. ACh is biosynthesized when choline is taken into a neuron by the high-affinity 
choline transporter (ChT) whereupon the enzyme choline acetyltransferase (ChAT) 
catalyzes the transfer of an acetyl group from acetyl-CoA to choline (Figure 1.1)
1,2
. The 
neurotransmitter is then concentrated in synaptic vesicles by the vesicular acetylcholine 
transporter (VAChT) where it awaits a release into the cholinergic synapse 
1,2
. Once in 
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the synapse ACh is free to bind to ACh receptors, and this activity is attenuated by the 
hydrolase acetylcholinesterase (AChE) which rapidly degrades ACh by hydrolyzing it to 
choline and acetic acid. Following hydrolysis, choline may be reabsorbed by the ChT to 
begin the synthetic cycle anew
1,2
. 
 
 
Figure 1.1. Illustration of acetylcholine biosynthesis at the cholinergic synapse. Choline is taken up by the 
neuron via the high-affinity choline transporter (ChT) where it is acetylated by choline acetyltransferase 
(ChAT) utilizing acetate from acetyl coenzyme A (Acetyl CoA) to form acetylcholine (ACh). ACh is 
concentrated in synaptic vesicles by the vesicular acetylcholine transporter (VAChT) until it is released into 
the synapse where it may be degraded by acetylcholinesterase (AChE). 
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 ACh acts as the endogenous agonist to two classes of ACh receptors. One class, 
the nicotinic acetylcholine receptors (nAChRs), are pentameric, ligand-gated ion 
channels found in neuromuscular junctions, the CNS, and the autonomic ganglia where 
they mediate the ionotropic signaling of ACh
1,3
. The other class, and the subject of this 
dissertation, is the muscarinic acetylcholine receptors (mAChRs). In contrast to the 
nAChRs, the mAChRs are G protein-coupled receptors (GPCRs) consisting of five 
subtypes termed M1 through M5. The mAChR subtypes are found throughout the CNS 
and periphery where they mediate the metabotropic functions of ACh
1,3
. 
 
 
History and discovery of the muscarinic acetylcholine receptors 
 It has only been in recent decades that the scientific community has gained an 
understanding of the detailed structure and pharmacology of the cholinergic system; 
however, the cholinergic system has been studied with chemical probes since the early 
days of pharmacology. One of the first examples of this was in 1869, when the 
pharmacologist Oswald Schmiedeberg first described muscarine, a small molecule 
alkaloid isolated from the fly agaric mushroom (Amanita muscaria; Figure 1.2)
4,5
. In 
experiments exposing muscarine to frog hearts he noted the compound displayed a potent 
depressor effect similar to those effects observed upon electrical stimulation of the vagus 
nerve; furthermore, just as with the effects of the vagus nerve, Schmiedeberg found that 
the effects of muscarine could be blocked with atropine
4,5
. In addition to the depressor 
effect, Schmiedeberg and others observed that muscarine generally produced effects 
mimicking those seen as a result of stimulating cranial and sacral involuntary nerves (e.g. 
– pupil constriction, lacrimation, increased salivation, and urinary and fecal 
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incontinence)
4,5
. In an effort to elucidate the structure of muscarine, Schmiedeberg 
synthesized the nitrite ester of choline and, based on his observations that it exhibited 
many of the same effects as natural muscarine, reported it to be true synthetic 
muscarine
5,6
. 
 
Figure 1.2. A) A photograph of the fly agaric mushroom (Amanita muscaria) in its natural state7. B) The 
structure of the natural alkaloid muscarine, originally isolated from the extract of the fly agaric. 
 
 
 
Sir Henry Dale contradicted this assertion during his study of choline esters in 
1914
8. He observed that Schmiedeberg’s synthetic muscarine not only displayed effects 
associated with muscarine, but also exhibited effects previously attributed to the plant 
alkaloid nicotine
8
. Furthermore, the muscarinic or nicotinic effects could be selectively 
blocked using atropine or tubocurarine, respectively (Figure 1.3)
8
. Dale noted these dual 
muscarinic/nicotinic effects were displayed with much greater potency by acetylcholine, 
a choline ester discovered in and extracted from the ergot fungus, and further study led 
him to postulate that ACh was likely a naturally-occurring element of the nervous 
system
8,9
. Soon thereafter, Otto Loewi’s seminal experiments analyzing emissions of the 
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vagus nerve of frog hearts confirmed that ACh was indeed a chemical transmitter 
released by the vagus nerve
5,10
. In this way, ACh was discovered as the first 
neurotransmitter concomitantly with the revelation that its physiological actions were 
divided between the two functionally distinct categories of muscarinic and nicotinic. As 
receptor theory came to the forefront of pharmacology in the following decades, these 
functional differences were attributed to two receptor classes that became known as the 
nicotinic and muscarinic acetylcholine receptors. 
 
 
 
Figure 1.3. Chemical probes central to the discovery and early characterization of the muscarinic 
acetylcholine receptors. 
 
 
As more chemical tools became available, further pharmacological scrutiny of the 
muscarinic effects of ACh revealed functional heterogeneity amongst the mAChRs. The 
muscarinic antagonist pirenzepine played a major role in this revelation and by 
measurement of this compound’s differing binding affinities and functional selectivity the 
existence of at least three mAChR subtypes was established (Figure 1.3)
11–14
. By the late 
1980s, the number of confirmed mAChR subtypes was expanded as the genes for five 
distinct human muscarinic receptors was identified and sequenced (CHRM1 through 
CHRM5)
15–20
. Since the identification of these five subtypes, the study of mAChRs has 
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largely focused on the further elucidation of the structure, function, and therapeutic 
relevance of each mAChR subtype. 
 
Structure and function of M5 
The examination of the human and rat mAChR gene sequences provided valuable 
insight into mAChR structure and subsequent transfection into stable cell lines provided 
the means to study the structure and function of the mAChRs in an in vitro context. The 
mAChRs are class A, rhodopsin-like GPCRs
21
. Structurally, the receptors are single 
subunit proteins consisting of a seven α-helical transmembrane-spanning domain (7TM) 
with a large cytoplasmic loop connecting the fifth and sixth transmembrane domains 
(Figure 1.4)
21
. The proteins range in size from M1, with 460 amino acids, to M3, with 
590 amino acids. The human M5 muscarinic acetylcholine receptor (hM5) is a protein of 
532 amino acids
21
. Across all mAChR subtypes the amino terminal, carboxy terminal, 
and the cytoplasmic loops were shown to share less sequence identity; however, the 7TM 
domain is much more conserved. This conserved sequence homology is especially 
evident in the ACh-binding orthosteric site situated within the 7TM domain
21
. Overall, 
hM5 shares 89% sequence identity with the rat M5 muscarinic receptor (rM5), making M5 
the least conserved of the mAChR subtypes between the species
19
. Among other human 
mAChR subtypes, hM5 holds the most in common with hM3, sharing 73%, 85%, 68%, 
and 79% sequence identity with human M4, M3, M2, and M1, respectively
19,21
. 
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Figure 1.4. Illustrated model of a mAChR depicting the general structure and the two major signaling 
pathways mediated by Gαq and Gαi/o. Also shown is the putative location of an allosteric site in the 
extracellular portion of the 7TM domain in relation to the orthosteric site situated within the 7TM.  
 
 
 
M5 is comparable to M3 and M1 in its subcellular signaling pathways as well as in 
its sequence identity. In an active conformation, the M5, M3, and M1 receptors selectively 
bind to G protein heterotrimers possessing the Gαq subunit
22,23
. As the G protein 
exchanges GTP for GDP, the heterotrimer dissociates and Gαq upregulates the activity of 
phospholipase C (PLC) which in turn cleaves phosphatidylinositol 4,5-bisphosphate 
(PIP2) to the second messengers diacyl glycerol (DAG) and inositol 1,4,5-triphosphate 
(IP3)
22,23
. These second messengers subsequently activate multiple, predominantly 
stimulatory, downstream signaling pathways including calcium (Ca
2+
)
 
release from 
intracellular stores and the stimulation of protein kinase C (PKC; Figure 1.4)
22,23
. In 
contrast, the M2 and M4 receptors play a predominantly inhibitory role by selectively 
binding to the Gαi/o subunit, which subsequently downregulates the activity of adenylyl 
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cyclase (AC), thus lowering cellular concentrations of the secondary messenger cyclic 
adenosine monophosphate (cAMP)
22,23
. 
  
Localization of M5 
 The localization of the mAChRs has been investigated through a variety of 
techniques, including in situ mRNA hybridization, reverse transcription PCR, 
autoradiography, immunohistochemistry, immunocytochemistry, and 
immunoprecipitation. These studies have revealed mAChRs are distributed throughout 
the cholinergic system, in both the CNS and the periphery and in both neuronal and non-
neuronal contexts
21
. Moreover, each mAChR subtype displays a unique expression 
pattern, with M1, M4, and M5 primarily concentrated in the CNS and M2 and M3 located 
in both the CNS and the periphery 
21
. 
 Compared to other mAChR subtypes, M5 has a notably restricted expression 
pattern. Furthermore, the overall expression levels of M5 are relatively low compared to 
other subtypes, and it is estimated that M5 represents less than 2% of the total mAChR 
receptor load in the CNS
24
. Of this small percentage, the highest concentration of 
neuronal M5 is found within the midbrain. In the midbrain dopamine neurons of the 
ventral tegmental area (VTA) and the substantia-nigra pars compacta (SNc), M5 is the 
only mAChR detected, where it is coexpressed with D2 dopamine receptors 
25–27
. Non-
neuronally, M5 is concentrated on the endothelium of the cerebral vasculature and to a 
lesser extent throughout other cell types of the neurovascular unit
28,29
.  
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Effects of the genetic deletion of M5 
 The lack of M5-selective chemical probes combined with the relatively low 
abundance of the receptor presents a challenge to the study of M5. Hence, much of what 
is known about the physiological relevance of M5 has been deduced from mouse lines 
genetically engineered to lack functional M5 receptors. By examining the phenotypic 
characteristics of these M5 “knockout” (M5
-/-
) mice in comparison with wild type mice, 
much has been learned about the function and possible therapeutic relevance of M5. 
 Outwardly, M5
-/-
 mice appear healthy and display no major differences from their 
wild-type counterparts
30
. Yet a closer physiological examination reveals that the genetic 
knockout of M5 has striking effects on the cerebral vasculature. ACh is known to be a 
potent dilator of vascular beds, and the presence of M5 throughout the endothelium of the 
cerebral vasculature led researchers to hypothesize that M5 may play a central role in the 
cerebral vasodilatory process 
28,29,31
. In M5
-/-
 mice, the ability of ACh to dilate peripheral 
arteries remains intact; however, ACh has no effect on the dilation of cerebral arteries 
and arterioles in the M5
-/-
 mice
30
. Moreover, the cerebral vasculature is constitutively 
constricted in M5
-/-
 mice
32
. This constitutive constriction of the cerebral vasculature 
resulted in reduced cerebral blood flow and was observed alongside significant atrophy of 
the cortical and hippocampal pyramidal neurons
32
. The impact of this atrophy was 
reflected in behavioral studies where M5
-/-
 mice displayed deficits in hippocampal-
dependent cognitive tasks
32
. Additionally, electrophysiological studies of hippocampal 
brain slices from M5
-/-
 mice revealed impaired long-term potentiation at the mossy fiber 
CA3 synapse
32
. While these studies seem to indicate that the lack of M5 receptors in the 
CNS leads to severe impairment of hippocampal circuitry, it is unclear if this evidence 
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indicates direct involvement of M5 in the development and maintenance of these brain 
regions or if deficits in cerebral blood flow throughout development, due to the lack of 
endothelial M5, that result in the observed atrophy. 
Another brain region notably affected by the genetic deletion of M5 is the 
midbrain. In order to investigate of the role of M5 in the VTA, where it is the sole 
mAChR subtype present on dopaminergic neurons, researchers examined the 
pedunculopontine (PPT) and laterodorsal tegmental (LDT) nuclei, both of which provide 
cholinergic inputs to the VTA. In wild type mice, the electrical stimulation of these nuclei 
resulted in acute and prolonged dopamine (DA) release in the nucleus accumbens 
(NAcc); however, this effect was absent in M5
-/-
 mice
33–36
. DA release from the 
dopaminergic projections of the VTA to the NAcc is postulated to play a central role in 
the rewarding and reinforcing effects of drugs of addiction such as morphine and 
cocaine
37,38
. Consistent with these data, M5
-/-
 mice show impairments in reward seeking 
behavior. Compared to wild type mice, the rewarding effects of both cocaine and 
morphine were significantly attenuated in M5
-/-
 mice, as tested in conditioned place 
preference and self-administration experiments
39–41
. 
 The importance of M5 in the midbrain extends beyond the VTA. The presence of 
M5 as the only mAChR on dopaminergic projections from the SNc suggests that M5 is 
also involved in mediating DA release in the dorsal striatum
25,26
. Investigations using 
wild-type mouse striatal slice preparations revealed that mAChR agonists are capable of 
inducing DA release in the striatum; however, this effect was significantly attenuated, 
though not abolished, in M5
-/-
 mice
30,42
. Although these data suggest a pre-synaptic role 
for M5 in nigrostriatal dopaminergic signaling, recent electrophysiological studies with 
11 
 
the first M5-preferring ligand, VU0238429 (vide infra), revealed a more complicated 
picture wherein activation of somatodendritic M5 receptors in the SNc increases DA 
release, while activation of terminally-expressed M5 in the striatum decreases DA 
release
27
.  
 
Therapeutic potential of M5 
 Taken as a whole, the results from studies of M5
-/-
 mice strongly suggest that M5 
plays a central role in regulating the dopaminergic signaling of the midbrain as well as 
the vasodilation of the cerebral vasculature. Based on this information, the discovery of 
ligands designed to selectively activate or inhibit M5 would not only lead to continued 
study and understanding of the role of M5 in the CNS, but might also shed light on novel 
therapeutic strategies for a number of CNS diseases and disorders. 
The selective activation of M5 may prove most useful in the cerebral vasculature. 
The lack of a dilatory response to ACh in the cerebral vasculature of M5
-/-
 mice as well as 
the constitutively constricted nature of their cerebral arteries and arterioles presumably 
indicates that the selective activation of M5 would result in vasodilation. This hypothesis 
is further supported by evidence that activation of M5 is linked to the nitric oxide-
mediated vasodilatory pathway
43,44
. A compound that could induce cerebrovascular 
vasodilation via the selective activation of M5 could find therapeutic use in a range of 
diseases displaying deficiencies in cerebral blood flow, including acute ischemic stroke, 
cerebrovascular disease, cerebrovascular dementia, and Alzheimer’s disease (AD). 
Fortuitously, such a compound would not be required to penetrate the blood-brain barrier 
(BBB), thereby avoiding activity at M5 within the CNS.  
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 On the other hand, a centrally penetrant, selective inhibitor of M5 could prove 
useful in modulating the dopaminergic neurons of the midbrain. As outlined above, DA 
release in the NAcc appears to be regulated by M5 in the VTA and this pathway 
facilitates the rewarding and reinforcing effects of substance addiction. Thus, inhibition 
of M5 in the midbrain would presumably block the reward pathway activated by drugs of 
abuse and may represent a novel therapy for the treatment of drug addiction. 
Interestingly, this hypothesis is further supported by a study of a M5 single-nucleotide 
polymorphism (SNP) in Australians of European ancestry. Of the 815 subjects analyzed, 
19% carried an M5 SNP that conferred an addictive phenotype characterized by increased 
tobacco use and a heightened propensity for cannabis dependence
45
. Thus, in addition to 
evidence of involvement in addiction mechanisms in M5
-/-
 mouse studies, M5 has been 
directly associated with addictive behavior in humans and represents a worthwhile target 
for possible novel therapies for treating substance abuse. 
As of yet there have been no notable drug discovery efforts to elucidate the 
therapeutic value of selectively activating or inhibiting M5; however, targeting of 
mAChRs with small molecules for therapeutic benefit is not without precedent. For 
instance, deadly nightshade (Atropa belladonna) has been used since antiquity to treat 
various maladies, including opiate addiction
46,47
. It is now known that the active 
compounds in nightshade include the non-selective mAChR antagonists scopolamine, 
hyoscyamine, and atropine
46
. Unfortunately, the severe side effects of these compounds 
limit their usage to a few specialized circumstances
47
. More recently, the mAChR agonist 
xanomeline was studied for use in the treatment of schizophrenia and the psychosis-like 
symptoms of Alzheimer’s disease. Although pre-clinical and clinical studies 
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demonstrated efficacy, the compound was plagued by complications resulting from its 
severe side-effects, believed to be mediated via peripheral M2/M3 activation
48
. 
While these examples demonstrate the clear possibility for therapeutic benefits 
from targeting mAChRs, they also highlight that classical mAChR ligands often cause 
side effects that diminish their therapeutic value. The source of this limitation is the fact 
that the effects of classical mAChR ligands are mediated via interaction with the 
orthosteric binding site. As described above, the orthosteric site of mAChRs is highly 
conserved across the subtypes. Consequently, orthosteric mAChR ligands often have 
undesirable activity at multiple mAChR subtypes. Most often, the aforementioned 
negative side effects are the result of activation of peripheral M2 and/or M3 and may 
include bradycardia, salivation, lachrymation, sweating, and urinary and fecal 
incontinence
49,50
. As a result of this challenge, recent years have seen an increase in the 
research of small molecules targeting mAChR allosteric sites in order to achieve 
unprecedented mAChR subtype selectivity while also gaining new understanding of 
allosteric modes of pharmacology in mAChRs. 
 
Allosteric modulation of the M5 muscarinic acetylcholine receptor 
 
Allosteric modulation of mAChRs 
An allosteric site is a ligand binding site on a receptor that is topographically 
distinct from the orthosteric site
51–53
. The allosteric site is conformationally linked with 
the orthosteric site; thus the binding of an allosteric ligand can induce conformational 
changes to the receptor that modify receptor activity by modulating binding affinity 
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and/or efficacy of an orthosteric ligand for the receptor
51–54
. In essence, the allosteric 
ligand serves to stabilize a unique conformation of the receptor protein that possesses its 
own equally unique pharmacology
54
. 
In an effort to describe the diverse and complex interactions of GPCRs, 
orthosteric ligands, and allosteric modulators, multiple mathematical models of varying 
complexity and detail have been put forth. The most basic of these is the allosteric ternary 
complex model (ATCM; Figure 1.5)
55
. Within the ATCM, the binding of the orthosteric 
ligand (A) and the allosteric modulator (B) to the receptor (R) is described by several 
factors. The equilibrium dissociation constants, KA and KB, describe the binding of A and 
B, respectively, to their respective binding sites. In a traditional protein-ligand 
interaction, these constants may be enough to describe the interaction of the ligands with 
the receptor, but because the allosteric site is conformationally linked with the orthosteric 
site, binding of one ligand may affect the binding of the second ligand with positive or 
negative cooperativity. The magnitude and direction of the bound ligand’s effect on the 
other ligand’s binding affinity is described by the cooperativity factor α where α > 1 in 
cases of positive cooperativity, α < 1 in cases of negative cooperativity, and α = 1 in 
cases of neutral cooperativity where allosteric binding results in unchanged binding 
affinity
55
. In this way the ATCM has the capacity to quantitate the effects of one ligand 
on the second ligand’s binding affinity. Similarly, the magnitude and direction of the 
bound ligand’s effect on the second ligand’s efficacy is quantitated by the efficacy 
modulation factor β55.  
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Figure 1.5. The allosteric ternary complex model (ATCM). KA and KB are dissociation constants 
describing the interaction between the orthosteric ligand (A) and the allosteric ligand (B) with the receptor 
(R). Cooperativity factor α describes the magnitude and direction of one ligand’s effect on the binding 
affinity of the second ligand. Efficacy modulation factor β describes the magnitude and direction of the one 
ligand’s effect on the second ligand’s efficacy. 
 
 
From the standpoint of identifying a mAChR subtype-selective chemical probe, 
the primary advantage offered by targeting the allosteric site is selectivity. The allosteric 
sites of the mAChR family are far less conserved compared to the high sequence 
homology of the orthosteric site. Consequently, targeting the allosteric site can provide a 
higher degree of subtype selectivity in binding
53,56,57
. Even if an allosteric ligand lacks 
binding selectivity, the variation among mAChR allosteric sites might provide functional 
selectivity based on differences in cooperativity with the allosteric ligand
53,56,57
. From a 
therapeutic standpoint, allosteric modulators are preferable to direct orthosteric activation 
since the temporal and spatial activity of the endogenous ligand is preserved
53,56,57
. 
Furthermore, by avoiding the continual stimulation of the orthosteric site, an allosteric 
modulator may avoid development of tolerance effects often induced by exogenous 
orthosteric ligands (e.g. – less receptor desensitization or internalization)53,56,57.  
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Allosteric ligands may manifest a variety of activity profiles. An allosteric ligand 
that potentiates the receptor response to an orthosteric agonist is termed a positive 
allosteric modulator (PAM) while one that decreases the receptor response is termed a 
negative allosteric modulator (NAM)
53,56,57
. An allosteric ligand that in no way changes 
the response of the receptor to an orthosteric ligand, but simply occupies the allosteric 
site to no discernable effect is known as a neutral allosteric ligand (NAL)
53,56,57
.  
In addition to these ‘pure’ allosteric modulators, which possess no intrinsic 
activity of their own, some allosteric ligands, known as allosteric agonists, have been 
shown to directly activate the receptor in the absence of an orthosteric ligand
53,56–58
. 
Moreover, another category of ligand, ago-allosteric modulators, displays qualities of 
both orthosteric ligands and allosteric ligands. That is, an ago-allosteric modulator can 
function as an agonist on its own or as a modulator of the activity of another orthosteric 
ligand
53,56–58
. Ago-allosteric modulators are also known as bivalent ligands. In recent 
years the recognition and study of bivalent ligands has been further enriched by bitopic 
ligands. Bitopic ligands are compounds typically composed of two distinct 
pharmacophores covalently linked by a flexible tether region. One of these 
pharmacophores targets a receptor’s allosteric site while the other targets the orthosteric 
site
53,59
. As a result of this unique composition, bitopic ligands display highly versatile 
binding properties. Current proposed modes of binding reflect how a bitopic ligand could 
(a) occupy both the allosteric and orthosteric site simultaneously, (b) alternate between 
occupation of only the orthosteric or the allosteric site, or (c) cooperatively occupy both 
the allosteric and orthosteric site in conjunction with a second bitopic ligand
60,61
.  
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Characterization of allosteric modulators 
 Due to the complex nature of the pharmacology at the allosteric site, a wide range 
of functional and binding assays have been designed to characterize allosteric ligands. 
Cell-based fluorometric functional assays are among the most common assays used in 
screens to discover novel allosteric modulators
62
. These assays employ stably transfected 
cell lines expressing the receptor of interest and detect receptor activation via 
fluorometric measurement of various downstream indicators of receptor activation
62
. For 
instance, in the study of M5, which is coupled to the Gαq pathway, intracellular Ca
2+
 
mobilization is commonly used as a measure of receptor activation.  
In order to discover allosteric ligands in a high throughput screening (HTS) 
scenario, a ‘single point’ assay is generally employed62. In this experiment, the test 
compound is added to the cells at a fixed concentration and allowed to incubate for 
several minutes. Next, a submaximal concentration of orthosteric ligand (~EC20) is 
added. In this so-called ‘double-add’ format, PAMs will be observed to potentiate the 
EC20 (Figure 1.6)
62,63
. Contrastingly, a higher submaximal concentration (~EC80) may be 
used to detect NAMs or other inhibitors, as these compounds will be observed to 
attenuate the EC80 response
62,63
. Some HTS campaigns choose to combine these two 
formats into a single ‘triple-add’ format in which the test compound is added to the cells, 
followed by an ~EC20 to test for PAM activity, and finally an ~EC80 to test for inhibitory 
activity
62,63
. 
 
18 
 
 
Figure 1.6. Example fluorometric data illustrating the detection of a PAM in a single point, double-add 
assay format (from Bridges et al., 200863). 
 
  
 Once an allosteric modulator has been identified, multiple secondary assays will 
be carried out to further characterize a compound’s activity and selectivity. To determine 
the EC50 of a PAM (or the IC50 in the case of a NAM/inhibitor) the double-add assay 
format will again be utilized, but in this instance the effects of multiple concentrations of 
test compound on the EC20 (or EC80) will be measured in order to obtain a full 
concentration response curve (CRC) for the test compound (Figure 1.7)
62,63
. A related 
functional assay measures the CRC of an orthosteric ligand in the presence and absence 
of fixed concentrations of an allosteric modulator. In this way an allosteric modulator’s 
maximum efficacy may be measured in terms of the ‘fold shift’ induced by the modulator 
on the orthosteric ligand’s EC50  (Figure 1.8)
62,63
. The fold shift assay is most commonly 
used for PAMs. NAMs and other noncompetitive antagonists will depress the CRC of an 
orthosteric antagonist without shifting the EC50 (given a system with no receptor reserve). 
In general, it is the information provided by these three assays (single point, full CRC, 
19 
 
and fold shift), that supports and guides probe discovery campaigns in identifying, 
characterizing, and optimizing allosteric modulators.  
 
 
Figure 1.7. Example data demonstrating the modulatory effects of a PAM (left panel) and a NAM/inhibitor 
(right panel) in full CRC assays in double-add format. 
 
  
 
Figure 1.8. Example data demonstrating a PAM inducing a leftward shift in the CRC of an orthosteric 
ligand in a fold shift assay (left panel) and a NAM depressing the CRC of an orthosteric ligand in a manner 
characteristic of noncompetitive antagonism (right panel). 
 
 
 
 In addition to the standard repertoire of functional assays, allosteric modulators 
can be characterized based on binding assays as well. Binding assays generally employ 
membrane preparations containing the receptor of interest and use radioligands (ligands 
labeled with radioactive isotopes) to probe the binding of the allosteric ligand with the 
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receptor as measured by the radioactive decay of the radioligand. In terms of allosteric 
modulators, competition binding is a commonly used assay that investigates if a test 
compound interacts with the orthosteric site. In this assay a known orthosteric radioligand 
is allowed to label the orthosteric site of a portion of receptors prior to the addition of 
increasing concentrations of test compound. If the test compound displaces the 
radioligand in a concentration-dependent manner, this suggests that the test compound 
binds orthosterically (although pronounced negative cooperativity could conceivably 
elicit a similar result)
62
. 
 Binding assays may also be used to examine the kinetics of ligand association and 
dissociation. This is especially useful in the identification of NAMs. Because NAMs and 
orthosteric antagonists would presumably produce identical readouts in an initial 
functional assay (as opposed to a PAM versus an agonist), further confirmation of the 
mode of action is needed. Although a competition binding assay may reveal a putative 
NAM to be unable to displace an orthosteric radioligand, this represents negative data 
(inconclusive with respect to mode of action). In these cases, assays examining the 
dissociation kinetics of the orthosteric ligand in the presence and absence of the putative 
NAM may prove useful in revealing the binding cooperativity between the allosteric and 
the orthosteric ligands
62
.  
 
Allosteric modulators of M5 
 To date, the majority of allosteric modulators that are active at M5 have been non-
selective and exhibit allosteric activity at one or more mAChR subtypes besides M5. 
Additionally, many of these compounds possess off-target activity outside of the 
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mAChRs that precludes their use in the detailed study of M5. Among this diverse 
collection of non-selective M5 allosteric modulators are the neuromuscular blocking 
agents gallamine and alcuronium, the neurotoxins strychnine and brucine, the 
antiarrhythmic drug amiodarone, and the symmetrical bis-onium probe compound C7/3-
phth (Figure 1.9) 
64–68
. Clearly, non-selective mAChR allosteric modulators can possess 
an eclectic spectrum of chemical structures and activity profiles, yet only a single 
example of an allosteric modulator targeting M5 specifically had been reported prior to 
the research contained in this dissertation. 
 
 
Figure 1.9. Structures of selected non-selective M5 allosteric modulators. 
 
 The discovery of the first M5-preferring PAM was the serendipitous result of a 
drug discovery campaign at Vanderbilt University searching for an M1-selective PAM. A 
functional, cell-based HTS of the VHTSC (~160,000 compounds at the time of 
screening) searching for M1 PAMs discovered a number of PAMs with varied mAChR 
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subtype-selectivity profiles
69
. Most interesting among these was N-p-bromobenzyl isatin, 
VU0119498, which displayed activity as a pan-Gαq-coupled mAChR PAM (Figure 1.10). 
That is, in functional Ca
2+
 mobilization assays, VU0119498 exhibited PAM activity 
towards the natively Gαq-coupled M1, M3, and M5 receptors with similar potency and 
efficacy (EC50 = ~4-6 μM, %AChMax = 66-82), while having no activity at natively Gαi/o-
coupled M2 and M4 receptors, which were expressed in recombinant cells co-transfected 
with chimeric Gαqi5 to facilitate coupling to the Ca
2+
 mobilization pathway (Figure 
1.10)
69
. This unique selectivity profile led to the hypothesis that optimization of the SAR 
around the chemical scaffold of VU0119498 could dial-out M1 and M3 activity, 
producing a highly selective M5 PAM
70,71
. 
 
 
Figure 1.10. Structure, potency, and human mAChR selectivity of VU0119498. Ca2+ mobilization assays 
with hM1-hM5 cells were used to obtain CRCs of VU0119498 in the presence of a fixed submaximal 
(~EC20) concentration of ACh (EC50 values: hM5 EC50 = 4.1 μM, %AChMax = 74; hM3 EC50 = 6.4 μM, 
%AChMax = 66; hM1 EC50 = 6.0 μM, %AChMax = 82; hM2, hM4 EC50 >30 μM. (modified from Marlo et al., 
200969). 
 
 An optimization campaign employing a strategy of multidimensional iterative 
parallel synthesis was subsequently initiated. Early in this campaign, a matrix-analog 
library exploring combinations of substitutions around the isatin benzo ring with 
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substitutions around the N-benzyl region of VU0119498 discovered that the combination 
of a 5-trifluoromethoxyisatin with an N-p-methoxybenzyl substitution conferred an 
unprecedented degree of potency and M5-selectivity. This compound, VU0238429, 
displayed PAM activity at hM5 with an EC50 equal to 1.1 μM and >30-fold subtype 
selectivity against the remaining mAChR subtypes as measured by in vitro Ca
2+
 
mobilization assays, earning it the distinction of being the first M5-preferring PAM 
(Figure 1.11)
70,71
.  
 
 
Figure 1.11. Structure, potency, and human mAChR selectivity of VU0238429. Ca2+ mobilization assays 
with hM1-hM5 cells were used to obtain CRCs of VU0238429 in the presence of a fixed submaximal 
(~EC20) concentration of ACh (EC50 values: hM5 EC50 = 1.1 μM, %AChMax = 91; hM1-hM4 EC50 >30 μM. 
(modified from Bridges et al., 201071). 
 
Unfortunately, upon assessment of in vivo pharmacokinetics and brain penetrance 
in rat models it became clear that the compound exhibited poor systemic absorption and 
brain penetrance, limiting the utility of VU0238429 as an in vivo tool; however, this 
impediment has not limited the compound’s utility as an in vitro probe70,71. Indeed, a 
recent electrophysiological study of M5 function in mouse brain slices using VU0238429 
found that the M5 receptor mediates differential effects on nigrostriatal dopaminergic 
neurons based upon where on the receptor is located on the neuron; moreover, this study 
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marks the first time M5 has been demonstrated pharmacologically to be functionally 
expressed in the dopaminergic neurons of the midbrain
27
. 
This recent electrophysiological data on M5 represents a landmark discovery that 
was made possible due to the availability of an M5-preferring ligand. The interwoven 
relationship between the availability of practical chemical probes and progress in 
understanding the pharmacology of the CNS underscores the need for more highly 
optimized M5-selective ligands that are suitable not just for in vitro use, but for in vivo 
use as well. A novel, highly-selective M5 PAM or NAM that could serve as an in vivo 
probe would revolutionize the study of M5 and possibly shed light on the therapeutic 
relevance of modulating M5 activity. Ideally, such a compound should have drug-like 
properties, meaning it should possess high potency, high M5-selectivity, a satisfactory 
metabolic and pharmacokinetic (DMPK) profile, and amenable physicochemical 
properties. The following chapters of this dissertation describe our efforts in the 
optimization and characterization of four novel, M5-selective chemical series with the 
goal of providing new and improved chemical tools for the study of M5 in the CNS. 
 
Notes on the numbering of figures, schemes, tables, and compounds 
 
 In order to present the information contained in the following chapters in a more 
comprehensible and orderly fashion, the numbering for all figures, tables, schemes, and 
compounds is uniform and specific to each Chapter. Each category of data follows the 
arbitrary format of “Figure/Table/Scheme [Chapter number].[figure/table/scheme 
number]” (e.g. Figure 3.1, Figure 3.2, Figure 3.3… etc.). Compounds and 
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intermediates described in each Chapter are numbered in a similar pattern (e.g. compound 
3.1, analog 3.2, reactants 3.3a, 3.3b, and 3.3c… etc.). This compound numbering system 
is used in place of full VU number registration codes (e.g. VU0467903) to increase 
readability, although relevant VU numbers are referenced with compound numbers where 
appropriate. 
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Chapter II 
 
MATERIALS AND METHODS 
 
General optimization strategy 
 
 The general synthetic approach to all chemical scaffold optimization projects 
contained herein was based on the strategy of potency optimization via multidimensional 
iterative parallel synthesis. That is, at the genesis of an optimization effort, a chemical 
scaffold would be retrosynthetically divided into regions deemed logical and amenable to 
library synthesis. Next, libraries ranging in size from 5-50+ members, containing analogs 
considered to be of interest to the exploration of the chemical scaffold’s SAR, would be 
designed around the individual regions. These libraries were then synthesized in parallel 
and subsequently purified. Following purification, all final compounds would be diluted 
to a concentration of 10 mM in DMSO and transferred to 4 mL 2D barcoded vials. The 
compounds were then assigned 7-digit VU numbers (e.g. – VU0481443) and the 
compound’s notebook number(s), structure, and accompanying data were then registered 
with the Vanderbilt Center for Neuroscience Drug Discovery Chemcart database to aid in 
storing and tracking compounds. 
Once registered, all newly synthesized library analogs would be characterized in 
one or more in vitro pharmacological assays described in the pharmacology section of 
this Chapter. These primary assays functioned to provide feedback on how the chosen 
structural changes affected the activity and/or the receptor subtype selectivity of the 
chemical scaffold. Based on this SAR data, the field of viable structural modifications to 
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the region under study would be narrowed and another round of library design, synthesis, 
purification, and cell-based assays could proceed with greater insight into the studied 
region of the chemical scaffold. In this way, the SAR of individual regions of the 
chemical scaffolds was characterized over multiple iterative rounds to arrive at one or 
more optimized structures (Figure 2.1).  
Frequently the compatibility of regional SAR discoveries would be studied in 
matrix libraries. These matrix libraries brought together several optimized structures that 
resulted from regional optimization efforts (e.g. - three optimized structures from Region 
I combined with three optimized structures from Region II results in 9 matrix library 
analogs). The SAR data gained from assaying these multidimensional libraries in vitro in 
turn informs on how to proceed with further matrix libraries; thus, the multidimensional 
iterative parallel synthesis process continues until a lead analog is obtained that fulfills 
the optimization effort’s goals (Figure 2.1).  
In this way, a multidimensional iterative parallel synthesis effort can rapidly 
produce a multitude of analogs based around a chemical scaffold, enabling detailed study 
of all aspects of a chemical scaffold’s SAR. The remainder of this Chapter focuses in 
detail on the procedures employed in the study of the four chemical scaffolds that are the 
subjects of Chapters III-VI. As the synthesis of each project’s chemical scaffold was 
based on straightforward and reliable synthetic methods, we were confident in limiting 
full characterization to a select handful of significant and representative compounds. In 
the case of compounds whose synthesis is not described in detail below, synthetic 
conditions and yields are summarized in the text, figures, and schemes of their respective 
Chapters. 
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Figure 2.1. Generalized workflow diagram illustrating multidimensional iterative parallel synthesis and 
testing of analog libraries optimizing multiple regions of a lead chemical series.  
 
 
 
Medicinal Chemistry 
 
 
 
General synthetic methods and instrumentation 
All chemical reactions were carried out in library format on small scale (15-100 
mg). A minority of analogs were synthesized as standalone compounds (i.e. - an 
individual synthesis of a target not connected to a larger library). All reactions were 
carried out employing standard chemical techniques under inert atmosphere. Solvents 
used for extraction, washing, and chromatography were HPLC grade. Unless otherwise 
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noted, all reagents and starting materials were purchased from Aldrich Chemical 
Company and were used without further purification. Thermally heated reactions were 
warmed in temperature controlled silicone oil baths. Chilled reactions were cooled to 0 
°C with a water and ice bath, and to -78 °C with an acetone and dry ice bath. Reactions 
cooled to < -78 °C were chilled a Thermo Scientific Neslab cc100 immersion cooler. 
Microwave-assisted syntheses were conducted using a Biotage Initiator 60 microwave 
reactor. 
Analytical thin layer chromatography was performed on 250 μm silica gel plates 
from Sorbent Technologies. Analytical HPLC was performed on an Agilent 1200 LCMS 
with UV detection at 214 nm and 254 nm along with ELSD detection. All NMR spectra 
were recorded on a 400 MHz Brüker AV-400 instrument or a 500 Mhz Brüker DRX-500 
instrument. 
1H chemical shifts are reported as δ values in ppm relative to the residual 
solvent peak (MeOD = 3.31, CDCl3 = 7.26). Data are reported as follows: chemical shift, 
multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m 
= multiplet), coupling constant (Hz), and integration. 
13C chemical shifts are reported as δ 
values in ppm relative to the residual solvent peak (MeOD = 49.0, CDCl3 = 77.16). Low 
resolution mass spectra were obtained on an Agilent 1200 LCMS with electrospray 
ionization. High resolution mass spectra were recorded on a Waters QToF-API-US plus 
Acquity system with electrospray ionization. Automated flash column chromatography 
was performed on a Teledyne ISCO Combiflash Rf system. Preparative purification of 
library compounds was performed on a Gilson 215 preparative LC system. Chiral 
separations were performed on a Waters Investigator II SFC utilizing a Lux cellulose-3 
column. Optical rotations were acquired on a Jasco P-2000 polarimeter at 23 °C and 589 
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nm. The specific rotations were calculated according to the equation [α]
  
 
 = 
    
     
 where l 
is path length in decimeters and c is the concentration in g/100 mL. 
 
Isatin-based M5 PAM chemical experimentals and characterization 
3.39 (VU0467903, ML326). 1-(2-phenoxyethyl)-5-(trifluoromethoxy)indoline-
2,3-dione. To a solution of 5-(trifluoromethoxy)isatin (460 mg, 2.0 mmol, 1.0 eq.), 
K2CO3 (550 mg, 4.0 mmol, 2.0 eq.), KI (33 mg, 0.20 mmol, 0.1 eq.) in acetonitrile (20 
mL, 0.1 M) in a 20 mL microwave reaction vial was added 2-bromoethylphenyl ether 
(480 mg, 2.4 mmol, 1.2 eq.). The microwave vial was sealed with a crimp cap and the 
vessel was heated in a microwave reactor at 160 °C for 10 minutes, with magnetic 
stirring. After cooling to ambient temperature, the reaction was diluted with DCM (~20 
mL) and washed with brine. The organic layer was separated and dried over Na2SO4. 
Solvent was removed under reduced pressure and the crude product was purified via 
automated silica gel flash chromatography. Product containing fractions were combined 
and the solvents removed under reduced pressure to obtain 583 mg of pure product as a 
red-orange powder (83% yield). TLC Rf = 0.79 (hexane/ethyl acetate 1:1, UV-Vis). 
1
H 
NMR (400.1 MHz, CDCl3) δ (ppm): 7.52-7.46 (m, 2H); 7.31-7.25 (m, 3H); 6.98 (t, J = 
7.4 Hz, 1H); 6.82 (d, J = 7.9 Hz, 2H); 4.28 (t, J = 5.0 Hz, 2H); 4.17 (t, J = 5.0 Hz, 2H); 
13
C NMR (125 MHz, CDCl3) δ (ppm): 182.25, 158.27, 157.93, 150.01, 145.44, 131.02, 
129.78, 121.75, 118.32, 114.39, 112.89, 65.94, 40.62. HRMS (TOF, ES+) C17H13NO4F3 
[M+H]
+
 calc. mass 352.0797, found 352.0795. 
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Non-isatin M5 PAM chemical experimentals and characterization 
4.1 (VU0472882). N-benzyl-1-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-
N-ethylpiperidine-4-carboxamide. To a solution of N-benzyl-N-ethylpiperidine-4-
carboxamide HCl (20 mg, 0.071 mmol, 1.0 eq.) and DIPEA (74 μL, 0.213 mmol, 3.0 eq.) 
in DCM (1 mL, 0.071 M) was added 1,4-benzodioxan-6-sulfonyl chloride (25 mg, 0.107 
mmol, 1.5 eq.). The reaction was magnetically stirred at ambient temperature for 2 hours. 
The reaction was quenched with saturated aqueous NaHCO3 and the phases were 
separated. The aqueous layer was extracted with DCM. The combined organic layers 
were then washed with brine and dried over MgSO4. Following filtration, the solvent was 
removed under reduced pressure. Crude product was purified via Gilson preparative LC 
to obtain 26 mg pure product (84% yield). TLC Rf = 0.64 (hexane/ethyl acetate 1:1). 
1
H 
NMR (1.3:1 rotamer ratio, asterisk denotes minor rotamer peaks, 400.1 MHz, CDCl3) δ 
(ppm): 7.38-6.89 (m, 8H); 4.55, 4.48* (s, 2H); 4.35-4.24 (m, 4H); 3.84-3.67 (m, 2H); 
3.37*, 3.21 (q, J = 7.1 Hz, 2H); 2.51-2.22 (m, 3H), 2.08-1.88 (m, 2H), 1.84-1.65 (m, 2H), 
1.15- 1.02 (m, 3H). 
13
C NMR (1.2:1 rotamer ratio, asterisk denotes minor rotamer peaks, 
100.6 MHz, CDCl3) δ (ppm): 174.17*, 174.05, 147.56, 143.66*, 137.86, 137.07*, 
129.08*, 128.82*, 128.71, 128.67*, 127.93, 127.79, 127.43, 126.13*, 121.52, 121.47*, 
117.80, 117.38, 117.33*, 64.64, 64.29, 50.34*, 47.83, 45.68, 45.61*, 41.38, 41.15*, 
37.98*, 37.78, 28.46, 28.33*, 14.52, 12.76*. LCMS (215 nm) RT = 1.09 min (>98%); m/z 
445 [M+H]
 +
. HRMS (TOF, ES+) C23H29N2O5S [M+H]
+
 calc. mass 445.1797, found 
445.1796. 
4.3. tert-butyl 4-(benzylcarbamoyl)piperidine-1-carboxylate. To a solution of 
1-tert-butoxycarbonylpiperidine-4-carboxylic acid (600 mg, 2.62 mmol, 1.0 eq.; 
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Oakwood company, No. 019200, Lot No. F23F), benzylamine (273 μL, 3.93 mmol, 1.5 
eq.), and DIPEA (898 μL, 5.24 mmol, 2.0 eq.) in DCM (10 mL, 0.26 M) was added 
HATU (1.99 g, 5.24 mmol, 2.0 eq.; Oakwood company, No. 023926, Lot No. G02L). 
The reaction was magnetically stirred at ambient temperature for 4 hours. The reaction 
was quenched with saturated aqueous NaHCO3 and the phases were separated. The 
aqueous layer was extracted with DCM. The combined organic layers were then washed 
with brine and dried over MgSO4. Following filtration, the solvent was removed under 
reduced pressure. Crude product was purified via automated silica gel flash 
chromatography. Product containing fractions were combined and the solvents removed 
under reduced pressure to obtain 834 mg of product (99% yield). TLC Rf = 0.52 
(hexane/ethyl acetate 1:1, p-anisaldehyde stain). 
1
H NMR (~1:1 rotamer ratio, asterisk 
denotes rotamer peak, 400.1 MHz, CDCl3) δ (ppm): 7.35-7.22 (m, 5H); 5.83 (br, 1H); 
4.44*, 4.42* (s, 2H); 4.20-4.08 (m, 2H); 2.79-2.66 (m, 2H); 2.30-2.20 (m, 1H); 1.87-1.78 
(m, 2H); 1.71-1.59 (m, 2H); 1.45 (s, 9H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 
174.29, 154.78, 138.34, 128.89, 127.87, 127.72, 79.75, 43.65, 43.49, 28.79, 28.56. LCMS 
(215 nm) RT = 1.01 min (>98%); m/z 263 [M+H]
 +
, minus t-butyl. HRMS (TOF, ES+) 
C18H27N2O3 [M+H]
+
 calc. mass 319.2022, found 319.2021. 
4.4. tert-butyl 4-(benzyl(ethyl)carbamoyl)piperidine-1-carboxylate. To a 
solution of tert-butyl 4-(benzylcarbamoyl)piperidine-1-carboxylate (700 mg, 2.20 mmol, 
1.0 eq.) in THF (10 mL, 0.22 M) was added NaO
t
Bu (254 mg, 2.64 mmol, 1.2 eq.) and 
15-crown-5 (524 μL, 2.64 mmol, 1.2 eq.). The reaction was magnetically stirred at 
ambient temperature for 30 minutes at which time ethyl iodide (355 μL, 4.40 mmol, 2.0 
eq.) was added to the reaction mixture. The reaction was then magnetically stirred at 
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ambient temperature for 3 hours. The reaction was quenched with water and the phases 
were separated. The aqueous layer was extracted with ethyl acetate. The combined 
organic layers were then washed with brine and dried over MgSO4. Following filtration, 
the solvent was removed under reduced pressure. Crude product was purified via 
automated silica gel flash chromatography. Product containing fractions were combined 
and the solvents removed under reduced pressure to obtain 596 mg of product (78% 
yield). TLC Rf = 0.64 (hexane/ethyl acetate 1:1, p-anisaldehyde stain). 
1
H NMR (1.4:1 
rotamer ratio, asterisk denotes minor rotamer peaks, 400.1 MHz, CDCl3) δ (ppm): 7.39-
7.11 (m, 5H); 4.58, 4.55* (s, 2H); 4.26-4.02 (m, 2H); 3.40*, 3.28 (q, J = 7.1 Hz, 2H); 
2.85-2.49 (m, 3H); 1.90-1.55 (m, 4H); 1.45, 1.43* (s, 9H); 1.15, 1.08* (t, J = 7.1 Hz, 3H). 
13
C NMR (1.5:1 rotamer ratio, asterisk denotes minor rotamer peaks, 100.6 MHz, CDCl3) 
δ (ppm): 174.78*, 174.64, 154.78, 138.02, 137.35*, 129.04*, 128.66, 127.90, 127.74*, 
127.34, 126.26*, 79.64, 79.59*, 50.46*, 47.79, 43.38, 41.40, 41.16*, 39.09*, 38.87, 
28.88, 28.71*, 28.54, 14.54, 12.77*. LCMS (215 nm) RT = 1.14 min (>98%); m/z 291 
[M+H]
 +
, minus t-butyl. HRMS (TOF, ES+) C20H31N2O3 [M+H]
+
 calc. mass 347.2335, 
found 347.2333. 
4.5. N-benzyl-N-ethylpiperidine-4-carboxamide HCl. tert-butyl 4-
(benzyl(ethyl)carbamoyl)piperidine-1-carboxylate (500 mg, 1.44 mmol, 1.0 eq.) was 
dissolved neat in 4N HCl/dioxane. The reaction was magnetically stirred at ambient 
temperature for 1 hour. Solvent was then removed under reduced pressure to obtain 407 
mg of product (quantitiative yield). TLC Rf = 0.01 (hexane/ethyl acetate 1:1, p-
anisaldehyde stain). 
1
H NMR (1.3:1 rotamer ratio, asterisk denotes minor rotamer peaks, 
400.1 MHz, MeOD) δ (ppm): 7.33-7.09 (m, 5H); 4.63*, 4.50 (s, 2H); 3.41-3.25 (m, 4H); 
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3.21 (quint, J = 1.6 Hz, 1H); 3.11-2.84 (m, 3H); 1.97-1.70 (m, 4H), 1.10, 1.00* (t, J = 
7.1, 3H). 
13
C NMR (1.5:1 rotamer ratio, asterisk denotes minor rotamer peaks, 100.6 
MHz, MeOD) δ (ppm): 175.67*, 175.60, 138.90, 138.65*, 129.99*, 129.64, 128.71*, 
128.62, 128.37, 127.68*, 51.79, 44.28, 44.19*, 43.25, 42.84*, 37.30*, 36.93, 26.94, 
26.75*, 14.73, 12.83*. LCMS (215 nm) RT = 0.62 min (>98%); m/z 247 [M+H]
 +
. HRMS 
(TOF, ES+) C15H23N2O [M+H]
+
 calc. mass 247.1810, found 247.1810. 
4.67. (R)-tert-butyl 4-((1-phenylethyl)carbamoyl)piperidine-1-carboxylate. To 
a solution of 1-tert-butoxycarbonylpiperidine-4-carboxylic acid (500 mg, 2.18 mmol, 1.0 
eq.; Oakwood company, No. 019200, Lot No. F23F), (R)-(+)-α-methylbenzylamine (334 
μL, 2.62 mmol, 1.2 eq.), and DIPEA (747 μL, 4.36 mmol, 2.0 eq.) in DCM (10 mL, 0.22 
M) was added HATU (1.04 g, 2.73 mmol, 1.25 eq.; Oakwood company, No. 023926, Lot 
No. G02L). The reaction was magnetically stirred at ambient temperature for 4 hours. 
The reaction was quenched with saturated aqueous NaHCO3 and the phases were 
separated. The aqueous layer was extracted with DCM. The combined organic layers 
were then washed with brine and dried over MgSO4. Following filtration, the solvent was 
removed under reduced pressure. Crude product was purified via automated silica gel 
flash chromatography. Product containing fractions were combined and the solvents 
removed under reduced pressure to obtain 584 mg of product (81% yield). TLC Rf = 0.52 
(hexane/ethyl acetate 1:1, p-anisaldehyde stain). 
1
H NMR (~1:1 rotamer ratio, asterisk 
denotes rotamer peak, 400.1 MHz, CDCl3) δ (ppm): 7.38-7.22 (m, 5H); 5.70 (br, 1H); 
5.12 (quint, J = 7.2 Hz, 1H); 4.12 (br, 2H); 2.79-2.64 (m, 2H); 2.27-2.15 (m, 1H); 1.85-
1.73 (m, 2H); 1.70-1.54 (m, 2H); 1.49*, 1.47* (s, 3H); 1.45 (s, 9H). 
13
C NMR (100.6 
MHz, CDCl3) δ (ppm): 173.47, 154.80, 143.24, 128.86, 127.56, 126.22, 79.74, 48.67, 
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43.51, 28.78, 28.73, 28.56, 21.82. LCMS (215 nm) RT = 1.05 min (>98%); m/z 277 
[M+H]
 +
, minus t-butyl. HRMS (TOF, ES+) C19H28N2O3FNa [M+H]
+
 calc. mass 
355.1998, found 355.1996. Specific rotation [α] 
  
 
 = 62.9° (c = 0.57, CHCl3). 
4.69. (R)-tert-butyl 4-(ethyl(1-phenylethyl)carbamoyl)piperidine-1-
carboxylate. To a solution of (R)-tert-butyl 4-((1-phenylethyl)carbamoyl)piperidine-1-
carboxylate (100 mg, 0.301 mmol, 1.0 eq.) in THF (2 mL, 0.15 M) was added NaO
t
Bu 
(43 mg, 0.451 mmol, 1.5 eq.) and 15-crown-5 (90 μL, 0.451 mmol, 1.5 eq.). The reaction 
was magnetically stirred at ambient temperature for 30 minutes at which time ethyl 
iodide (49 μL, 0.602 mmol, 2.0 eq.) was added to the reaction mixture. The reaction was 
then magnetically stirred at ambient temperature for 24 hours. The reaction was quenched 
with water and the phases were separated. The aqueous layer was extracted with DCM. 
The combined organic layers were then washed with brine and dried over MgSO4. 
Following filtration, the solvent was removed under reduced pressure. Crude product was 
purified via automated silica gel flash chromatography. Product containing fractions were 
combined and the solvents removed under reduced pressure to obtain 27 mg of product 
(25% yield). TLC Rf = 0.65 (hexane/ethyl acetate 1:1, p-anisaldehyde stain). 
1
H NMR 
(~2:1 rotamer ratio, asterisk denotes minor rotamer peaks, 400.1 MHz, CDCl3) δ (ppm): 
7.40-7.18 (m, 5H); 6.04, 5.13* (q, J = 6.9 Hz, 1H); 4.18 (br, 2H); 3.52-2.86 (m, 2H); 
2.86-2.48 (m, 3H); 1.95-1.73 (m, 2H); 1.72-1.57 (m, 3H); 1.56-1.49 (m, 2H); 1.48- 1.38* 
(m, 9H); 1.03*, 0.98 (t, J = 6.9, 3H). 
13
C NMR (~2:1 rotamer ratio, asterisk denotes 
minor rotamer peaks, 100.6 MHz, CDCl3) δ (ppm): 174.96, 174.46*, 154.82, 141.38, 
141.05*, 128.85*, 128.51, 127.65*, 127.51, 127.39, 126.60*, 79.70, 79.64*, 54.98*, 
50.73, 39.73, 39.50*, 38.58*, 37.91, 29.12, 29.08*, 28.83*, 28.76, 28.57, 19.20*, 17.27, 
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16.94, 14.56*. LCMS (215 nm) RT = 1.18 min (>98%); m/z 305 [M+H]
 +
, minus t-butyl. 
HRMS (TOF, ES+) C21H32N2O3Na [M+H]
+
 calc. mass 383.2311, found 383.2309. 
Specific rotation [α] 
  
 
 = 124.7° (c = 0.61, CHCl3). 
4.71. (R)-N-ethyl-N-(1-phenylethyl)piperidine-4-carboxamide HCl. (R)-tert-
butyl 4-(ethyl(1-phenylethyl)carbamoyl)piperidine-1-carboxylate (347 mg, 0.963 mmol, 
1.0 eq.) was dissolved neat in 4N HCl/dioxane. The reaction was magnetically stirred at 
ambient temperature for 1 hour. Solvent was then removed under reduced pressure to 
obtain 255 mg of product (89% yield). TLC Rf = 0.01 (hexane/ethyl acetate 1:1, p-
anisaldehyde stain). 
1
H NMR (1.5:1 rotamer ratio, asterisk denotes minor rotamer peaks, 
400.1 MHz, MeOD) δ (ppm): 7.43-7.24 (m, 5H); 5.86, 5.38* (q, J = 7.1 Hz, 1H); 3.51-
2.93 (m, 7H); 2.08-1.87 (m, 4H); 1.70*, 1.55 (d, J = 7.0 Hz, 3H); 0.99, 0.97* (t, J = 7.1 
Hz, 3H). 
13
C NMR (1.5:1 rotamer ratio, asterisk denotes minor rotamer peaks, 100.6 
MHz, MeOD) δ (ppm): 175.78, 175.29*, 142.02, 129.82*, 129.59, 128.75*, 128.60, 
128.45, 127.97*, 56.66*, 53.02, 44.31*, 44.28, 39.58*, 39.41, 37.80, 37.47*, 27.12*, 
27.06, 26.99*, 26.88, 19.20*, 17.17, 17.12, 14.52*. LCMS (215 nm) RT = 0.74 min 
(>98%); m/z 261 [M+H]
 +
. HRMS (TOF, ES+) C16H25N2O [M+H]
+
 calc. mass 261.1967, 
found 261.1968. Specific rotation [α] 
  
 
 = 121.4° (c = 0.65, CHCl3). 
4.75 (VU0476212). (R)-1-((1H-indazol-5-yl)sulfonyl)-N-ethyl-N-(1-
phenylethyl)piperidine-4-carboxamide. To a solution of (R)-N-ethyl-N-(1-
phenylethyl)piperidine-4-carboxamide HCl (20 mg, 0.067 mmol, 1.0 eq.) and DIPEA (23 
μL, 0.134 mmol, 2.0 eq.) in DCM (0.7 mL, 0.1 M) was added 1H-indazole-5-sulfonyl 
chloride (22 mg, 0.101 mmol, 1.5 eq.). The reaction was magnetically stirred at ambient 
temperature for 2 hours. The reaction was quenched with saturated aqueous NaHCO3 and 
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the phases were separated. The aqueous layer was extracted with DCM. The combined 
organic layers were then washed with brine and dried over MgSO4. Following filtration, 
the solvent was removed under reduced pressure. Crude product was purified via Gilson 
preparative LC to obtain 26 mg pure product (88% yield). TLC Rf = 0.23 (hexane/ethyl 
acetate 1:1). 
1
H NMR (1.7:1 rotamer ratio, asterisk denotes minor rotamer peaks, 400.1 
MHz, CDCl3) δ (ppm): 8.32-8.17 (m, 2H); 7.79-7.56 (m, 2H); 7.35-7.10 (m, 5H); 5.99, 
5.00* (q, J = 7.1 Hz, 1H); 3.96-3.76 (m, 2H), 3.50-2.80 (m, 2H), 2.57-2.30 (m, 3H); 2.12- 
1.88 (m, 2H); 1.85-1.69 (m, 2H); 1.60*, 1.47 (d, J = 7.1 Hz, 3H); 0.99*, 0.87 (t, J = 7.1, 
3H). 
13
C NMR (1.7:1 rotamer ratio, asterisk denotes minor rotamer peaks, 100.6 MHz, 
CDCl3) δ (ppm): 174.47, 173.94*, 141.40, 140.64*, 136.20, 129.41, 129.26*, 128.88*, 
128.57, 127.75*, 127.52, 127.49, 126.49, 125.46, 122.80, 110.76, 55.06*, 50.98, 45.71, 
38.65*, 38.55, 38.34*, 37.97, 28.66*, 28.41, 19.15*, 17.18, 16.92, 14.51*. LCMS (215 
nm) RT = 1.01 min (>98%); m/z 441 [M+H]
 +
. HRMS (TOF, ES+) C23H29N4O3S [M+H]
+
 
calc. mass 441.1960, found 441.1961. Specific rotation [α] 
  
 
 = 65.1° (c = 0.11, CHCl3). 
4.158. tert-butyl 4-((2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-
carboxylate. To a solution of 1-tert-butoxycarbonylpiperidine-4-carboxylic acid (573 
mg, 2.5 mmol, 1.0 eq.; Oakwood company, No. 019200, Lot No. F23F), 2-
(trifluoromethyl)benzylamine (421 μL, 3 mmol, 1.2 eq.), and DIPEA (857 μL, 5 mmol, 
2.0 eq.) in DCM (12 mL, 0.21 M) was added HATU (1.43 g, 3.75 mmol, 1.5 eq.; 
Oakwood company, No. 023926, Lot No. G02L). The reaction was magnetically stirred 
at ambient temperature for 24 hours. The reaction was quenched with saturated aqueous 
NaHCO3 and the phases were separated. The aqueous layer was extracted with DCM. 
The combined organic layers were then washed with brine and dried over MgSO4. 
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Following filtration, the solvent was removed under reduced pressure. Crude product was 
purified via automated silica gel flash chromatography. Product containing fractions were 
combined and the solvents removed under reduced pressure to obtain 607 mg of product 
(63% yield). TLC Rf = 0.55 (hexane/ethyl acetate 1:1). 
1
H NMR (400.1 MHz, CDCl3) δ 
(ppm): 7.68-7.62 (m, 1H); 7.55-7.49 (m, 2H); 7.43- 7.34 (m, 1H); 5.85 (br, 1H); 4.67-
4.56 (m, 2H); 4.20-4.04 (m, 2H); 2.80-2.64 (m, 2H); 2.31-2.18 (m, 1H); 1.85-1.74 (m, 
2H); 1.70-1.55 (m, 2H); 1.44 (s, 9H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 174.27, 
154.78, 136.76, 132.55, 131.07 (q, JCF = 1.4 Hz), 128.04 (q, JCF = 32.3 Hz), 127.88, 
126.19 (q, JCF = 5.5 Hz), 124.59 (q, JCF = 272.5 Hz), 79.78, 43.42, 40.29, 40.27, 28.69, 
28.56. LCMS (215 nm) RT = 1.18 min (>98%); m/z 330 [M+H]
 +
, minus t-butyl. HRMS 
(TOF, ES+) C19H25N2O3F3Na [M+H]
+
 calc. mass 409.1715, found 409.1713. 
4.159. tert-butyl 4-(ethyl(2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-
carboxylate. To a solution of tert-butyl 4-((2-
(trifluoromethyl)benzyl)carbamoyl)piperidine-1-carboxylate (394 mg, 1.020 mmol, 1.0 
eq.) in THF (6.8 mL, 0.15 M) was added NaO
t
Bu (147 mg, 1.529 mmol, 1.5 eq.) and 15-
crown-5 (405 μL, 2.039 mmol, 2 eq.). The reaction was magnetically stirred at ambient 
temperature for 30 minutes at which time ethyl iodide (164 μL, 2.0392 mmol, 2.0 eq.) 
was added to the reaction mixture. The reaction was then magnetically stirred at ambient 
temperature overnight. The reaction was quenched with brine and the phases were 
separated. The aqueous layer was extracted with EtOAc. The combined organic layers 
were then dried over MgSO4. Following filtration, the solvent was removed under 
reduced pressure. Crude product was purified via automated silica gel flash 
chromatography. Product containing fractions were combined and the solvents removed 
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under reduced pressure to obtain 350 mg of product (83% yield). TLC Rf = 0.69 
(hexane/ethyl acetate 1:1, UV-Vis). 
1
H NMR (~1:1 rotamer ratio, asterisk denotes 
rotamer peak, 400.1 MHz, CDCl3) δ (ppm): 7.75-7.18 (m, 4H); 4.80*, 4.72* (s, 2H); 
4.28-4.03 (m, 2H); 3.45*, 3.31* (q, J = 7.3 Hz, 2H); 2.87-2.30 (m, 3H); 1.94-1.51 (m, 
4H); 1.46*, 1.43* (s, 9H); 1.18*, 1.13* (t, J = 7.1 Hz, 3H). 
13
C NMR (~1:1 rotamer ratio, 
asterisk denotes rotamer peak, 100.6 MHz, CDCl3) δ (ppm): 175.15, 154.83*, 154.76*, 
136.76*, 136.39*, 132.67*, 132.30*, 128.30 (q, JCF = 30.7 Hz), 128.11*, 127.77*, 
127.15*, 126.65*, 126.62*, 125.97* (q, JCF = 5.4 Hz), 124.44*, 124.50* (q, JCF = 273.5 
Hz), 79.77*, 79.65*, 46.98*, 44.02*, 43.39; 42.05*, 41.88*, 39.20*, 38.87*, 28.93*, 
28.65*, 28.58*, 28.55*, 14.53*, 12.79*. LCMS (215 nM) RT = 0.69 min (>98%); m/z 359 
[M+H]
 +
, minus t-butyl. HRMS (TOF, ES+) C21H30N2O3F3 [M+H]
+
 calc. mass 415.2209, 
found 415.2207. 
4.160. N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide HCl. 
tert-butyl 4-(ethyl(2-(trifluoromethyl)benzyl)carbamoyl)piperidine-1-carboxylate (297 
mg, 0.717 mmol, 1.0 eq.) was dissolved neat in 4N HCl/dioxane. The reaction was 
magnetically stirred at ambient temperature for 1 hour. Solvent was then removed under 
reduced pressure to obtain 247 mg of product (98% yield). TLC Rf = 0.01 (hexane/ethyl 
acetate 1:1, p-anisaldehyde stain). 
1
H NMR (~2.5:1 rotamer ratio, asterisk denotes minor 
rotamer peaks, 400.1 MHz, MeOD) δ (ppm): 7.82-7.22 (m, 4H); 4.88*, 4.79 (s, 2H); 
3.54-3.36 (m, 4H); 3.25-3.11 (m, 2H); 3.01-2.82 (m, 1H); 2.14-1.86 (m, 4H); 1.22, 1.12* 
(t, J = 7.2 Hz, 3H). 
13
C NMR (2.5:1 rotamer ratio, asterisk denotes minor rotamer peaks, 
100.6 MHz, MeOD) δ (ppm): 176.09, 175.85*, 137.17, 137.07*, 134.08*, 133.61, 
129.21*, 128.96 (q, JCF = 30.7 Hz), 128.77, 128.58, 128.40*, 127.6*, 127.13 (q, JCF = 5.6 
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Hz), 126.10 (q, JCF = 272.6 Hz), 126.02*, 45.93*, 45.89, 44.28, 44.12*, 43.83, 42.98*, 
37.20*, 36.88, 26.94, 26.70*, 14.62, 12.63*. LCMS (215 nm) RT = 0.86 min (>98%); m/z 
315 [M+H]
 +
. HRMS (TOF, ES+) C16H22N2OF3 [M+H]
+
 calc. mass 315.1684, found 
315.1682. 
4.161 (VU0481443, ML380). 1-((1H-indazol-5-yl)sulfonyl)-N-ethyl-N-(2-
(trifluoromethyl)benzyl)piperidine-4-carboxamide. To a solution of N-ethyl-N-(2-
(trifluoromethyl)benzyl)piperidine-4-carboxamide HCl (20 mg, 0.063 mmol, 1.0 eq.) and 
DIPEA (33 μL, 0.196 mmol, 2.0 eq.) in DCM (0.7 mL, 0.1 M) was added 1H-indazole-5-
sulfonyl chloride (20.5 mg, 0.095 mmol, 1.5 eq.). The reaction was magnetically stirred 
at ambient temperature for 2 hours. The reaction was quenched with MeOH and solvent 
was removed under reduced pressure. Crude product was purified via Gilson preparative 
LC to obtain 4.2 mg pure product (15.3% yield). TLC Rf = 0.35 (hexane/ethyl acetate 
1:1). 
1
H NMR (1.25:1 rotamer ratio, asterisk denotes minor rotamer peak, 400.1 MHz, 
CDCl3) δ (ppm): 8.31 (s, 1H); 8.25 (m, 1H); 7.78, 7.72* (d, J = 8.8 Hz, 1H); 7.68-7.57 
(m, 2H); 7.52*, 7.46 (t, J = 7.6 Hz, 1H); 7.38*, 7.32 (t, J = 7.6 Hz, 1H); 7.21-7.13 (m, 
1H); 4.76, 4.64* (s, 2H); 3.95-3.86, 3.85-3.76* (m, 2H); 3.41*, 3.22 (q, J = 7.2 Hz, 2H); 
2.60-2.46 (m, 2H); 2.37-2.26 (m, 1H); 2.11-1.92 (m, 2H); 1.91-1.81, 1.74-1.65* (m, 2H); 
1.16-1.05 (m, 3H).
 13
C NMR (1.35:1 rotamer ratio, asterisk denotes minor rotamer peak, 
100.6 MHz, CDCl3) δ (ppm): 174.70; 141.40, 141.34*; 136.29, 135.77*; 135.95; 
132.67*, 132.31; 129.31*, 129.19; 127.94, 127.86*; 127.90 (q, J = 30.3 Hz); 126.65 (q, 
JCF = 5.3 Hz); 126.47; 126.26 (q, JCF = 245 Hz); 126.04 (q, J = 5.6 Hz); 122.81, 122.73*; 
122.66; 110.92, 110.89*; 46.94*, 44.23; 45.64, 45.46*; 42.12, 41.87*; 37.96*, 37.68; 
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28.48, 28.27*; 14.44, 12.67*. LCMS (215 nm) RT = 1.11 min (>98%); m/z 495 [M+H]
 +
. 
HRMS (TOF, ES+) C23H26N4O3F3S [M+H]
+
 calc. mass 495.1678, found 495.1679. 
 
M5 NAM chemical experimentals and characterization 
5.1 (VU0352221), 1-(4-fluorobenzoyl)-9b-phenyl-2,3-dihydro-1H-imidazo[2,1-
a]isoindol-5(9bH)-one. To a solution of 9b-phenyl-1, 2, 3, 9b-tetrahydro-5H-
imidazo[2,1-a]isoindol-5-one (20 mg, 0.080 mmol, 1.0 eq.; Bionet, 2M-569S, Batch No. 
26684) and DIPEA (27 μL, 0.160 mmol, 2.0 eq.) in DCM (0.8 mL, 0.1 M) was added 4-
fluorobenzoyl chloride (14 μL, 0.120 mmol, 1.5 eq.). The reaction was magnetically 
stirred at ambient temperature for 2 hours. The reaction was quenched with methanol and 
the organics were concentrated on a heated air-drying block. Crude product was purified 
via Gilson preparative LC. Product containing fractions were combined and the solvents 
removed under reduced pressure to obtain 24.8 mg of product (83% yield). TLC Rf = 0.60 
(hexane/ethyl acetate 1:1). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 8.04 (d, J = 7.4 Hz, 
1H); 7.89-7.86 (m, 1H); 7.64-7.55 (m, 2H); 7.52-7.46 (m, 2H); 7.40-7.34 (m, 3H); 7.25-
7.20 (m, 2H); 7.13-7.06 (m, 2H); 4.35-4.28 (m, 1H); 4.04-3.95 (m, 1H); 3.82-3.76 (m, 
1H); 3.36-3.26 (m, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 172.22, 168.21, 165.12, 
162.62, 146.33, 138.11, 133.32, 132.58 (d, JC-F = 3.2 Hz), 132.09, 130.29, 129.25, 129.20 
(d, J = 3.4 Hz), 128.87, 128.81, 126.07, 123.81, 115.86 (d, J = 22 Hz), 87.74, 52.37, 
39.56. LCMS (214 nM) RT = 1.08 min (>98%); m/z 373 [M+H]
 +
. HRMS (TOF, ES+) 
C23H18N2O2F [M+H]
+
 calc. mass 373.1352, found 373.1349. 
5.14 (VU0478141). 1-(3,4-difluorobenzoyl)-9b-phenyl-2,3-dihydro-1H-
imidazo[2,1-a]isoindol-5(9bH)-one. To a solution of 9b-phenyl-1, 2, 3, 9b-tetrahydro-
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5H-imidazo[2,1-a]isoindol-5-one (15 mg, 0.060 mmol, 1.0 eq.; Bionet, 2M-569S, Batch 
No. 26684) and DIPEA (267 μL, 0.120 mmol, 2.0 eq.) in DCM (0.6 mL, 0.1 M) was 
added 3,4-difluorobenzoyl chloride (11 μL, 0.090 mmol, 1.5 eq.). The reaction was 
magnetically stirred at ambient temperature for 2 hours. The reaction was quenched with 
methanol and the organics were concentrated on a heated air-drying block. Crude product 
was purified via Gilson preparative LC. Product containing fractions were combined and 
the solvents removed under reduced pressure to obtain 13.4 mg of product (57% yield). 
TLC Rf = 0.74 (hexane/ethyl acetate 1:1). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 8.06-
8.00 (m, 1H); 7.91-7.86 (m, 1H); 7.64-7.56 (m, 2H); 7.40-7.31 (m, 4H); 7.25-7.17 (m, 
4H); 4.37-4.29 (m, 1H); 4.03-3.94 (m, 1H); 3.83-3.76 (m, 1H); 3.38-3.28 (m, 1H). 
13
C 
NMR (100.6 MHz, CDCl3) δ (ppm): 172.16, 166.82, 151.72 (dd, JC-F = 253.3 Hz, 12.0 
Hz), 150.35 (dd, JC-F = 251.2 Hz, 13.1 Hz), 146.12, 137.9, 133.37, 133.22 (t, J = 4.6 Hz), 
132.05, 130.40, 129.15, 128.98, 128.87, 126.02, 123.89, 123.58 (dd, J = 7.1 Hz, 4.0 Hz), 
117.90 (d, 17.8 Hz), 116.80 (d, 18.9 Hz), 87.84, 52.32, 39.55. LCMS (214 nM) RT = 1.12 
min (>98%); m/z 391 [M+H]
 +
. HRMS (TOF, ES+) C23H17N2O2F2 [M+H]
+
 calc. mass 
391.1258, found 391.1257. 
5.66 (VU006006). 9b-(4-chlorophenyl)-2,3-dihydro-1H-imidazo[2,1-
a]isoindol-5(9bH)-one. To a mixture of 2-(4-chlorobenzoyl)benzoic acid (5.21 g, 20.0 
mmol, 1 eq.) and ethylenediamine (2.67 mL, 40.0 mmol, 2 eq.) in toluene (30 mL, 0.67 
M) was added p-toluenesulfonic acid monohydrate (~0.1 g, 3 mol%). A Dean-Stark trap 
was used to remove water while the mixture was magnetically stirred and heated to reflux 
for 4 hours. After cooling to ambient temperature, the reaction mixture was dissolved in 
dichloromethane. The organic layer was washed with a saturated aqueous solution of 
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sodium bicarbonate and then with brine. Solvent was removed under reduced pressure 
and the crude product was recrystallized from ethanol to give 2.86 g of pure product 
(50.2% yield). TLC Rf = 0.38 (hexane/ethyl acetate 1:1). 
1
H NMR (400.1 MHz, CDCl3) δ 
(ppm): 7.81-7.76 (m, 1H); 7.66-7.60 (m, 2H); 7.49-7.44 (m, 2H); 7.34-7.30 (m, 2H); 
7.28-7.23 (m, 1H); 3.85-3.77 (m, 1H); 3.70-3.62 (m, 1H); 3.28-3.13 (m, 2H); 2.10-2.02 
(m, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 172.65, 147.54, 137.74, 134.44, 
132.94, 131.79, 130.01, 129.03, 127.91, 124.60, 123.40, 89.25, 50.83, 41.85. LCMS (214 
nM) RT = 0.837 min (>98%); m/z 285 [M+H]
 +
. HRMS (TOF, ES+) C16H14N2OCl 
[M+H]
+
 calc. mass 285.0795, found 285.0794. 
5.67 (VU0331642). 9b-(4-fluorophenyl)-2,3-dihydro-1H-imidazo[2,1-
a]isoindol-5(9bH)-one. To a mixture of 2-(4-fluorobenzoyl)benzoic acid (2.44 g, 10.0 
mmol, 1 eq.) and ethylenediamine (1.34 mL, 20.0 mmol, 2 eq.) in toluene (15 mL, 0.67 
M) was added p-toluenesulfonic acid monohydrate (~0.5 g, 3 mol%). A Dean-Stark trap 
was used to remove water while the mixture was magnetically stirred and heated to reflux 
for 4 hours. After cooling to ambient temperature, the reaction mixture was dissolved in 
dichloromethane. The organic layer was washed with a saturated aqueous solution of 
sodium bicarbonate and then with brine. Solvent was removed under reduced pressure 
and the crude product was recrystallized from ethanol to give 1.49 g of pure product 
(55.5% yield). TLC Rf = 0.40 (hexane/ethyl acetate 1:1). 
1
H NMR (400.1 MHz, CDCl3) δ 
(ppm): 7.81-7.75 (m, 1H); 7.70-7.63 (m, 2H); 7.50-7.43 (m, 2H); 7.29-7.24 (m, 1H); 
7.06-6.70 (m, 2H); 3.85-3.78 (m, 1H); 3.69-3.62 (m, 1H); 3.28-3.13 (m, 2H); 2.14-1.97 
(br, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 172.65, 164.18, 161.73, 147.81, 134.80 
(d, JC-F = 28 Hz), 132.90, 131.76, 129.92, 128.24 (d, J = 8.29 Hz), 124.56, 123.40, 
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115.69 (d, J = 21.63 Hz), 89.29, 50.82, 41.82. LCMS (214 nM) RT = 0.766 min (>98%); 
m/z 269 [M+H]
 +
. HRMS (TOF, ES+) C16H14N2OF [M+H]
+
 calc. mass 269.1090, found 
269.1089. 
5.68 (VU0478193). 9b-(p-tolyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-
5(9bH)-one. To a mixture of 2-(4-methylbenzoyl)benzoic acid (4.81 g, 20.0 mmol, 1 eq.) 
and ethylenediamine (2.67 mL, 40.0 mmol, 2 eq.) in toluene (30 mL, 0.67 M) was added 
p-toluenesulfonic acid monohydrate (~0.1 g, 3 mol%). A Dean-Stark trap was used to 
remove water while the mixture was magnetically stirred and heated to reflux for 4 hours. 
After cooling to ambient temperature, the reaction mixture was dissolved in 
dichloromethane. The organic layer was washed with a saturated aqueous solution of 
sodium bicarbonate and then with brine. Solvent was removed under reduced pressure 
and the crude product was recrystallized from ethanol to give 2.88 g of pure product 
(54.5% yield). TLC Rf = 0.38 (hexane/ethyl acetate 1:1). 
1
H NMR (400.1 MHz, CDCl3) δ 
(ppm): 7.81-7.74 (m, 1H); 7.57 (d, J = 7.93 Hz, 2H); 7.48-7.41 (m, 2H); 7.33-7.27 (m, 
1H); 7.16 (d, J = 7.93 Hz, 2H); 3.86-3.77 (m, 1H); 3.68-3.59 (m, 1H); 3.33-3.13 (m, 2H); 
2.34 (s, 3H); 2.04 (br, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 172.66, 148.14, 
138.25, 136.00, 132.77, 131.86, 129.70, 129.54, 126.22, 124.42, 123.43, 89.58, 50.84, 
41.76, 21.23. LCMS (214 nM) RT = 0.741 min (>98%); m/z 265 [M+H]
 +
. HRMS (TOF, 
ES+) C17H17N2O [M+H]
+
 calc. mass 265.1341, found 265.1340. 
5.76 (VU0326724). 9b-(4-chlorophenyl)-1-(4-fluorobenzoyl)-2,3-dihydro-1H-
imidazo[2,1-a]isoindol-5(9bH)-one. To a solution of 9b-(4-chlorophenyl)-2,3-dihydro-
1H-imidazo[2,1-a]isoindol-5(9bH)-one (15 mg, 0.053 mmol, 1.0 eq.) and DIPEA (18 μL, 
0.105 mmol, 2.0 eq.) in DCM (0.53 mL, 0.1 M) was added 4-fluorobenzoyl chloride (9.5 
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μL, 0.079 mmol, 1.5 eq.). The reaction was magnetically stirred at ambient temperature 
for 2 hours. The reaction was quenched with methanol and the organics were 
concentrated on a heated air-drying block. Crude product was purified via Gilson 
preparative LC. Product containing fractions were combined and the solvents removed 
under reduced pressure to obtain 12.5 mg of product (58.0 % yield). TLC Rf = 0.69 
(hexane/ethyl acetate 1:1). 
1H NMR (400.1 MHz, MeOD) δ (ppm): 7.87-7.81 (m, 3H); 
7.65-7.54 (m, 2H); 7.45-7.41 (m, 2H); 7.39-7.35 (m, 2H); 7.34-7.31 (m, 1H); 7.24-7.12 
(m, 2H); 3.92-3.83 (m, 1H); 3.74-3.66 (m, 1H); 3.54-3.46 (m, 1H); 3.32-3.25 (m, 1H). 
13C NMR (100.6 MHz, MeOD) δ (ppm): 170.48, 169.18, 167.45, 164.96, 150.86, 139.49, 
135.51, 134.31, 131.79 (d, JC-F = 2.4 Hz), 131.37, 130.90, 130.81, 130.74, 129.80, 
129.05, 123.99 (d, J = 5.7 Hz), 116.46, 116.24, 92.45, 40.69, 39.87. LCMS (214 nM) RT 
= 1.205 min (>98%); m/z 407 [M+H]
 +
. HRMS (TOF, ES+) C23H17N2O2FCl [M+H]
+
 
calc. mass 407.0963, found 407.0964.  
5.78 (VU0478333). 9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-
1H-imidazo[2,1-a]isoindol-5(9bH)-one. To a solution of 9b-(4-chlorophenyl)-2,3-
dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (15 mg, 0.053 mmol, 1.0 eq.) and DIPEA 
(18 μL, 0.105 mmol, 2.0 eq.) in DCM (0.53 mL, 0.1 M) was added 3,4-difluorobenzoyl 
chloride (9.9 μL, 0.079 mmol, 1.5 eq.). The reaction was magnetically stirred at ambient 
temperature for 2 hours. The reaction was quenched with methanol and the organics were 
concentrated on a heated air-drying block. Crude product was purified via Gilson 
preparative LC. Product containing fractions were combined and the solvents removed 
under reduced pressure to obtain 12.0 mg of product (53.3 % yield). TLC Rf = 0.71 
(hexane/ethyl acetate 1:1). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 8.03-8.00 (m, 1H); 
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7.90-7.86 (m, 1H); 7.65-7.57 (m, 2H); 7.37-7.31 (m, 3H); 7.25-7.19 (m, 2H); 7.19-7.14 
(m, 2H); 4.37-4.31 (m, 1H); 4.02-3.93 (m, 1H); 3.82-3.75 (m, 1H); 3.42-3.25 (m, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 172.08, 166.85, 151.87 (dd, JC-F = 254 Hz, 12.4 
Hz), 150.34 (dd, JC-F = 252 Hz, 12.9 Hz) 145.77, 136.65, 134.94, 133.56, 132.95 (t, J = 
4.5 Hz), 131.89, 130.61, 129.06, 128.97, 127.53, 124.04, 123.62 (dd, J1 = 6.8 Hz, 3.9 
Hz), 117.94 (d, J = 17.9 Hz), 116.3 (d, J = 18.5 Hz), 87.37, 52.25, 39.70. LCMS (214 
nM) RT = 1.189 min (>98%); m/z 425 [M+H]
 +
. HRMS (TOF, ES+) C23H17N2O2F2Cl 
[M+H]
+
 calc. mass 425.0868, found 425.0869.  
5.97 (VU0483253, ML375). (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-
2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one. From 5.78, the second eluting 
pure enantiomer was separated via CO2 supercritical fluid chromatography (Lux 
cellulose-3 10 x 250 mm column at 40 °C, backpressure regulated at 100 bar, MeOH co-
solvent, 10% isocratic prep over 7 minutes at 15 mL/min) and was determined to have an 
ee of >98% by chiral HPLC analysis (Lux cellulose-3 4.6 x 250 mm column at 40 °C, 
backpressure regulated at 100 bar, MeOH co-solvent, 5-50% over 7 minutes at 3.5 
mL/min). Crystals of pure compound were obtained by allowing a solution of MeOH 
saturated with pure compound to rest in a scored flask, for 5 hours. An x-ray crystal 
structure was determined using an Agilent Xcalibur PX II diffractometer employing an 
Enhance (Cu) X-ray source. 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 8.04-7.99 (m, 1H); 
7.90-7.85 (m, 1H); 7.65-7.56 (m, 2H); 7.38-7.30 (m, 3H); 7.25-7.19 (m, 2H); 7.18-7.14 
(m, 2H); 4.38-4.30 (m, 1H); 4.01-3.93 (m, 1H); 3.82-3.75 (m, 1H); 3.34-3.25 (m, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 172.07, 166.84, 151.81 (dd, JC=F = 254 Hz, 12.7 
Hz), 150.33 (dd, JC-F = 252 Hz, 13 Hz) 145.77, 136.65, 134.94, 133.55, 132.91 (t, J = 4.8 
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Hz), 131.88, 130.61, 129.06, 128.97, 127.53, 124.03, 123.62 (dd, J = 6.8 Hz, 4 Hz), 
117.94 (d, J = 17 Hz), 116.83 (d, J = 18 Hz), 87.37, 52.24, 39.70. SFC (214 nM) RT = 
3.591 min (>98%). HRMS (TOF, ES+) C23H16N2O2F2Cl [M+H]
+
 calc. mass 425.0868, 
found 425.0872. Specific rotation [α] 
  
 
 = -168.6° (c = 0.75, CHCl3). 
5.98 (VU0483252). (R)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-
dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one. From 5.78, the first eluting pure 
enantiomer was separated via CO2 supercritical fluid chromatography (Lux cellulose-3 10 
x 250 mm column at 40 °C, backpressure regulated at 100 bar, MeOH co-solvent, 10% 
isocratic prep over 7 minutes at 15 mL/min) and was determined to have an ee of >98% 
by chiral HPLC analysis (Lux cellulose-3 4.6 x 250 mm column at 40 °C, backpressure 
regulated at 100 bar, MeOH co-solvent, 5-50% over 7 minutes at 3.5 mL/min). 
1
H NMR 
(400.1 MHz, CDCl3) δ (ppm): 8.03-7.99 (m, 1H); 7.89-7.86 (m, 1H); 7.65-7.57 (m, 2H); 
7.37-7.31 (m, 3H); 7.25-7.19 (m, 2H); 7.18-7.14 (m, 2H); 4.38-4.31 (m, 1H); 4.01-3.94 
(m, 1H); 3.82-3.75 (m, 1H); 3.34-3.25 (m, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 
172.07, 166.84, 151.80 (dd, JC-F = 254 Hz, 12.3 Hz), 150.33 (dd, JC-F = 252 Hz, 12.8 Hz) 
145.76, 136.65, 134.93, 133.55, 132.91 (t, J = 4.5 Hz), 131.88, 130.60, 129.05, 128.97, 
127.53, 124.03, 123.63 (dd, J = 6.7 Hz, 4 Hz), 117.94 (d, J = 17.7 Hz), 116.82 (d, J = 
18.8 Hz), 87.37, 52.24, 39.70. SFC (214 nM) RT = 3.187 min (>98%). HRMS (TOF, 
ES+) C23H16N2O2F2Cl [M+H]
+
 calc. mass 425.0868, found 425.0870. Specific rotation 
[α] 
  
 
 = +167.2° (c = 0.87, CHCl3). 
5.99 (VU0485459). 10b-(4-chlorophenyl)-1,3,4,10b-tetrahydropyrimido[2,1-
a]isoindol-6(2H)-one. To a solution of 2-(4-chlorobenzoyl)benzoic acid (4.81 g, 20.0 
mmol, 1 eq.) and 1,3-diaminopropane (3.33 mL, 40.0 mmol, 2 eq.) in toluene (30 mL, 
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0.67 M) was added p-toluenesulfonic acid monohydrate (~0.1 g, 3 mol%). A Dean-Stark 
trap was used to remove water while the mixture was magnetically stirred and heated to 
reflux for 3 hours. After cooling to ambient temperature, a precipitate was isolated via 
vacuum filtration. The precipitate was then recrystallized from ethanol to give 3.75 g of 
pure product (62.8% yield). TLC Rf = 0.48 (hexane/ethyl acetate 1:1). 
1
H NMR (400.1 
MHz, CDCl3) δ (ppm): 7.88-7.82 (m, 1H); 7.52 (d, J = 8.6 Hz, 2H); 7.46-7.40 (m, 2H); 
7.34 (d, J = 8.8 Hz, 2H); 7.30-7.25 (m, 1H); 4.57-4.50 (m, 1H); 3.11-3.01 (m, 2H); 2.98-
2.85 (m, 1H); 1.84-1.67 (m, 1H); 1.59-1.51 (m, 1H). 
13
C NMR (100.6 MHz, CDCl3) δ 
(ppm): 166.64, 148.96, 137.24, 134.26, 132.23, 130.52, 129.54, 129.34, 128.33, 124.07, 
122.56, 78.74, 40.81, 36.83, 26.67. LCMS (214 nM) RT = 0.83 min (>98%); m/z 299 
[M+H]
 +
. HRMS (TOF, ES+) C17H16N2OCl [M+H]
+
 calc. mass 299.0951, found 
299.0950. 
5.106 (VU0478894). 10b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-1,3,4,10b-
tetrahydropyrimido[2,1-a]isoindol-6(2H)-one. To a solution of 10b-(4-chlorophenyl)-
1,3,4,10b-tetrahydropyrimido[2,1-a]isoindol-6(2H)-one (20 mg, 0.067 mmol, 1.0 eq.) and 
DIPEA (23 μL, 0.134 mmol, 2.0 eq.) in DCM (0.7 mL, 0.1 M) was added 3,4-
difluorobenzoyl chloride (13 μL, 0.101 mmol, 1.5 eq.). The reaction was magnetically 
stirred at ambient temperature for 2 hours. The reaction was quenched with methanol and 
the organics were concentrated on a heated air-drying block. Crude product was purified 
via Gilson preparative LC. Product containing fractions were combined and the solvents 
removed under reduced pressure to obtain 17.8 mg of product (60.5 % yield). TLC Rf = 
0.59 (hexane/ethyl acetate 1:1). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 7.95-7.87 (m, 
2H); 7.77-7.73 (m, 1H); 7.51-7.43 (m, 2H); 7.40-7.31 (m, 3H); 7.30-7.17 (m, 3H); 4.58-
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4.49 (m, 1H); 3.64-3.48 (m, 2H); 3.06-2.96 (m, 1H); 2.01-1.89 (m, 1H); 1.87-1.76 (m, 
1H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 170.44, 167.66, 152.14 (dd, JC-F = 254.7 
Hz, 12.6 Hz), 150.41 (dd, JC-F = 251.5 Hz, 12.6 Hz), 146.37, 136.06, 134.81, 132.81 (t, J 
= 4.5 Hz), 132.14, 130.60, 129.59, 127.84, 127.70, 124.40 (dd, J = 6.9 Hz, 3.9 Hz), 
123.65, 117.91 (d, J = 17.9 Hz), 117.70 (d, J = 18.1 Hz), 117.57 (d, J = 18.3 Hz), 81.89, 
45.87, 34.60, 24.18. LCMS (214 nM) RT = 1.18 min (>98%); m/z 372 [M+H]
 +
. HRMS 
(TOF, ES+) C24H18N2O2F2Cl [M+H]
+
 calc. mass 439.1025, found 439.1022. 
5.111 (VU0481528). 9b-phenyl-2,3-dihydro-1H-imidazo[1',2':1,5]pyrrolo[3,4-
b]pyridin-5(9bH)-one. To a mixture of 3-benzoylpicolinic acid (500 mg, 2.20 mmol, 1 
eq.) and ethylenediamine (294 μL, 4.40 mmol, 2 eq.) in toluene (10 mL, 0.2 M) was 
added p-toluenesulfonic acid monohydrate (~12 mg, 3 mol%). A Dean-Stark trap was 
used to remove water while the mixture was magnetically stirred and heated to reflux for 
2 hours. After cooling to ambient temperature, the reaction mixture was made basic with 
aqueous 1N NaOH. The organic layer was then separated and the aqueous layer was 
extracted with dichloromethane. The organic layers were then combined, washed with 
brine, and dried over magnesium sulfate. After filtration, the solvent was removed under 
reduced pressure and 378 mg of crude product was carried forward without purification 
(68% crude yield). TLC Rf = 0.65 (hexane/ethyl acetate 1:1). 
1
H NMR (400.1 MHz, 
CDCl3) δ (ppm): 8.76-8.71 (m, 1H); 7.69-7.64 (m, 3H); 7.39-7.29 (m, 4H); 3.95-3.86 (m, 
1H); 3.74-3.65 (m, 1H); 3.32-3.20 (m, 1H), 2.18 (br, 1H). 
13
C NMR (100.6 MHz, CDCl3) 
δ (ppm): 170.12, 152.40, 150.16, 142.35, 138.00, 131.71, 129.06, 128.86, 126.19, 126.12, 
87.48, 50.67, 41.95. LCMS (214 nM) RT = 0.61 min (>98%); m/z 252 [M+H]
 +
. HRMS 
(TOF, ES+) C15H14N3O [M+H]
+
 calc. mass 252.1137, found 252.1137. 
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5.117 (VU0481760). 1-(3,4-difluorobenzoyl)-9b-phenyl-2,3-dihydro-1H-
imidazo[1',2':1,5]pyrrolo[3,4-b]pyridin-5(9bH)-one. To a solution of 9b-phenyl-2,3-
dihydro-1H-imidazo[1',2':1,5]pyrrolo[3,4-b]pyridin-5(9bH)-one (20 mg, 0.080 mmol, 1.0 
eq.) and DIPEA (27 μL, 0.160 mmol, 2.0 eq.) in DCM (0.8 mL, 0.1 M) was added 3,4-
difluorobenzoyl chloride (15 μL, 0.120 mmol, 1.5 eq.). The reaction was magnetically 
stirred at ambient temperature for 2 hours. The reaction was quenched with methanol and 
the organics were concentrated on a heated air-drying block. Crude product was purified 
via Gilson preparative LC. Product containing fractions were combined and the solvents 
removed under reduced pressure to obtain 9.7 mg of product (31.0 % yield). TLC Rf = 
0.25 (hexane/ethyl acetate 1:1). 
1
H NMR (400.1 MHz, CDCl3) δ (ppm): 8.88-8.85 (m, 
1H); 8.39-8.36 (m, 1H); 7.48 (dd, J1 = 7.8 Hz, J2 = 4.8 Hz, 1H); 7.42-7.33 (m, 5H); 7.29-
7.21 (m, 3H); 4.47-4.40 (m, 1H); 4.07-3.99 (m, 1H); 3.86-3.80 (m, 1H); 3.43-3.34 (m, 
1H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 169.69, 167.10, 153.06, 151.72 (dd, JC-F = 
231.5 Hz, 12.0 Hz), 150.39 (dd, JC-F = 252.0 Hz, 12.7 Hz), 149.89, 141.05, 137.55, 
136.76, 132.64 (t, J = 4.5 Hz), 129.40, 129.17, 126.59, 125.91, 123.51 (dd, J = 6.7 Hz, 4 
Hz), 118.05 (d, J = 17.8 Hz), 116.77 (d, J = 18.7 Hz), 85.87, 52.11, 39.64. LCMS (214 
nM) RT = 0.98 min (>98%); m/z 392 [M+H]
 +
. HRMS (TOF, ES+) C22H16N3O2F2 [M+H]
+
 
calc. mass 392.1211, found 392.1210. 
 
M5 orthosteric antagonist chemical experimentals and characterization 
6.1 (VU0480131). 5-((3-acetylphenoxy)methyl)-N-methyl-N-(1-(pyridin-2-
yl)ethyl)isoxazole-3-carboxamide. To a solution of 5-((3-
acetylphenoxy)methyl)isoxazole-3-carboxylic acid (20 mg, 0.077 mmol, 1 eq.; Enamine, 
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BBV-32990746, Lot No. R36151), N-methyl-1-(pyridin-2-yl)ethanamine (12.5 mg, 0.092 
mmol, 1.2 eq.; ChemBridge, 4102794, Batch # 02), and DIPEA (26.4 μL, 0.154 mmol, 2 
eq.) in DCM (0.8 mL, 0.1 M) was added HATU (43.9 mg, 0.116 mmol, 1.5 eq). The 
reaction was magnetically stirred at ambient temperature for 2 hours. The reaction 
mixture was quenched with aqueous NaHCO3 and the organic layer was separated. The 
aqueous layer was extracted with DCM and the combined organic layers were dried over 
MgSO4. After filtration, the solvent was removed under reduced pressure. The crude 
product was purified via Gilson preparative LC to obtain 24.9 mg pure product (85% 
yield). TLC Rf = 0.21 (hexane/ethyl acetate 1:1). 
1
H NMR (~1:1 rotamer ratio, asterisk 
denotes rotamer peak, 500.1 MHz, MeOD) δ (ppm): 8.58-8.49 (m, 1H); 7.88-7.77 (m, 
1H); 7.66-7.53 (m, 2H); 7.50-7.23 (m, 4H); 6.79*, 6.77* (s, 1H); 5.94*, 5.50* (q, J = 6.7 
Hz, 1H); 5.34 (s, 2H); 3.00*, 2.82* (s, 3H); 2.57*, 2.56* (s, 3H), 1.70-1.65 (m, 3H). 
13
C 
NMR (~1:1 rotamer ratio, asterisk denotes rotamer peak, 125.8 MHz, MeOD) δ (ppm): 
199.76, 170.14*, 169.98*, 163.40*, 163.13*, 160.27*, 160.20*, 159.96*, 159.63*, 
159.43*, 159.39*, 150.08*, 149.76*, 139.82, 139.13*, 138.78*, 131.07, 124.20, 123.76, 
123.28, 123.17, 121.23*, 121.16*, 114.90*, 114.89*, 105.46*, 105.34*, 61.89*, 61.86*, 
59.40*, 55.34*, 32.73*, 28.99*, 26.83, 16.89*, 15.75*. LCMS (215 nM) RT = 0.84 min 
(>98%); m/z 380 [M+H]
 +
. HRMS (TOF, ES+) C21H22N3O4 [M+H]
+
 calc. mass 380.1610, 
found 380.1613. 
6.89. (R)-2-nitro-N-(1-(pyridin-2-yl)ethyl)benzenesulfonamide. To a solution 
of (R)-1-(pyridin-2-yl)ethanamine (200 mg, 1.64 mmol, 1 eq.; Ark Pharm, Inc., AK-
37082, Lot No. WZG111226-023A) and DIPEA (422 μL, 2.46 mmol, 1.5 eq.) in DCM (5 
mL, 0.33 M) was added nitrobenzenesulfonyl chloride (435 mg, 1.96 mmol, 1.2 eq.). The 
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reaction was magnetically stirred at ambient temperature for 1 hour. The reaction was 
quenched with aqueous NaHCO3 and the organic phase was separated. The aqueous layer 
was extracted with DCM and the combined organic layers were dried over MgSO4. After 
filtration, the solvent was removed under reduced pressure. The crude product was 
purified via silica gel column chromatography to obtain 459.2 mg of product (91% yield). 
TLC Rf = 0.33 (hexane/ethyl acetate 1:1). 
1
H NMR (~1:1 rotamer ratio, asterisk denotes 
rotamer peak, 400.1 MHz, CDCl3) δ (ppm): 8.31 (d, J = 4.6 Hz, 1H); 7.92*, 7.90* (d, J = 
1.4 Hz, 1H); 7.79*, 7.77* (d, J = 1.1 Hz, 1H); 7.61-7.50 (m, 3H); 7.16*, 7.14* (s, 1H); 
7.06*, 7.04* (d, J = 4.9 Hz, 1H); 6.75 (d, J = 7.7 Hz, 1H); 4.75 (quin, J = 7.2 Hz, 1H), 
1.52 (d, J = 6.8 Hz, 3H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 159.67, 149.16, 147.84, 
137.24, 134.96, 133.40, 132.92, 130.89, 125.52, 122.91, 121.38, 55.28, 23.75. LCMS 
(215 nM) RT = 0.67 min (>98%); m/z 308 [M+H]
 +
. HRMS (TOF, ES+) C13H14N3O4S 
[M+H]
+
 calc. mass 308.0705, found 308.0708. Specific rotation [α] 
  
 
 = 169.0° (c = 0.83, 
CHCl3). 
6.90. (S)-2-nitro-N-(1-(pyridin-2-yl)ethyl)benzenesulfonamide. To a solution 
of (S)-1-(pyridin-2-yl)ethanamine (500 mg, 4.09 mmol, 1 eq.; Ark Pharm, Inc., AK-
37110, Lot No. WZG120207-006) and DIPEA (1.05 mL, 6.14 mmol, 1.5 eq.) in DCM 
(10 mL, 0.41 M) was added nitrobenzenesulfonyl chloride (1.09 g, 4.91 mmol, 1.2 eq.). 
The reaction was magnetically stirred at ambient temperature for 1 hour. The reaction 
was quenched with aqueous NaHCO3 and the organic phase was separated. The aqueous 
layer was extracted with DCM and the combined organic layers were dried over MgSO4. 
After filtration, the solvent was removed under reduced pressure. The crude product was 
purified via silica gel column chromatography to obtain 974 mg of product (78% yield). 
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TLC Rf = 0.33 (hexane/ethyl acetate 1:1). 
1
H NMR (~1:1 rotamer ratio, asterisk denotes 
rotamer peak, 400.1 MHz, CDCl3) δ (ppm): 8.31 (d, J = 4.6 Hz, 1H); 7.92*, 7.90* (d, J = 
1.4 Hz, 1H); 7.79*, 7.77* (d, J = 1.1 Hz, 1H); 7.61-7.50 (m, 3H); 7.15*, 7.13* (s, 1H); 
7.06*, 7.04* (d, J = 4.9 Hz, 1H); 6.75 (d, J = 7.7 Hz, 1H); 4.75 (quin, J = 7.2 Hz, 1H), 
1.52 (d, J = 6.8 Hz, 3H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 159.67, 149.12, 147.84, 
137.29, 134.95, 133.40, 132.93, 130.90, 125.52, 122.93, 121.40, 55.26, 23.74. LCMS 
(215 nM) RT = 0.62 min (>98%); m/z 308 [M+H]
 +
. HRMS (TOF, ES+) C13H14N3O4S 
[M+H]
+
 calc. mass 308.0705, found 308.0707. Specific rotation [α] 
  
 
 = -160.0° (c = 
0.79, CHCl3). 
6.91. (R)-N-methyl-2-nitro-N-(1-(pyridin-2-yl)ethyl)benzenesulfonamide. To a 
solution of (R)-2-nitro-N-(1-(pyridin-2-yl)ethyl)benzenesulfonamide (1.13 g, 3.68 mmol, 
1 eq.), MeOH (223 μL, 5.52 mmol, 1.5 eq.), and PPh3 (1.93 g, 7.36 mmol, 2 eq.) in DCM 
(10 mL, 0.37 M) was added DIAD (1.45 mL, 7.36 mmol, 2 eq). The reaction was 
magnetically stirred at ambient temperature for 1 hour. The reaction was diluted with 
DCM and washed with aqueous 1N HCl and brine. The organic layer was separated and 
dried over MgSO4. After filtration, the solvent was removed under reduced pressure. The 
crude product was purified via silica gel column chromatography to obtain 772 mg of 
product (65% yield). TLC Rf = 0.55 (hexane/ethyl acetate 1:1). 
1
H NMR (1:1 rotamer 
ratio, asterisk denotes rotamer peak, 500.1 MHz, CDCl3) δ (ppm): 8.54 (d, J = 4.3 Hz, 
1H); 8.06*, 8.04* (br, 1H), 7.73-7.60 (m, 4H); 7.46*, 7.45* (s, 1H); 7.25-7.20 (m, 1H); 
5.35 (q, J = 6.8 Hz, 1H); 2.85 (s, 3H); 1.57 (d, J = 7.0 Hz, 3H). 
13
C NMR (125.8 MHz, 
CDCl3) δ (ppm): 158.85, 156.71, 148.67, 148.37, 137.83, 133.79, 133.46, 131.96, 131.26, 
124.49, 123.21, 57.12, 29.86, 16.08. LCMS (215 nM) RT = 0.744 min (>98%); m/z 322 
54 
 
[M+H]
 +
. HRMS (TOF, ES+) C14H16N3O4S [M+H]
+
 calc. mass 322.0862, found 
322.0860. Specific rotation [α] 
  
 
 = 48.2° (c = 0.72, CHCl3). 
6.92. (S)-N-methyl-2-nitro-N-(1-(pyridin-2-yl)ethyl)benzenesulfonamide. To a 
solution of (S)-2-nitro-N-(1-(pyridin-2-yl)ethyl)benzenesulfonamide (970 mg, 3.16 
mmol, 1 eq.), MeOH (192 μL, 4.73 mmol, 1.5 eq.), and PPh3 (1.66 g, 6.32 mmol, 2 eq.) 
in DCM (10 mL, 0.30 M) was added DIAD (1.24 mL, 6.32 mmol, 2 eq). The reaction 
was magnetically stirred at ambient temperature for 1 hour. The reaction was diluted with 
DCM and washed with aqueous 1N HCl and brine. The organic layer was separated and 
dried over MgSO4. After filtration, the solvent was removed under reduced pressure. The 
crude product was purified via silica gel column chromatography to obtain 750 mg of 
product (74% yield). TLC Rf = 0.55 (hexane/ethyl acetate 1:1). 
1
H NMR (~1:1 rotamer 
ratio, asterisk denotes rotamer peak, 400.1 MHz, CDCl3) δ (ppm): 8.48 (d, J = 4.3 Hz, 
1H); 8.02*, 8.00* (d, J = 1.8 Hz, 1H), 7.70-7.58 (m, 4H); 7.38*, 7.36* (s, 1H); 7.16*, 
7.14* (d, J = 4.8 Hz, 1H); 5.30 (q, J = 7.0 Hz, 1H); 2.81 (s, 3H); 1.52 (d, J = 7.0 Hz, 3H). 
13
C NMR (100.6 MHz, CDCl3) δ (ppm): 158.64, 148.77, 147.93, 136.79, 133.45, 133.03, 
131.59, 130.71, 124.03, 122.61, 122.46, 56.87, 29.35, 15.63. LCMS (215 nM) RT = 0.72 
min (>98%); m/z 322 [M+H]
 +
. HRMS (TOF, ES+) C14H16N3O4S [M+H]
+
 calc. mass 
322.0862, found 322.0862. Specific rotation [α] 
  
 
 = -76.3° (c = 0.48, CHCl3). 
6.93. (R)-N-methyl-1-(pyridin-2-yl)ethanamine. To a solution of (R)-N-methyl-
2-nitro-N-(1-(pyridin-2-yl)ethyl)benzenesulfonamide (770 mg, 2.40 mmol, 1 eq.) and 
K2CO3 (995 mg, 7.20 mmol, 3 eq.) in acetonitrile (10 mL, 0.24 M) was added 2-
chlorothiophenol (335 μL, 2.88 mmol, 1.2 eq.). The reaction was magnetically stirred at 
ambient temperature for 4 hours. The reaction was quenched with aqueous 1N NaOH and 
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the organic layer was separated. The aqueous layer was extracted with DCM and the 
combined organic layers were washed with brine and dried over MgSO4. After filtration, 
the solvent was removed under reduced pressure. The crude product was purified via 
silica gel column chromatography to obtain 166.4 mg of product (51% yield). TLC Rf = 
0.68 (hexane/ethyl acetate 1:1, ninhydrin stained). 
1
H NMR (500.1 MHz, MeOD) δ 
(ppm): 8.86 (d, J = 4.4 Hz, 1H); 8.47 (t, J = 7.5 Hz, 1H); 8.01 (d, J = 8.1 Hz, 1H); 7.8 (t, 
J = 6.1 Hz, 1H); 4.75 (q, J = 6.6 Hz, 1H); 2.76 (s, 3H); 1.78 (d, J = 6.7 Hz, 3H). 
13
C 
NMR (125.8 MHz, MeOD) δ (ppm): 154.17, 147.82, 144.41, 127.45, 125.89, 58.90, 
32.21, 18.64. HRMS (TOF, ES+) C8H13N2 [M+H]
+
 calc. mass 137.1079, found 137.1077. 
Specific rotation [α] 
  
 
 = 20.5° (c = 0.95, MeOH). 
6.94. (S)-N-methyl-1-(pyridin-2-yl)ethanamine. To a solution of (S)-N-methyl-
2-nitro-N-(1-(pyridin-2-yl)ethyl)benzenesulfonamide (750 mg, 2.33 mmol, 1 eq.) and 
K2CO3 (966 mg, 6.99 mmol, 3 eq.) in acetonitrile (10 mL, 0.23 M) was added 2-
chlorothiophenol (327 μL, 2.8 mmol, 1.2 eq.). The reaction was magnetically stirred at 
ambient temperature for 4 hours. The reaction was quenched with aqueous 1N NaOH and 
the organic layer was separated. The aqueous layer was extracted with DCM and the 
combined organic layers were washed with brine and dried over MgSO4. After filtration, 
the solvent was removed under reduced pressure. The crude product was purified via 
silica gel column chromatography to obtain 62.8 mg of product (20% yield). TLC Rf = 
0.68 (hexane/ethyl acetate 1:1, ninhydrin stained). 
1H NMR (400.1 MHz, MeOD) δ 
(ppm): 8.91 (br, 1H); 8.49 (br, 1H); 8.13 (br, 1H); 7.95 (br, 1H); 4.80 (br, 1H); 2.78 (s, 
3H); 1.83 (br, 3H). 
13C NMR (100.6 MHz, MeOD) δ (ppm): 154.12, 147.85, 146.84, 
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128.70, 127.12, 59.27, 33.24, 19.29. HRMS (TOF, ES+) C8H13N2 [M+H]
+
 calc. mass 
137.1079, found 137.1078. Specific rotation [α] 
  
 
 = -20.3° (c = 0.97, MeOH). 
6.95 (VU0487996). (R)-5-((3-acetylphenoxy)methyl)-N-methyl-N-(1-(pyridin-
2-yl)ethyl)isoxazole-3-carboxamide. To a solution of 5-((3-
acetylphenoxy)methyl)isoxazole-3-carboxylic acid (100 mg, 0.383 mmol, 1 eq.; 
Enamine, BBV-32990746, Lot No. R36151), (R)-N-methyl-1-(pyridin-2-yl)ethanamine 
(62.6 mg, 0.459 mmol, 1.2 eq.), and DIPEA (131.3 μL, 0.766 mmol, 2 eq.) in DCM (1.5 
mL, 0.25 M) was added HATU (218.6 mg, 0.575 mmol, 1.5 eq The reaction was 
magnetically stirred at ambient temperature for 2 hours. The reaction mixture was 
quenched with aqueous NaHCO3 and the organic layer was separated. The aqueous layer 
was extracted with DCM and the combined organic layers were dried over MgSO4. After 
filtration, the solvent was removed under reduced pressure. The crude product was 
purified via Gilson preparative LC to obtain 136.1 mg of product (94% yield). TLC Rf = 
0.27 (hexane/ethyl acetate 1:1). 
1
H NMR (~1:1 rotamer ratio, asterisk denotes rotamer 
peak, 500.1 MHz, CDCl3) δ (ppm): 8.60-8.55 (m, 1H); 7.71-7.64 (m, 1H); 7.59*, 7.58* 
(br, 1H); 7.54 (br, 1H); 7.42-7.31 (m, 2H); 7.24-7.13 (m, 2H); 6.71*, 6.69* (br, 1H); 
6.05*, 5.74* (q, J = 6.7 Hz, 1H); 5.23 (s, 2H); 3.08*, 2.85* (s, 3H); 2.58 (s, 3H), 1.72-
1.64 (m, 3H). 
13
C NMR (~1:1 rotamer ratio, asterisk denotes rotamer peak, 125.8 MHz, 
CDCl3) δ (ppm): 197.59, 167.88*, 167.68*, 161.13*, 160.90*, 159.33*, 159.18*, 
158.91*, 158.80*, 157.98, 149.24*, 148.92*, 138.76, 137.17*, 136.90*, 130.04, 122.98*, 
122.78*, 122.72*, 122.45, 122.16*, 120.30, 113.37*, 113.35*, 105.08*, 105.03*, 61.19*, 
61.14*, 57.87*, 53.77*, 32.06*, 28.70*, 26.81, 16.71*, 15.41*. LCMS (215 nM) RT = 
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0.87 min (>98%); m/z 380 [M+H]
 +
. HRMS (TOF, ES+) C21H22N3O4 [M+H]
+
 calc. mass 
380.1610, found 380.1611. Specific rotation [α] 
  
 
 = 134.8° (c = 0.78, CHCl3). 
6.96 (VU0488130, ML381). (S)-5-((3-acetylphenoxy)methyl)-N-methyl-N-(1-
(pyridin-2-yl)ethyl)isoxazole-3-carboxamide. To a solution of 5-((3-
acetylphenoxy)methyl)isoxazole-3-carboxylic acid (100 mg, 0.383 mmol, 1 eq.; 
Enamine, BBV-32990746, Lot No. R36151), (S)-N-methyl-1-(pyridin-2-yl)ethanamine 
(62.6 mg, 0.459 mmol, 1.2 eq.), and DIPEA (131.3 μL, 0.766 mmol, 2 eq.) in DCM (1.5 
mL, 0.25 M) was added HATU (218.6 mg, 0.575 mmol, 1.5 eq The reaction was 
magnetically stirred at ambient temperature for 2 hours. The reaction mixture was 
quenched with aqueous NaHCO3 and the organic layer was separated. The aqueous layer 
was extracted with DCM and the combined organic layers were dried over MgSO4. After 
filtration, the solvent was removed under reduced pressure. The crude product was 
purified via Gilson preparative LC to obtain 129.3 mg of product (89% yield). TLC Rf = 
0.27 (hexane/ethyl acetate 1:1). 
1
H NMR (~1:1 rotamer ratio, asterisk denotes rotamer 
peak, 400.1 MHz, CDCl3) δ (ppm): 8.59-8.55 (m, 1H); 7.70-7.63 (m, 1H); 7.59*, 7.57* 
(m, 1H); 7.55-7.52 (m, 1H); 7.42-7.31 (m, 2H); 7.23-7.14 (m, 2H); 6.71*, 6.68* (s, 1H); 
6.05*, 5.74* (q, J = 6.9 Hz, 1H); 5.23 (s, 2H); 3.07*, 2.85* (s, 3H); 2.58 (s, 3H), 1.70-
1.64 (m, 3H). 
13
C NMR (~1:1 rotamer ratio, asterisk denotes rotamer peak, 100.6 MHz, 
CDCl3) δ (ppm): 197.59, 167.88*, 167.67*, 161.13*, 160.88*, 159.33*, 159.17*, 
158.96*, 158.79*, 157.97, 149.27*, 149.05*, 138.75, 137.03*, 136.86*, 130.03, 122.91*, 
122.73*, 122.70*, 122.44, 122.13*, 120.29, 113.36*, 113.34*, 105.07*, 105.02*, 61.17*, 
61.12*, 57.87*, 53.73*, 31.98*, 28.69*, 26.80, 16.69*, 15.39*. LCMS (215 nM) RT = 
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0.85 min (>98%); m/z 380 [M+H]
 +
. HRMS (TOF, ES+) C21H22N3O4 [M+H]
+
 calc. mass 
380.1610, found 380.1607. Specific rotation [α] 
  
 
 = -125.8° (c = 0.69, CHCl3). 
 
In vitro pharmacology 
 
Calcium mobilization assays 
All functional cell-based Ca
2+
 mobilization assays were performed on a 
FLEXStation II (Molecular Devices, Sunnyvale, CA) essentially as previously 
described
69,72,73. Initial, single point (10 or 30 μM) characterization of test compounds 
was performed in stable Chinese hamster ovary (CHO) cell lines constitutively 
expressing hM5 receptors. These were plated at 50,000 cells per well in Costar 96-well 
black-walled, TC-treated, clear-bottomed plates (Fisher) in Ham’s F12 medium 
supplemented with 10% FBS and 20 mM HEPES. Cells were incubated overnight at 37 
°C under 5% CO2. The following day, medium was removed and replaced with 50 μL of 
2 μM Fluo-4 AM (Invitrogen) calcium sensitive dye in calcium assay buffer (Hank’s 
Balanced Salt Solution supplemented with 20 mM HEPES and 2.5 mM Probenecid, pH 
7.4) and the cells were then incubated 45 minutes at 37 °C under 5% CO2. Dye was then 
removed and replaced with 45 μL of fresh assay buffer. Test compounds were serially 
diluted into assay buffer at 2X (20 μM) stock concentration in 0.6% dimethylsulfoxide 
(DMSO); stock compounds were added to the assay for a final stock concentration of 10 
or 30 μM and a final DMSO concentration of 0.3%. Acetylcholine (Sigma-Aldrich) was 
serial diluted into assay buffer to 10X submaximal (~EC20 or EC80, determined 
empirically on day of assay) and 10X maximal (10 μM) stock concentrations. After 
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establishing baseline fluorescence, test compounds (45 μL) were added to the cells using 
the FLEXStation II’s integrated pipettor and allowed to equilibrate for 150 seconds 
before addition of acetylcholine (10 μL). Data were obtained as max-min fluorescent 
ratios and then normalized to a percentage of maximal acetylcholine response. The single 
point values represent mean values obtained from at least three independent 
determinations performed in triplicate or greater (error bars represent +/- SEM) unless 
otherwise specified.  
For Ca
2+
 mobilization assays measuring ACh CRC fold shift, CHO cells stably 
expressing hM5 were plated in the manner described above. Test compounds were 
serially diluted into assay buffer to a 2X (20 or 60 μM) stock concentration in 0.6% 
DMSO; stock compounds were added to the assay for a final stock concentration of 10 or 
30 μM and a final DMSO concentration of 0.3%. An eight-point concentration range of 
ACh was serial diluted in assay buffer to 10X final concentration. FLEXStation II 
protocols were carried out as described above; data were obtained as max-min fluorescent 
ratios and then normalized to a percentage of the maximum ACh response. Calculation of 
the ACh EC50 was performed using the curve-fittign software of GraphPad Prism 
(version 5.01). ACh fold shift was calculated as a ratio of ACh EC50 in the presence of 
vehicle to the ACh EC50 in the presence of test compound. Data shown represent mean 
values obtained from at least three independent determinations performed in triplicate or 
greater (error bars represent +/- SEM) unless otherwise specified.  
For selectivity assays, CHO cells stably expressing hM1, hM2/Gqi5, hM3, 
hM4/Gqi5, hM5, rM1, rM2/Gqi5, rM3, rM4/Gqi5, or rM5 were plated in the manner described 
above. An eight-point concentration range of test compound was serial diluted in assay 
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buffer to 2X final concentration and acetylcholine was diluted in assay buffer to 10X 
submaximal (~EC20 or EC80, determined empirically on day of assay) and 10X maximal 
(10 μM for M1-5; 100 μM for M2, M4) stock concentrations. FLEXstation II protocols 
were carried out as described above; data were obtained as max-min fluorescent ratios 
and then normalized to percentage of maximum acetylcholine response. Calculation of 
EC50 or IC50 was performed using the curve-fitting software of GraphPad Prism (version 
5.01). Data shown represent mean values obtained from at least three independent 
determinations performed in triplicate or greater (error bars represent ± SEM) unless 
otherwise specified. 
 
[
3
H]-NMS competition binding 
Membranes were prepared from stable CHO cell lines constitutively expressing 
human M5 receptors according to previously described protocols
69,72,73
. Binding reactions 
were carried out in 2 mL, clear, 96-well, deep well plates (Axygen Scientific) and 
contained 0.3 nM [
3
H]-NMS (PerkinElmer), 10 μg of membrane protein, and an eleven-
point concentration range of test compound or atropine in a total volume of 500 μL assay 
buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4). Nonspecific binding was 
determined in the presence of 10 μM atropine. The KD of [
3
H]-NMS was determined 
empirically to be 0.264 nM. Binding reactions were performed at ambient temperature 
and allowed to incubate for 3 hours on a Lab-Line Titer plate shaker at setting 7 (~750 
rpm). Reactions were terminated by rapid filtration through GF/B glass microfiber filter 
plates (1 μm pore size) using a 96-well Brandel harvester and washed 3X with ice-cold 
harvesting buffer (50 mM Tris-HCl, 0.9% NaCl, pH 7.4). Filter plates were dried 
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overnight and counted in a PerkinElmer TopCount scintillation counter (PerkinElmer 
Life and Analytical Sciences). Actual [
3
H]-NMS concentration was back-calculated after 
counting aliquots of 10X [
3
H]-NMS used in the reaction. For all assays, radioligand 
depletion was kept to approximately 18% or less. Plotting of data and calculation of Ki 
was performed using the curve-fitting software of GraphPad Prism (version 5.01). Data 
shown represent mean values obtained from three independent determinations performed 
using three or more replicates (error bars represent +/- SEM). 
 
[
3
H]-NMS dissociation kinetics 
Membranes were prepared from stable CHO cell lines constitutively expressing 
human M5 receptors cells according to a previously described protocol
69,72,73
. Binding 
reactions were carried out in 2 mL, clear, 96-well, deep well plates (Axygen Scientific) 
and initially contained M5 CHO cell membranes (10 μg ) and a saturating amount (0.3 
nM) of [
3
H]-NMS. Binding was allowed to equilibrate at ambient temperature for 3 hours 
on a Lab-Line Titer plate shaker at setting 7 (~750 rpm). Atropine (10 μM) and either 
vehicle or test compound (10 μM) were then added at various time points over 3.5 hours 
in a final volume of 500 μL. Plate agitation was continued between additions. 
Nonspecific binding was determined in the presence of 10 μM atropine. Reactions were 
terminated by rapid filtration through GF/B glass microfiber filter plates (1 μm pore size) 
using a 96-well Brandel harvester and washed 3X with ice-cold harvesting buffer (50 
mM Tris-HCl, 0.9% NaCl, pH 7.4). Filter plates were dried overnight and counted in a 
PerkinElmer TopCount scintillation counter (PerkinElmer Life and Analytical Sciences). 
Actual [
3
H]-NMS concentration was back-calculated after counting aliquots of 10X [
3
H]-
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NMS used in the reaction. For all assays, radioligand depletion was kept to 
approximately 15% or less. Plotting of data and calculation of t1/2 was performed using 
the curve-fitting software of GraphPad Prism (version 5.01). Data shown represent mean 
values obtained from three independent determinations performed using three or more 
replicates (error bars represent +/- SEM).  
 
Ancillary/off-target screening assays 
 Prior to conducting in vivo experiments, compounds were submitted to Eurofins 
Panlabs Leadprofiling screening panel of 68 GPCRs, ion channels, enzymes, transporters, 
and nuclear hormone receptors. Test compounds (10 μM) were evaluated in competition 
binding assays using standard orthosteric radioligands for each target (n = 2). Results 
were calculated as % inhibition of radioligand binding, with >50% inhibition representing 
significant activity at a given target. 
 
In vitro DMPK 
 
Plasma protein and brain homogenate binding 
Plasma protein and brain homogenate binding measurements were performed 
essentially as previously described
73
. The protein binding of each compound was 
determined in plasma via equilibrium dialysis employing rapid equilibrium dialysis 
(RED) plates (ThermoFisher Scientific, Rochester, NY). Plasma was added to a 96 well 
plate containing test compound and mixed thoroughly for a final compound concentration 
of 5 µM. Subsequently, an aliquot of the plasma-compound mixture was transferred to 
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the cis chamber (red) of the RED plate, with phosphate buffer (25 mM, pH 7.4) in the 
trans chamber. The RED plate was sealed and incubated for 4 hours at 37 °C with 
shaking. At completion, aliquots from each chamber were diluted 1:1 with either plasma 
(cis) or buffer (trans) and transferred to a new 96 well plate, at which time ice-cold 
acetonitrile containing internal standard (50 ng/mL carbamazepine) (2 volumes) was 
added to extract the matrices. The plate was centrifuged (3000 rcf, 10 min) and 
supernatants transferred and diluted 1:1 (supernatant: water) into a new 96 well plate, 
which was then sealed in preparation for LC/MS/MS analysis. Each compound was 
assayed in triplicate within the same 96-well plate. Fraction unbound was determined 
using the following equation: 
plasma
buffer
u
Conc
Conc
f   
A similar approach was used to determine the degree of brain homogenate 
binding, which employed the same methodology and procedure with the following 
modifications: 1) a final compound concentration of 1 µM was used, 2) naïve rat brains 
were homogenized in DPBS (1:3 composition of brain:DPBS, w/w) using a Mini-Bead 
Beater™ machine in order to obtain brain homogenate, which was then utilized in the 
same manner as plasma in the previously described plasma protein binding assay. 
Fraction unbound was determined using the following equations: 
Diluted: 
plasma
buffer
du
Conc
Conc
f ,  
Undiluted: fu = 
   
{(
 
   
)  }    
 , where D = dilution factor 
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Hepatic microsome intrinsic clearance 
The intrinsic clearance of each test compound was determined essentially as 
previously described
73
. Human or rat hepatic microsomes (0.5 mg/mL) and 1 µM test 
compound were incubated in 100 mM potassium phosphate pH 7.4 buffer with 3 mM 
MgCl2 at 37 C with constant shaking. After a 5 min preincubation, the reaction was 
initiated by addition of NADPH (1 mM). At selected time intervals (0, 3, 7, 15, 25, and 
45 min), aliquots were taken and subsequently placed into a 96-well plate containing cold 
acetonitrile with internal standard (50 ng/mL carbamazepine). Plates were then 
centrifuged at 3000 rcf (4 C) for 10 min, and the supernatant was transferred to a 
separate 96-well plate and diluted 1:1 with water for LC/MS/MS analysis. The in vitro 
half-life (T1/2, min, Eq. 1), intrinsic clearance (CLint, mL/min/kg, Eq. 2) and subsequent 
predicted hepatic clearance (CLhep, mL/min/kg, Eq. 3) was determined employing the 
following equations: 
(1) 
k
T
)2ln(
2/1    
where k represents the slope from linear regression analysis of the natural log percent 
remaining of test compound as a function of incubation time. 
(2) 
wtbodykg
livergram
x
livergram
microsomesmg
x
microsomesmg
incubationmL
x
Tvitroin
CL
a2045693.0
2/1
int   
a
scale-up factor: 20 (human) or 45 (rat) 
(3) 
int
int
CLQ
CLQ
CL
h
h
hep


  
where Qh (hepatic blood flow in mL/min/kg) is 21 (human) or 70 (rat). 
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LC/MS/MS bioanalysis of samples from plasma protein/brain homogenate binding and 
hepatic microsome intrinsic clearance assays 
Samples were analyzed essentially as previously described
73
 on a Thermo 
Electron TSQ Quantum Ultra triple quad mass spectrometer (San Jose, CA) via 
electrospray ionization (ESI) with two Themo Electron Accella pumps (San Jose, CA), 
and a Leap Technologies CTC PAL autosampler (Carrboro, NC). Analytes were 
separated by gradient elution on a dual column system with two Thermo Hypersil Gold 
(2.1 x 30 mm, 1.9 µm) columns (San Jose, CA) thermostated at 40 °C. HPLC mobile 
phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in 
acetonitrile. The gradient started at 10% B after a 0.2 min hold and was linearly increased 
to 95% B over 0.8 min; hold at 95% B for 0.2 min; returned to 10% B in 0.1 min. The 
total run time was 1.3 min and the HPLC flow rate was 0.8 mL/min. While pump 1 ran 
the gradient method, pump 2 equilibrated the alternate column isocratically at 10% B. 
Compound optimization, data collection and processing was performed using Thermo 
Electron's QuickQuan software (v2.3) and Xcalibur (v2.0.7 SP1). 
 
Inhibition of cytochrome P450 enzymes 
Cytochrome P450 inhibition studies were performed essentially as previously 
described
73
. A cocktail of substrates for cytochrome P450 enzymes (1A2: Phenacetin, 10 
µM; 2C9: Diclofenac, 5 µM; 2D6: Dextromethorphan, 5 µM; 3A4: Midazolam, 2 µM) 
were mixed for cocktail analysis. The positive control for pan-P450 inhibition 
(miconazole) was included alongside each test compound in analysis. 
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A reaction mixture of 100 mM potassium phosphate buffer, pH 7.4, 0.1 mg/mL 
human liver microsomes (HLM) and Substrate Mix is prepared and aliquoted into a 96-
deepwell block. Test compound and positive control (in duplicate) were then added such 
that the final concentration of test compound ranged from 0.1 – 30 µM. The plate was 
vortexed briefly and then pre-incubated at 37
o 
C while shaking for 15 minutes. The 
reaction was initiated with the addition of NADPH (1 mM final concentration). The 
incubation continued for 8 min and the reaction quenched by 2x volume of cold 
acetonitrile containing internal standard (50 nM carbamazepine). The plate was 
centrifuged for 10 minutes (4000 rcf, 4 °C) and the resulting supernatant diluted 1:1 with 
water for LC/MS/MS analysis. A 12-point standard curve of substrate metabolites (1A2: 
Acetaminophen; 2C9: 4-Hydroxydiclofenac; 2D6: Dextrorphan tartrate; 3A4: 1-
Hydroxymidazolam) over the range of 0.98 nM to 2000 nM was utilized. 
Samples were analyzed via electrospray ionization (ESI) on an AB Sciex API-
4000 (Foster City, CA) triple-quadrupole instrument that was coupled with Shimadzu 
LC-10AD pumps (Columbia, MD) and a Leap Technologies CTC PAL auto-sampler 
(Carrboro, NC). Analytes were separated by gradient elution using a Fortis C18 3.0 x 50 
mm, 3 µm column (Fortis Technologies Ltd, Cheshire, UK) thermostated at 40 °C. HPLC 
mobile phase A was 0.1% formic acid in water (pH unadjusted), mobile phase B was 
0.1% formic acid in acetonitrile (pH unadjusted). The gradient started at 10% B after a 
0.2 min hold and was linearly increased to 90% B over 1.2 min; held at 90% B for 0.1 
min and returned to 10% B in 0.1 min followed by a re-equilibration (0.9 min). The total 
run time was 2.5 min and the HPLC flow rate was 0.5 mL/min. The source temperature 
was set at 500 °C and mass spectral analyses were performed using multiple reaction 
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monitoring (MRM), with transitions specific for each compound utilizing a Turbo-
Ionspray® source in positive ionization mode (5.0 kV spray voltage). 
The IC50 values for each compound were obtained for the individual CYP 
enzymes by quantitating the inhibition of metabolite formation for each probe substrate. 
A 0 µM compound condition (or control) was set to 100% enzymatic activity and the 
effect of increasing test compound concentrations on enzymatic activity could then be 
calculated from the % of control activity. Curves were fitted using XLfit 5.2.2 (four-
parameter logistic model, equation 201) to determine the concentration that produces 
half-maximal inhibition (IC50). 
 
Caco-2/MDCK-MDR1 transwell assays 
Measurements of bidirectional efflux in Caco-2 or MDCK-MDR1 (P-gp) cell 
monolayer transwell assays were performed via contract with Absorption Systems 
(Exton, PA; http://www.absortption.com). 
 
In vivo DMPK 
 
Statement on animal care and use 
All animal study procedures were approved by the Institutional Animal Care and 
Use Committee and were conducted in accordance with the National Institutes of Health 
regulations of animal care covered in Principles of Laboratory Animal Care (National 
Institutes of Health). 
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Pharmacokinetic/plasma-brain level studies in rat 
 Intravenous (IV) pharmacokinetics (PK) of non-isatin M5 PAM compound 4.161 
(VU0481443, ML380) and M5 orthosteric antagonist 6.96 (VU0488130, ML381) were 
obtained via contract with Frontage Laboratories (Exton, PA). Serial sampling of plasma 
(10 time points) following a single intravenous administration (1 mg/kg: formulated at 1 
mg/mL in 10% ethanol, 50% PEG400, 40% saline vehicle) to male Sprague-Dawley rats 
(n = 3). Non-compartmental analysis was performed in order to obtain PK parameters. 
After 24 hours re-administration of the same dose (and formulation) was performed, and 
single time point (0.25 hours post re-administration) samples of plasma and brain were 
collected in order to assess brain distribution (brain:plasma partition coefficient, Kp). 
Rat IV/PO PK of M5 NAM compound 5.97 (VU0483253, ML375) was carried 
out using four male, Sprague Dawley adult rats, each weighing approximately 360 – 380 
grams. Two rats received a single dose (1 mg/kg) of a 1 mg/mL dosing solution (10% 
ethanol, 50% PEG 400, and 40% saline vehicle) of 5.97 administered as an intravenous 
(IV) bolus via a surgically implanted jugular vein catheter. In the other arm of the study, 
two rats received a single dose (10 mg/kg) of a 1 mg/mL dosing solution (0.1% Tween 80 
in 0.5% methyl cellulose) of 5.97 administered orally. Plasma was collected serially at 
0.0333, 0.117, 0.25, 0.5, 1, 2, 4, 7, and 24 hours in the IV arm and at 0.25, 0.5, 1, 2, 4, 7, 
and 24 hours in the PO arm. Plasma samples were prepared in chilled, EDTA-fortified 
tubes by centrifugation (10 minutes; 3000 RCF; 4 °C) of blood samples; brain samples 
(collected after the final time point) were rinsed (cold, phosphate-buffered saline) and 
frozen (dry ice), and all samples were stored (-80 °C) until analysis by LC-MS/MS.  
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On the day of analysis, frozen whole-rat brains were weighed and diluted with 1:3 
(w/w) parts of 70:30 isopropanol:water. The mixture was then subjected to mechanical 
homogenation employing a Mini-Beadbeater™ and 1.0 mm Zirconia/Silica Beads 
(BioSpec Products) followed by centrifugation. The sample extraction of plasma (20 μL) 
or brain homogenate (20 μL) was analyzed by a method based on protein precipitation 
using three volumes of ice-cold acetonitrile containing an internal standard (50 ng/mL 
carbamazepine). The samples were centrifuged (3000 rcf, 5 min) and supernatants 
transferred and diluted 1:1 (supernatant: water) into a new 96 well plate, which was then 
sealed in preparation for LC/MS/MS analysis.  
In vivo samples were analyzed via electrospray ionization (ESI) on an AB Sciex 
API-5500 QTrap (Foster City, CA) instrument that was coupled with Shimadzu LC-
20AD pumps (Columbia, MD) and a Leap Technologies CTC PAL auto-sampler 
(Carrboro, NC). Analytes were separated by gradient elution using a Fortis C18 3.0 x 50 
mm, 3 µm column (Fortis Technologies Ltd, Cheshire, UK) thermostated at 40 °C. HPLC 
mobile phase A was 0.1% formic acid in water (pH unadjusted), mobile phase B was 
0.1% formic acid in acetonitrile (pH unadjusted). The gradient started at 30% B after a 
0.2 min hold and was linearly increased to 90% B over 0.8 min; held at 90% B for 0.5 
min and returned to 30% B in 0.1 min followed by a re-equilibration (0.9 min). The total 
run time was 2.5 min and the HPLC flow rate was 0.5 mL/min. The source temperature 
was set at 500 °C and mass spectral analyses were performed using MRM, with 
transitions specific for each compound utilizing a Turbo-Ionspray® source in positive 
ionization mode (5.0 kV spray voltage). The calibration curves were constructed in blank 
plasma. All data were analyzed using AB Sciex Analyst software v1.5.1.  
70 
 
Pharmacokinetic study in non-human primate 
An in vivo PK study of M5 NAM 5.97 (VU0483253, ML375) in non-human 
primates (cynomolgus monkey) was performed by contract with Frontage Laboratories 
(Exton, PA). 5.97 was administered IV as a single dose (1 mg/kg: formulated at 1 mg/mL 
in 10% ethanol 70% PEG400 20% saline vehicle) to male cynomolgus monkeys (n = 3), 
and plasma was collected serially at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours. 
Non-compartmental analysis was performed to obtain PK parameters. 
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Chapter III 
 
DEVELOPMENT OF THE FIRST HIGHLY SELECTIVE, SUB-MICROMOLAR 
M5 POSITIVE ALLOSTERIC MODULATOR 
 
Prior discovery of the first M5-preferring PAM 
 
 To date, very few PAMs selective for M5 have been reported
70,71,74
. As discussed 
in the introduction (Chapter I), our laboratory previously reported the first highly M5-
preferring PAM, the isatin-based compound VU0238429 (3.2), which was discovered 
after a campaign exploring and optimizing the SAR surrounding the chemical scaffold of 
M1/3/5 PAM VU0119498 (3.1)
70,71
. Further rounds of iterative parallel synthesis 
extensively characterized the SAR of biaryl ether substitutions in the southern N-benzyl 
region of the 3.2 pharmacophore, producing multiple potent and M5-selective analogs 
(Figure 3.1)
3
. Unfortunately, as with 3.2, these early M5 PAMs failed to display the 
DMPK and physicochemical profile necessary to serve as an in vivo probe into the role of 
selective M5 activation
70,71,74
. Despite this hindrance, aspects of the 3.2 chemical scaffold 
remained to be explored, so a new optimization campaign was launched with the goals of 
improving the chemical series’ physicochemical and DMPK profile whilst maintaining 
potency and M5 selectivity
75
. 
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Figure 3.1. Structures and activities of M5-preferring PAM VU0238429 (3.2) and selected M5-selective 
PAM analogs 3.3 and 3.4. All three were developed from a pan-M1, M3, M5 PAM, VU0119498 (3.1) that 
afforded both M1-selective PAMs and, by virtue of the 5-OCF3 moiety, M5-selective PAMs
70,71,74. 
 
 
 
 
Figure 3.2. Structure and activity of VU0366369 (3.5). Multiple productive replacements (tertiary 
hydroxyls, dioxolanes, and spirocyclic tetrahydrofurans/pyrrolidines) were identified for the isatin core of 
3.5 that maintained selective M1 PAM activity
76–78. 
 
We were encouraged in this effort by a previous project in our lab based around a 
similar isatin pharmacophore: the highly selective, isatin-based M1 PAM, 3.5 
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(VU0366369; Figure 3.2)
76–78
. In exploring the SAR surrounding 3.5, a number of 
replacements for the isatin moiety were discovered that maintained M1 PAM activity 
while offering novel SAR and relieving the potential DMPK liability of the isatin 
ketone
76–78
. Therefore, our optimization plan for 3.2 emulated this campaign, evaluating 
spirocyclic and tertiary hydroxyl replacements for the isatin moiety, while also 
continuing to investigate the rich SAR of the southern N-benzyl region in an effort to 
furnish a novel M5 PAM possessing a satisfactory DMPK profile and potency in the 
submicromolar range (Figure 3.3). 
 
 
Figure 3.3. Structure, planned SAR exploration, potency, and selectivity of M5 PAM 3.2 (VU0238429). 
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Optimization of VU0238429 to obtain the first sub-micromolar M5 PAM VU0467903 
 
Replacement of the isatin carbonyl with tertiary hydroxyl moieties 
The keto-amide moiety of 3.2 (VU0238429) was of particular interest for removal 
or substitution due to the 3-keto moiety’s reactivity as an electrophile. This reactivity 
could lead to multiple problems in a biological system, including transient reactions with 
endogenous nucleophiles or the irreversible covalent inhibition of cysteine proteases
79
. 
Furthermore, it was hypothesized that the 3-keto may also represent a DMPK liability as 
a substrate for efflux pumps. 
 
 
Figure 3.4. Structures and potencies of previously studied replacements for the 3-keto moiety of the isatin 
chemical scaffold80. 
 
 
Previous SAR in this region revealed that any attempt to remove the 3-position 
ketone resulted in loss of activity. The exception to this pattern was a 3-hydroxyl-3-
methyl analog 3.8 which maintained activity, albeit at greatly decreased potency (Figure 
3.4)
80
. Thus we set out to more extensively explore tertiary hydroxyl moieties possessing 
diverse functionalities.  
Treatment of 3.2 with DABCO in neat nitromethane afforded our first tertiary 
alcohol analog 3.9 in quantitative yield (Scheme 3.1)
81
. Upon evaluating compound 3.9 
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in a full CRC Ca
2+
 mobilization assay at hM5 in the presence of an ACh EC20, we 
observed that 3.9 maintained PAM activity and was of comparable potency and efficacy 
to 3.2 (hM5 EC50 = 1.3 μM, 75% AChMax). Although this result encouraged us to further 
pursue a library of tertiary alcohol analogs, 3.9 itself was not attractive as a probe due to 
the metabolic instability of its nitro moiety. 
 
 
Scheme 3.1. Synthesis and activity of compound 3.9 (VU0462442). Ca2+ mobilization assays in hM5 cells 
were used to obtain CRCs of compound 3.9 in the presence of a fixed submaximal (~EC20) concentration of 
ACh. Data represent the mean of at least 3 independent experiments with similar results. 
 
 
 We next pursued a small library of tertiary alcohols possessing substituted 
pyridines. Here, we employed two synthetic routes to survey pyridyl analogs 3.10 and 
3.11, and pyridyl methyl homologs 3.12-3.14. Utilizing 3.2 as a starting material, 
exposure to functionalized pyridyl boronic acids under Cu(OTf)2 catalysis afforded 
analogs 3.10 and 3.11 (Scheme 3.2)
82
. It should be noted that the synthesis of multiple 
pyridyl analogs was attempted using this procedure; however, yields were miniscule and 
pure compound could not be isolated for biological testing. The homologated congeners 
3.12-3.14 were accessed utilizing substituted picolines under Brønsted acid catalysis 
(Scheme 3.3)
83
. When tested in single point (30 μM) Ca2+ mobilization assays at hM5 in 
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the presence of an ACh ~EC20, SAR proved to be shallow, with most analogs 
demonstrating little or no PAM activity (Figure 3.5, Table 3.1). Only compound 3.10 
displayed any considerable activity, potentiating the ACh EC20 to 77% of the ACh 
maximum in the 30 μM single point assay. When Ca2+ mobilization assays were 
performed at hM5 to obtain full CRCs of 3.10 in the presence of an ACh EC20, we 
observed the compound to have low micromolar activity (hM5 EC50 = 2.0 μM, AChMax = 
73; Figure 3.6).  
 
 
Scheme 3.2. Copper-mediated synthesis of tertiary hydroxyl library compounds 3.10 and 3.1182. 
 
 
 
 
Scheme 3.3. Brønsted acid catalyzed synthesis of picolines to form homologated tertiary hydroxyl library 
compounds 3.12-3.1483. 
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Figure 3.5. Comparison of the single point (30 μM) screen results of the tertiary hydroxyl library, analogs 
3.10-3.14. Ca2+ mobilization was used to obtain %AChMax values for each compound in the presence of a 
fixed submaximal (~EC20) concentration of ACh in cell lines expressing hM5. Data represent the mean ± 
S.E.M. of at least 3 replicate experiments with similar results. 
 
 
Table 3.1. Structures for tertiary hydroxyl analogs 3.10-3.14 and associated PAM activity data from the 
single point (30 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported as a 
percentage of the maximum ACh response. VU number denotes the compound identifier assigned by 
Vanderbilt University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
3.10 VU0464634 76.9 
 
3.11 VU0464633 33.7 
78 
 
 
3.12 VU0465833 17.5 
 
3.13 VU0465746 55.3 
 
3.14 VU0465801 58.3 
 
 
 
 
Figure 3.6. Structure, potency, and selectivity of benzamide analog 3.10 (VU0464634). Ca2+ mobilization 
assays with hM5 cells were used to obtain CRCs of compound 3.10 in the presence of a fixed submaximal 
(~EC20) concentration of ACh (EC50 values: hM5 EC50 = 2.0 μM, %AChMax = 72.8). Data represent the 
mean ± S.E.M. of at least 3 independent experiments with similar results. 
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Replacement of the isatin carbonyl with a spiro-oxetane bioisostere 
In response to the shallow SAR surrounding the 3-carbonyl position, we elected 
to introduce a more subtle variant of the isatin carbonyl in the form of a spiro-oxetane, a 
common bioisostere of a carbonyl. In terms of improving the isatin DMPK profile, the 
oxetane offers several advantages over the carbonyl. Like a carbonyl, an spiro-oxetane 
has a similar spatial disposition and is an H-bond acceptor; however, unlike a carbonyl, 
the oxetane is more metabolically stable
84
.  
From 3.2, a Wittig reaction with (methoxymethyl)triphenylphosphonium chloride 
provided 3.15. In one pot, 3.15 was treated with pTSA to reveal the aldehyde which was 
subsequently converted to diol 3.16 under Aldol-Tishchenko reaction conditions. Mono-
triflation of 3.16 and subsequent nucleophilic displacement proceeded in low yield (~6%) 
to the spiro-oxetane 3.17 (Scheme 3.4). Interestingly, both diol 3.16 and spiro-oxetane 
3.17 were completely inactive in Ca
2+
 mobilization assays at hM5 in the presence of an 
ACh ~EC20 (EC50 >>30 μM). 
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Scheme 3.4. Synthetic pathway to spiro-oxetane isatin carbonyl analog 3.17 (VU0467863). 
 
 
 
Isatin core/phenethyl ether matrix library and the discovery of VU0467903 
Concurrent with our efforts to optimize of 3.2, an HTS campaign was initiated in 
2012 in conjunction with SRIMSC under the MLPCN to directly interrogate the chemical 
landscape possessing selective M5 functional activity. The HTS employed the MLPCN 
screening deck and was conducted using a single-point, triple-add, functional, 
fluorescence-based Ca
2+
 mobilization assay in CHO cell lines stably expressing hM5 (see 
Chapter IV for a more detailed description of the 2012 M5 HTS). Early in the analysis of 
this HTS, prior to official ‘hit’ confirmation, we noticed an isatin-based compound, 
CID2145491 (3.18), that registered as a weak single-point (31% AChMax at 30 μM) hit at 
hM5 (Figure 3.7). This ‘hit’ possessed the familiar isatin core, but also a unique N-
phenethyl ether substitution. Furthermore, we were intrigued to find an isatin compound 
lacking the 5-OCF3 moiety, a SAR element previously observed to be vital to M5-
selectivity, which maintained activity at M5.  
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Figure 3.7. Structure of 3.18 (CID2145491), discovered in HTS of MLPCN screening deck. 
 
 
 
 
Figure 3.8. Structure of 3.2 (VU0238429) and the proposed structure resulting from the juxtaposition of 
structural elements from HTS lead compound 3.18. 
 
 
 
We immediately questioned whether the juxtaposition of the 3.2 5-OCF3 isatin 
core with the phenethyl ether moiety of compound 3.18 would lead to an improved M5 
PAM. Structurally, a juxtaposed analog would be comparable to a disconnection and 
inversion of the 3.2 N-p-methoxybenzyl group (Figure 3.8). Thus a matrix library was 
constructed comparing 5-OCF3 and 7-methyl isatin cores. We also included 5-methyl 
isatin cores in order to determine if the activity of an isatin methyl substituent might 
transfer to alternative positions. Ten N-phenethyl ether variants were then selected to 
cross with the three isatin cores. These phenethyl ether analogs were selected with the 
goal of exploring multiple dimensions of SAR around this moiety, including substitution 
of the phenyl ring, variation of the ether, and homologation of the alkyl chain.  
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Scheme 3.5. Matrix library synthesis of analogs 3.18, 3.21-3.48. 
 
 
 
All matrix library analogs, including a resynthesis of the HTS lead 3.18, were 
prepared by alkylating the core isatin with alkyl halide versions of the phenethyl ether 
analogs under microwave-assisted conditions (Scheme 3.5). The PAM activity of the 
library analogs was subsequently tested in single-point (30 μM) Ca2+ mobilization assays 
at hM5 in the presence of an ACh ~EC20 (Figure 3.9, Table 3.2). 
 
 
 
Figure 3.9. Comparison of the single point (30 μM) screen results of the isatin matrix library, analogs 3.18, 
3.21-3.48. Ca2+ mobilization was used to obtain %AChMax values for each compound in the presence of a 
fixed submaximal (~EC20) concentration of ACh in cell lines expressing hM5. Data represent the mean ± 
S.E.M. of at least 3 replicate experiments with similar results. 
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Table 3.2. Structures for matrix library analogs 3.18, 3.21-3.48 and associated PAM activity data from the 
initial single point (30 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported as a 
percentage of the maximum ACh response. VU number denotes the compound identifier assigned by 
Vanderbilt University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
3.18 VU0336754 33.1 
 
3.21 VU0297422 26.8 
 
3.22 VU0267572 23.1 
 
3.23 VU0468696 34.2 
 
3.24 VU0468939 26.5 
 
3.25 VU0468703 26.7 
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3.26 VU0469051 29.9 
 
3.27 VU0469065 27.3 
 
3.28 VU0195631 42.6 
 
3.29 VU0294899 44.7 
 
3.30 VU0297289 45.0 
 
3.31 VU0300264 8.8 
 
3.32 VU0468709 60.5 
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3.33 VU0468998 40.4 
 
3.34 VU0468654 40.4 
 
3.35 VU0468952 40.9 
 
3.36 VU0468949 42.6 
 
3.37 VU0468683 27.9 
 
3.38 VU0288396 13.6 
 
3.39 VU0467903 85.8 
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3.40 VU0467974 70.8 
 
3.41 VU0468196 87.5 
 
3.42 VU0468690 81.9 
 
3.43 VU0468957 84.7 
 
3.44 VU0468685 87.8 
 
3.45 VU0468948 81.5 
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3.46 VU0469054 95.8 
 
3.47 VU0468702 18.6 
 
3.48 VU0467973 53.5 
  
 
 
The single-point data revealed eight compounds that potentiated the ACh EC20 to 
>70% at 30 μM. Notably, all of these compounds possessed the 5-OCF3 substituted isatin 
core, while all methyl substituted isatin core analogs appeared relatively inactive. 
Furthermore, this group of highly active compounds included compound 3.39, which 
represents the envisioned juxtaposition of structural elements from 3.2 and 3.18 shown in 
Figure 3.8. Potency data for all eight highly active compounds as well as the HTS lead 
compound 3.18 was subsequently obtained in CRC Ca
2+
 mobilization assays at hM5 in 
the presence of an ACh ~EC20 (Table 3.3).  
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Table 3.3. Potencies at hM5 and hM3 for the 8 highly active matrix library analogs selected from the initial 
single point (30 μM) screen. Also included is the hM5 CRC data for the HTS lead 3.18. Ca
2+ mobilization 
assays with hM5 cells were used to obtain CRCs of compounds in the presence of a fixed submaximal 
(~EC20) concentration of ACh. Data represent the mean of at least 3 independent experiments with similar 
results. ---, not determined.  
 
 
Curiously, HTS lead compound 3.18 proved to be devoid of PAM activity. 
Despite this, we were pleased to see that six of the eight compounds tested displayed 
potencies in the submicromolar range. The most potent of these, 3.39 (VU0467903) and 
3.42 (VU0468690), were counterscreened in Ca
2+
 mobilization assays at hM3 in the 
presence of an ACh ~EC20 to ascertain their general selectivity for M5 (Table 3.3). Both 
compounds showed weak activity at hM3; however, 3.39 displayed a greater selectivity 
window for M5. 
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In vitro pharmacological characterization of M5 PAM VU0467903 
 
Characterization of mAChR subtype selectivity of VU0467903 
Encouraged by the selectivity of 3.39 (VU0467903) for hM5 versus hM3, a full 
mAChR subtype-selectivity profile was obtained. Counterscreening was carried out 
against the remaining human mAChR subtypes as well as for all rat mAChR subtypes 
(with M2 and M4 co-expressing Gαqi5; Figure 3.10). The latter selectivity panel was 
performed to ensure that 3.39, which had so far been only tested on human isoforms of 
the mAChRs, was active and selective at rat isoforms as well. This examination of 
species difference was an important step as we ultimately desired an in vivo tool 
compound with which to study M5 in the CNS, and rat is the standard in vivo model 
system for such studies.  
 
 
Figure 3.10. Potency and selectivity of compound 3.39 (VU0467903) at all human and rat mAChR 
subtypes. Ca2+ mobilization assays with hM1-hM5 cells and with rM1-rM5 cells (M2 and M4 co-expressing 
Gαqi5) were used to obtain CRCs of 3.39 in the presence of a fixed submaximal (~EC20) concentration of 
ACh (EC50 values: hM5 EC50 = 0.41 μM, %AChMax = 91; hM3 EC50 = 3.0 μM, %AChMax = 41; hM1, hM2, 
hM4 EC50 >30 μM; rM5 EC50 = 0.47 μM, %AChMax = 55; rM1-rM4 EC50 >30 μM). Data represent the mean 
± S.E.M. of at least 3 independent experiments with similar results. Note: human selectivity studies were 
performed in standard double-add mode on a Molecular Devices FLEXStation II, while rat studies were 
performed in triple-add mode on a Hamamatsu FDSS 6000. Rat selectivity studies performed by A. 
Lamasal. 
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Figure 3.11. ACh CRC fold-shifts of compound 3.39 (VU0467903) at hM5 (left panel) and rM5 (right 
panel). Ca2+ mobilization assays with hM5 cells and rM5 cells were used to obtain ACh CRCs in the 
presence of vehicle or 30 μM compound 3.39 (EC50 values: hM5 EC50 of ACh + vehicle = 933 pM, hM5 
EC50 of ACh + 3.39 = 50.4 pM, hM5 fold-shift = 18.5; rM5 EC50 of ACh + vehicle = 4.58 nM, rM5 EC50 of 
ACh + 3.39 = 225 pM, rM5 fold-shift = 20.4). Data represent the mean ± S.E.M. of at least 3 independent 
experiments with similar results. 
 
 The mAChR selectivity panel revealed that 3.39 possesses good selectivity for M5 
in both rat and human isoforms (hM5 EC50 = 0.41 μM, %AChMax = 91; hM3 EC50 = 3.0 
μM, %AChMax = 41; hM1, hM2, hM4 EC50 >30 μM; rM5 EC50 = 0.47 μM, %AChMax = 55; 
rM1-rM4 EC50 >30 μM). Further characterization of the compound’s efficacy was probed 
in ACh fold shift assays. In these assays 3.39 (30 μM) induced a robust 20-fold leftward 
shift of the ACh CRC in rM5 and 19-fold leftward shift in hM5 (Figure 3.11). Based on 
the unprecedented submicromolar potency, M5-selectivity, and ACh fold shift exhibited 
by compound 3.39, it was declared an MLPCN probe and given the identifier ML326. 
 
Confirmation of the allosteric mechanism of VU0467903 
Although evidence of an allosteric mode of action for 3.39 (VU0467903, ML326) 
was strongly supported by its behavior in double-add Ca
2+
 mobilization assays (i.e. – 3.39 
displays no intrinsic activity, yet potentiates an ACh EC20) and by prior [
3
H]-NMS 
competition binding data on the parent compound 3.2, we nonetheless desired to confirm 
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an allosteric mechanism via [
3
H]-NMS competition binding with 3.39 (Figure 3.12). As 
predicted, the study revealed that, when competing with the orthosteric antagonist [
3
H]-
NMS in hM5 membrane preparations, 3.39 does not compete for the orthosteric site. This 
competition binding data, when taken into account with the aforementioned evidence of 
an allosteric mechanism, strongly suggests that 3.39 is indeed an allosteric modulator. 
 
 
Figure 3.12. [3H]-NMS competition binding assay with 3.39 (VU0467903, ML326) in an hM5 membrane 
preparation. [3H]-NMS and a CRC of either Atropine (control) or 3.39 were allowed to equilibrate for 3 
hours in the hM5 membrane preparation before filtration and scintillation counting (Ki values: Atropine Ki = 
1.57 nM, 3.39 Ki >> 10 μM). Data represent the mean ± S.E.M. of at least 3 independent experiments with 
similar results. 
 
 
Ancillary pharmacology of the VU0467903 
In order to obtain a general impression of the propensity for off-target binding by 
compound 3.39, it was entered into a commercial radioligand competition binding screen 
of 67 GPCRs, ion channels, and transporters (Table 3.4). Unfortunately this screen 
revealed that 3.39 competed with ligand binding significantly at numerous off-target 
GPCRs and transporters, including NET. 
92 
 
Table 3.4. Ancillary/off-target competition binding screen results for 3.39 (VU0467903, ML326). 3.39 was 
dosed at 10 μM for single point competition binding assays. Targets displaying significant binding (≥50% 
at 10 μM) are outlined. Data represent the mean of 2 independent experiments with similar results. Studies 
performed by Eurofins Panlabs, Inc. 
 
Target/Protein Species % Inhibition 
Adenosine A1 Human -3 
Adenosine A2A Human 7 
Adenosine A3 Human 57 
Adrenergic α1A Rat 71 
Adrenergic α1B Rat 66 
Adrenergic α1D Human 44 
Adrenergic β1 Human 33 
Adrenergic β2 Human 8 
Androgen (Testosterone) AR Rat 24 
Bradykinin B1 Human 12 
Bradykinin B2 Human 5 
Calcium Channel L-Type, Benzothiazepine Rat -16 
Calcium Channel L-Type, Dihydropyridine Rat 44 
Calcium Channel N-Type Rat 1 
Cannabinoid CB1 Human 72 
Dopamine D1 Human 73 
Dopamine D2S Human 31 
Dopamine D3 Human 59 
Dopamine D4.2 Human 46 
Endothelin ETA Human 44 
Endothelin ETB Human 3 
Epidermal Growth Factor (EGF) Human 4 
Estrogen ERα Human 5 
GABAA, Flunitrazepam, Central Rat -2 
GABAA, Muscimol, Central Rat 6 
GABAB1A Human -3 
Glucocorticoid Human 88 
Glutamate, Kainate Rat -5 
Glutamate, NMDA, Agonism Rat 9 
Glutamate, NMDA, Glycine Rat 19 
Glutamate, NMDA, Phencyclidine Rat 4 
Histamine H1 Human 41 
Histamine H2 Human 95 
Histamine H3 Human -3 
Imidazoline I2, Central Rat 33 
Interleukin IL-1 Mouse -2 
Leukotriene, Cysteinyl CysLT1 Human 26 
Melatonin MT1 Human 40 
Muscarinic M1 Human 22 
Muscarinic M2 Human -2 
Muscarinic M3 Human -2 
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Neuropeptide Y Y1 Human 29 
Neuropeptide Y Y2 Human 12 
Nicotinic Acetylcholine Human -26 
Nicotinic Acetylcholine α1, Bungarotoxin Human 5 
Opiate δ1 (OP1, DOP) Human 12 
Opiate κ (OP2, KOP) Human 42 
Opiate μ (OP3, MOP) Human 78 
Phorbol Ester Mouse 9 
Platelet Activating Factor (PAF) Human 37 
Potassium Channel [KATP] Human 10 
Potassium Channel hERG Human 21 
Prostanoid EP4 Human -3 
Purinergic P2X Rabbit 4 
Purinergic P2Y Rat 4 
Rolipram Rat -6 
Serotonin (5-HT1A) Human -9 
Serotonin (5-HT2B) Human 1 
Serotonin (5-HT3) Human -12 
Sigma σ1 Human -35 
Sodium Channel, Site 2 Rat 38 
Tachykinin NK1 Human -19 
Thyroid Hormone Rat 2 
Transporter, Dopamine (DAT) Human 42 
Transporter, GABA Rat 7 
Transporter, Norepinephrine (NET) Human 77 
Transporter, Serotonin (SERT) Human 8 
 
 
Continued optimization of M5 PAM VU0467903 
 
Replacement of the isatin carbonyl in the presence of the phenethyl ether moiety 
 In light of the great increase in potency provided by the N-phenethyl ether 
substitution, we questioned if the chemical scaffold may now tolerate a substitution of the 
isatin carbonyl. Thus we again turned our efforts to substituting the isatin carbonyl with 
spirocyclic heterocycles and tertiary hydroxyl moieties. 
 The low yields of the reactions previously employed to synthesize tertiary 
hydroxyl analogs (vide supra) compelled us to employ the more reliable method of direct 
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lithiation to construct a small library of tertiary hydroxyl analogs in the context of the 
southern phenethyl ether moiety. The treatment of heteroaryl iodides with 
n
BuLi before 
the addition of 3.39 produces the desired tertiary hydroxyl analogs 3.50-3.55 swiftly and 
in high yields (Scheme 3.6). In addition to heterocyclic analogs, we utilized methyl 
lithium to synthesize the 3-hydroxy-3-methyl analog 3.56 to mimic the substitution 
previously observed to be weakly active in analog 3.8 of the 3.2 series of M5 PAMs 
(Figure 3.4). The library analogs were subsequently tested in single-point (30 μM) Ca2+ 
mobilization assays to assess their activity (Figure 3.13, Table 3.5). 
 
 
  
Scheme 3.6. Library synthesis of tertiary hydroxyl isatin analogs 3.50-3.55. 
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Figure 3.13. Comparison of the single point (30 μM) screen results of the tertiary hydroxyl library, analogs 
3.50-3.56. Ca2+ mobilization was used to obtain %AChMax values for each compound in the presence of a 
fixed submaximal (~EC20) concentration of ACh in cell lines expressing hM5. Data represent the mean ± 
S.E.M. of at least 3 replicate experiments with similar results. 
 
 
 
Table 3.5. Structures for tertiary hydroxyl analogs 3.50-3.56 and associated PAM activity data from the 
single point (30 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported as a 
percentage of the maximum ACh response. VU number denotes the compound identifier assigned by 
Vanderbilt University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
3.50 VU0472634 30.6 
 
3.51 VU0472612 31.5 
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3.52 VU0472606 35.1 
 
3.53 VU0472601 38.8 
 
3.54 VU0472617 39.1 
 
3.55 VU0472826 11.4 
 
3.56 VU0470221 61.5 
 
 
 Even in the context of the southern phenethyl ether moiety, no tertiary hydroxyl 
analogs exhibited any notable PAM activity at 30 μM. The best response was given by 
the 3-hydroxy-3-methyl analog 3.56; however, upon testing in a full CRC Ca
2+
 
mobilization assay at hM5 in the presence of an ACh ~EC20 this analog displayed weak 
potency (hM5 EC50 > 10 μM, %AChMax = 67).  
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We next combined the phenethyl ether SAR with spirocyclic replacements for the 
isatin ketone. Spiro-pyrrolidine and spiro-dioxolane analogs were chosen as targets due to 
the activity these moieties displayed when applied to the M1 PAM isatin scaffold 3.5.  
 
 
Scheme 3.7. Structure and synthesis of spiro-dioxolane analog 3.57 (VU0472603). 
 
 
Scheme 3.8. Structure and synthesis of spiro-pyrrolidine analog 3.62 (VU0472720). 
 
The spiro-dioxolane analog 3.57 was easily accessed by treating 3.39 with pTSA 
and ethylene glycol (Scheme 3.7). The spiro-pyrrolidine analog synthesis began from 
3.39 as well. Condensation with Ellman’s sulfinamide provided intermediate 3.58 which 
was subsequently treated with Grignard reagent 3.59 to furnish intermediate 3.60. 
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Deprotection of the aldehyde and amine was simultaneously accomplished by treatment 
with TFA to provide the dihydropyrrole 3.61. Finally, MP-(OAc)3BH was used to reduce 
the spirocycle to the pyrrolidine 3.62 (Scheme 3.8). Interestingly, when subjected to full 
CRC Ca
2+
 mobilization assays, neither of the spirocyclic analogs displayed PAM activity 
at hM5, signifying a notable disconnect in isatin SAR between M1 and M5 PAMs.  
 
In vitro and in vivo DMPK characterization of M5 PAM VU0467903 
 
 Discouraged by the intractable SAR around the isatin moiety, we returned to the 
highly potent and M5-selective 3.39 (VU0467903, ML326) to characterize its DMPK 
profile via multiple assays, including plasma protein binding, rat brain homogenate 
binding, rat and human microsomal stability, and CYP inhibition studies. In addition to 
these in vitro assays, 3.39 was intravenously administered to male Sprague-Dawley rats 
at a dose of 1 mg/kg to determine in vivo rat PK/CNS exposure.  
The CYP inhibition assay revealed that 3.39 possessed a relatively clean CYP 
profile (IC50s: 1A2 = 1.5 μM; 2C9 = 8.6 μM; 2D6 = 11.3 μM; 3A4 = 7.5 μM); however, 
the remainder of the DMPK studies were halted as insurmountable LCMS/MS analytical 
quantization issues were encountered. Ionization of 3.39 using ESI, APPI, and APCI 
ionization probes all resulted in untraceable daughter ions which prevented the 
determination of DMPK parameters and in vivo rat exposure. Alternative methods of 
analysis, including chemical derivatization and UV absorbance also failed to provide the 
requisite sensitivity for detection of 3.39. As a result of these issues, we were unable to 
complete DMPK characterization of 3.39. 
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 In response to our complications in characterizing the DMPK profile of 3.49, we 
attempted DMPK characterization of other promising, highly potent M5 PAM analogs 
such as 3.42, 3.43, 3.45 and 3.46. Unfortunately, they too suffered from poor ionization 
profiles which precluded DMPK profiling.  
Taking into account the lack of tractable SAR found in continued optimization 
attempts of 3.39, the LCMS/MS ionization issues that precluded DMPK characterization, 
and the promising nature of separate, concurrently studied M5-selective ligands (Chapters 
IV, V, and VI), further work at the optimization of compound 3.39 was put on hold.  
 
Summary and future directions 
 
 In summary, we endeavored to improve the potency and metabolic stability of the 
first-generation, isatin-based M5 PAM 3.2 (VU0238429, ML129) via targeted SAR 
exploration and optimization of the chemical scaffold. In the course of this optimization 
campaign we synthesized over 60 novel analogs, but SAR was found to be intractable 
and many of these analogs exhibited no activity at M5. Insight from a weak M5 PAM 
HTS lead 3.18 led to its hybridization with 3.2 and resulted in compound 3.39 
(VU0467903, ML326), the first highly M5-preferring and sub-micromolar M5 PAM 
(Figure 3.14). 
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Figure 3.14. A summary and comparison of the structure, potency, and SAR found around the first M5-
preferring PAM 3.2 (VU0238429, ML129) that led to the discovery of the novel, sub-micromolar M5 PAM 
3.39 (VU0467903, ML326).  
 
Future directions for the 3.39 chemical series are limited. Further optimization of 
the isatin M5 PAM scaffold was halted due to the inability to obtain a detailed DMPK 
profile of 3.39 or its analogs due to the scaffold’s poor ionization profile. As a result of 
this barrier to analysis, 3.39 and its analogs are unlikely to be utilized as in vivo tool 
compounds. This does not, however, precluded the use of the 3.39 M5 PAM series as in 
vitro or ex vivo probes. Recently, M5 was shown to be functional in a native system via 
an electrophysiological study of M5 function carried out in mouse brain slices using the 
M5 PAM 3.2 in conjunction with the acetylcholine analogs oxotremorine-M and 
carbachol. By using 3.2 to selectively potentiate M5, this study revealed the differential 
effects of the M5 receptor on dopaminergic neurons based upon where the receptor is 
physically located on the neuron
27
. Thus, despite their limited utility as in vivo probes, the 
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present series of isatin-based M5 PAMs hold the potential to be valuable in vitro probes 
for pharmacological studies of the potentiation of M5 in the CNS.  
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Chapter IV 
 
 
 
IDENTIFICATION, OPTIMIZATION, AND CHARACTERIZATION OF A  
NON-ISATIN M5 POSITIVE ALLOSTERIC MODULATOR 
 
 
HTS identification of a novel, M5-selective ligand with PAM activity 
 
 
 
 The extensive study of the SAR surrounding isatin-based M5 PAMs VU0238429 
and VU0467903 (Chapter III) confirmed targeting the M5 allosteric site as a viable 
strategy of gaining a high degree of M5 selectivity
70,71,74,75
. In response to this, an HTS 
campaign was initiated in 2012 in conjunction with SRIMSC under the MLPCN to 
directly interrogate the chemical landscape possessing selective M5 functional activity. 
The HTS employed the MLPCN screening deck (~360,000 compounds at the time of 
screening, PubChem AID 624103), and was conducted using a single-point, triple-add, 
functional, fluorescence-based Ca
2+
 mobilization assay in CHO cell lines stably 
expressing hM5. The triple-add mode (i.e. – test compound addition, followed by ACh 
EC20 addition, followed by ACh EC80 addition) is particularly advantageous to a HTS as 
it enables the screen to identify activators (agonists and PAMs), while also searching for 
inhibitors (antagonists and NAMs). The initial screen identified 3920 M5 primary hits 
(1.07% hit rate). The primary hits were next counterscreened in the same manner against 
the parental CHO cell line and two CHO cell lines expressing hM1 and hM4, respectively 
(with M4 co-expressing Gαqi5). The compounds that appeared most promising as M5 
activators were then purchased from commercial sources as fresh powder and 
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reconfirmed in triple-add 10-point CRC experiments. This process resulted in the 
identification of nine confirmed M5 PAMs as well as nine M5 antagonists (two of which 
are discussed in chapters V and VI).  
Owing to its novel chemotype and the modular composition, compound 4.1 
(VU0472882) was deemed the most intriguing and structurally tractable M5 PAM lead. 
The activity of the 4.1 was reconfirmed via in-house resynthesis and retesting in double-
add CRC Ca
2+
 mobilization assays at all human mAChR subtypes as well as rM5 
(Scheme 4.1, Figure 4.1). This in-house resynthesis and reconfirmation was a vital step 
as lead compounds from HTS campaigns can occasionally fail to reconfirm. This failure 
can be caused by a variety of factors, including sample impurity, sample contamination, 
or incorrect structural assignment from the compound vendor or the HTS effort’s 
compound management system. 
 
 
Scheme 4.1. Synthesis of HTS lead compound 4.1 (VU0472882). 
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Beginning from the N-Boc protected carboxylic acid core 4.2, a HATU-mediated 
peptide coupling with benzylamine furnished the secondary amide 4.3. The amide was 
deprotonated with tert-butoxide followed by treatment with iodoethane to form tertiary 
amide 4.4. Removal of the Boc protecting group was accomplished under standard 
anhydrous HCl conditions to provide HCl salt 4.5. Finally, the secondary amine was 
sulfonylated with 1,4-benzodioxan-6-sulfonyl chloride to form the HTS lead compound 
4.1 (Scheme 4.1). 4.1 was tested in CRC Ca
2+
 mobilization assays in CHO cell lines 
stably expressing individual human mAChR subtypes as well as rM5. The HTS lead was 
verified to possess weak PAM activity at both human and rat isoform of M5 (EC50 >10 
μM) and no activity was observed at hM1-hM4 (EC50 >>30 μM; Figure 4.1); furthermore, 
at 10 μM 4.1 was found to shift the ACh CRC 2.3-fold at hM5 and 2.5-fold at rM5 
(Figure 4.2). 
 
 
Figure 4.1. Structure, planned SAR exploration, potency, and selectivity of HTS hit compound 4.1 
(VU0472882). Ca2+ mobilization assays with hM1-hM5 (M2 and M4 co-expressing Gαqi5) and rM5 cells were 
used to obtain CRCs of resynthesized compound 4.1 in the presence of a fixed submaximal (~EC20) 
concentration of ACh (EC50 values: hM5 EC50 > 10 μM, %AChMax = 76; hM1-hM4 EC50 >>30 μM; rM5 
EC50 > 10 μM, %AChMax = 71). Data represent the mean ± S.E.M. of at least 3 independent experiments 
with similar results. 
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Figure 4.2. ACh CRC fold shifts of compound 4.1 (VU0472882) at hM5 (left panel) and rM5 (right panel). 
Ca2+ mobilization assays with hM5 cells and rM5 cells were used to obtain ACh CRCs in the presence of 
vehicle or 10 μM compound 4.1 (EC50 values: hM5 EC50 of ACh + vehicle = 517 pM, hM5 EC50 of ACh + 
4.1 = 224 pM, hM5 fold shift = 2.3; rM5 EC50 of ACh + vehicle = 2.20 nM, rM5 EC50 of ACh + 4.1 = 873 
pM, rM5 fold shift = 2.5). Data represent the mean ± S.E.M. of at least 3 independent experiments with 
similar results. 
 
Despite the weak potency and fold shift of 4.1 we were heartened to see the 
compound’s selectivity for M5. Previous to this HTS campaign the only known M5 
selective compounds were invariably centered on an isatin-based chemical scaffold with 
few tractable points of SAR (Chapters I and III). We now possessed a lead that, in stark 
contrast to the isatin M5 PAM scaffold, exhibited a modular scaffold amenable to a broad 
range of modifications; thus, we hypothesized that further exploration of the wide range 
of SAR possibilities around the chemical scaffold would result in improved potency 
whilst maintaining M5 selectivity
85
.  
 
Optimization of VU0472882 to obtain non-isatin M5 PAM VU0476212 
 
Optimization of eastern sulfonamide region SAR 
Our laboratory’s experiences with previous medicinal chemistry projects 
optimizing GPCR allosteric modulators often found that subtle structural changes can 
have a drastic effect on a chemical scaffold’s physicochemical and pharmacological 
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characteristics. Given the several structural regions of the non-isatin M5 PAM lead 
scaffold we proposed to address the exploration of each region in an iterative manner, 
optimizing a single region whilst holding the rest of the molecule constant. Once an 
optimal structure for one region was found, it was held constant while the next region 
was addressed, and so on.  
The first region that we turned our attention to was the eastern sulfonamide 
substituent. We coupled the piperidine amine, compound 4.5, to a wide variety of 
substituted sulfonyl halides, including aryl, heteroaryl, and alkyl substituents. The 
starting material 4.5 was easily obtained in high yields from the synthetic pathway 
depicted in Scheme 4.1 and was sulfonylated with a library of >60 sulfonyl chlorides 
under standard acyl chloride amide coupling conditions (Scheme 4.2). The resulting 
analogs (compounds 4.6-4.66), as well as the unreacted amine 4.5 were then screened in 
single point (30 μM) Ca2+ mobilization assays in the presence of an ACh  ~EC20 in CHO 
cells stably expressing hM5. The results of this single point screen are shown in Figure 
4.3 and Table 4.1. 
 
 
 
Scheme 4.2. Synthetic scheme for sulfonamide library analogs 4.6-4.66 from intermediate 4.5. 
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Figure 4.3. Comparison of single point (30 μM) screen results of the sulfonamide library, analogs 4.5-4.66. 
Also included is the single point Ca2+ mobilization response of the initial hit, compound 4.1. Ca2+ 
mobilization was used to obtain % AChMax values for each compound in the presence of a fixed 
submaximal (~EC20) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 replicate 
experiments with similar results. 
 
 
 
Table 4.1. Structures for sulfonamide analogs 4.5-4.66 and associated PAM activity data from the single 
point (30 μM) screen at hM5. Also included is the structure and single point Ca
2+ mobilization response of 
the HTS hit, compound 4.1. Ca2+ mobilization responses for each compound are reported as a percentage of 
the maximum ACh response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
4.1 VU0472882 81.4 
 
4.5 VU0472883 14.9 
 
4.6 VU0472804 48.0 
 
4.7 VU0472801 71.5 
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4.8 VU0475780 28.1 
 
4.9 VU0472822 72.2 
 
4.10 VU0472783 78.4 
 
4.11 VU0472815 56.0 
 
4.12 VU0475696 38.4 
 
4.13 VU0475727 63.2 
 
4.14 VU0475750 56.2 
 
4.15 VU0475706 33.6 
 
4.16 VU0475695 65.3 
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4.17 VU0475772 62.1 
 
4.18 VU0475723 21.7 
 
4.19 VU0475782 63.9 
 
4.20 VU0475728 62.6 
 
4.21 VU0475681 24.0 
 
4.22 VU0475674 61.0 
 
4.23 VU0475771 17.5 
 
4.24 VU0475773 71.7 
 
4.25 VU0475698 70.2 
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4.26 VU0475774 66.1 
 
4.27 VU0475751 58.4 
 
4.28 VU0475785 28.6 
 
4.29 VU0475700 63.8 
 
4.30 VU0475699 73.7 
 
4.31 VU0475763 24.5 
 
4.32 VU0475764 64.3 
 
4.33 VU0475783 62.9 
 
4.34 VU0475786 66.7 
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4.35 VU0475682 59.3 
 
4.36 VU0486994 36.4 
 
4.37 VU0487015 34.5 
 
4.38 VU0487479 24.7 
 
4.39 VU0475701 50.1 
 
4.40 VU0475777 30.0 
 
4.41 VU0475720 62.5 
 
4.42 VU0475787 56.9 
 
4.43 VU0475749 70.0 
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4.44 VU0472827 63.4 
 
4.45 VU0472800 77.9 
 
4.46 VU0111215 40.8 
 
4.47 VU0475661 84.3 
 
4.48 VU0486967 71.5 
 
4.49 VU0487026 51.4 
 
4.50 VU0475778 83.1 
 
4.51 VU0487157 62.3 
 
4.52 VU0487160 64.9 
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4.53 VU0475765 82.1 
 
4.54 VU0487151 78.6 
 
4.55 VU0475713 33.7 
 
4.56 VU0475677 68.8 
 
4.57 VU0475678 25.9 
 
4.58 VU0475784 16.0 
 
4.59 VU0475680 5.3 
 
4.60 VU0475721 26.2 
 
4.61 VU0475714 25.5 
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4.62 VU0474010 14.1 
 
4.63 VU0474011 17.3 
 
4.64 VU0475722 20.8 
 
4.65 VU0475760 21.3 
 
4.66 VU0475679 17.0 
 
 
 
 This initial single point screen revealed that SAR around the sulfonamide 
substituent was rich and highly flexible. Many of the aryl and heteroaryl sulfonamide 
analogs potentiated of the ACh EC20 to over 70% of the maximal ACh response. In 
exception to this, ortho-substituted aryl sulfonamides were notably disfavored. Likewise, 
alkyl and benzyl sulfonamide analogs showed little potentiator response, as did the 
unreacted starting material, compound 4.5. Based on this screen, 29 compounds were 
tested in full CRC Ca
2+
 mobilization assays at hM5 to determine potency (Table 4.2). 
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Table 4.2. Potencies at hM5 for 29 aryl & heteroaryl sulfonamide analogs selected from the single point (30 
μM) screen. Ca2+ mobilization assays with hM5 cells were used to obtain CRCs of compounds in the 
presence of a fixed submaximal (~EC20) concentration of ACh. Data for the two most potent compounds, 
4.47 and 4.50, are bolded. Data represent the mean of at least 3 independent experiments with similar 
results. 
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From these data it was clear that manipulation of the sulfonamide substituent had 
the potential to greatly increase the potency of the compound over the original HTS lead. 
The unadorned bezenesulfonamide 4.7 displayed a slight increase in potency over the 
lead, but further increases in potency were attained by introducing substituents around the 
ring. Both 3- and 4-methoxybenzenesulfonamide analogs 4.9 and 4.10 greatly increased 
potency; however, the relative inactivity of the 2-methoxybenzenesulfonamide analog 4.8 
again underscored the observation that ortho-substituents are not tolerated. Interestingly, 
the 3,4-dimethoxybenzenesulfonamide analog 4.11 showed greatly reduced potency and 
efficacy compared to the individual 3- and 4- methoxy substituents as well as the HTS 
lead.  
 
 
Figure 4.4. Potency and selectivity of analogs 4.47 (VU0475661; left panel) and 4.50 (VU0475778; right 
panel). Ca2+ mobilization assays with hM1-hM5 (M2 and M4 co-expressing Gαqi5) and rM5 cells were used to 
obtain CRCs of the compounds in the presence of a fixed submaximal (~EC20) concentration of ACh (4.47 
EC50 values: hM5 EC50 = 1.6 μM, %AChMax = 86; hM1-hM4 EC50 >30 μM; rM5 EC50 = 1.5 μM, %AChMax = 
82%; 4.50 EC50 values: hM5 EC50 = 1.7 μM, %AChMax = 87; hM1-hM4 EC50 >30 μM; rM5 EC50 = 1.9 μM, 
%AChMax = 85%). Data represent the mean ± S.E.M. of at least 3 independent experiments with similar 
results. 
 
Out of all analogs tested, the two indazolyl sulfonamide analogs, compounds 4.47 
(VU0475661) and 4.50 (VU0475778), showed the greatest potency and were subjected to 
further counter screening against the remaining human mAChR subtypes as well as rM5 
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(Figure 4.4). We were pleased to see that both 4.47 and 4.50 maintained their activity at 
rM5 (4.47: rM5 EC50 = 1.5 μM, %AChMax = 82; 4.50: rM5 EC50 = 1.9 μM, % AChMax = 
85) while also maintaining selectivity for M5 versus other human mAChR subtypes (hM1-
hM4 EC50 >30 μM). In addition to potency data, fold shift data for 4.47 and 4.50 at 10 
μM was gathered at hM5 and rM5 (4.47 hM5 fold shift = 5.4, rM5 fold shift = 3.6; 4.50 
hM5 fold shift = 4.8, rM5 fold shift = 5.2), revealing a ~2-fold improvement over the HTS 
lead 4.1 (Figure 4.5, Figure 4.6). In light of the potency increase and efficacy over the 
HTS lead, we deemed the 5- and 6-indozolyl sulfonamide analogs to be the preferred 
substituents for the sulfonamide region as we moved forward in the optimization effort. 
 
 
Figure 4.5. ACh CRC fold shifts of compound 4.47 (VU0475661) at hM5 (left panel) and rM5 (right 
panel). Ca2+ mobilization assays with hM5 cells and rM5 cells were used to obtain ACh CRCs in the 
presence of vehicle or 10 μM compound 4.47 (EC50 values: hM5 EC50 of ACh + vehicle = 539 pM, hM5 
EC50 of ACh + 4.47 = 100 pM, hM5 fold shift = 5.4; rM5 EC50 of ACh + vehicle = 1.12 nM, rM5 EC50 of 
ACh + 4.47 = 313 pM, rM5 fold shift = 3.6). Data represent the mean ± S.E.M. of at least 3 independent 
experiments with similar results. 
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Figure 4.6. ACh CRC fold shifts of compound 4.50 (VU0475778) at hM5 (left panel) and rM5 (right 
panel). Ca2+ mobilization assays with hM5 cells and rM5 cells were used to obtain ACh CRCs in the 
presence of vehicle or 10 μM compound 4.50 (EC50 values: hM5 EC50 of ACh + vehicle = 517 pM, hM5 
EC50 of ACh + 4.50 = 107 pM, hM5 fold shift = 4.8; rM5 EC50 of ACh + vehicle = 2.20 nM, rM5 EC50 of 
ACh + 4.50 = 421 pM, rM5 fold shift = 5.2). Data represent the mean ± S.E.M. of at least 3 independent 
experiments with similar results. 
 
 
 
Introduction of benzylic methyl and discovery of enantiospecific activity 
 Having settled upon a set of optimized sulfonamide moieties for the eastern 
region of the chemical scaffold we next sought to explore SAR surrounding the western 
side of the molecule, including the benzyl ring and the amide N-alkyl substituent. 
Noticing an opportunity to introduce chirality, we first experimented with placing a 
methyl at the benzylic position of the benzyl ring. Due to an inconsistent commercial 
supply of the preferred indazolyl sulfonyl chlorides, we initially conducted experiments 
with benzylic SAR in the context of the 4-methoxysulfonamide in the pharmacophore’s 
eastern region. Beginning from the commercial (S)- or (R)-1-phenylethanamine the 
analogs (R)-4.73 and (S)-4.74 were synthesized in the previously described manner 
(Scheme 4.3).  
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Scheme 4.3. Synthesis of benzylic methyl analogs (R)-4.73 and (S)-4.74. 
 
 
 Upon testing the compounds in full CRC Ca
2+
 mobilization assays at hM5 we 
observed the compounds to exhibit enantiospecific PAM activity, with (R)-4.73 
(VU0475757) exhibiting sub-micromolar potency (hM5 EC50 = 0.97 μM, %AChMax = 90) 
while (S)-4.74 (VU0475756) displayed no PAM activity (hM5 EC50 > 30 μM; Figure 
4.7A). 
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Figure 4.7. A) CRCs comparing activities of 4.73 (VU0475757; hM5 EC50 = 0.97 μM, %AChMax = 90), and 
4.74 (VU0475756; hM5 EC50 > 30 μM) at hM5. B) Potency and selectivity of analog 4.73. Ca
2+ 
mobilization assays with hM1-hM5 (M2 and M4 co-expressing Gαqi5) and rM5 cells were used to obtain 
CRCs of the compounds in the presence of a fixed submaximal (~EC20) concentration of ACh (4.73 EC50 
values: hM5 EC50 = 0.97 μM, %AChMax = 90; hM1-hM4 EC50 >30 μM; rM5 EC50 = 1.4 μM, %AChMax = 
88). Data represent the mean ± S.E.M. of at least 3 independent experiments with similar results. 
 
 
 
 Impressed by yet another leap in the potency of this chemical series we obtained 
potency and selectivity data for 4.74 at rM5 as well as at the remaining human mAChRs. 
The compound exhibited a slight decrease in potency at rM5 (rM5 EC50 = 1.4 μM), but it 
maintained complete selectivity for M5 versus hM1-hM4 (hM1-hM4 EC50 >30 μM; Figure 
4.7B) and, at 10 μM, produced a fold shift of 7.7- and 7.0-fold at hM5 and rM5, 
respectively (Figure 4.8). Given these data, 4.73 represented a >10-fold improvement in 
potency over the HTS lead 4.1 and the first sub-micromolar, M5-selective, non-isatin M5 
PAM that we had developed. 
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Figure 4.8. ACh CRC fold shifts of compound 4.73 (VU0475757) at hM5 (left panel) and rM5 (right 
panel). Ca2+ mobilization assays with hM5 cells and rM5 cells were used to obtain ACh CRCs in the 
presence of vehicle or 10 μM compound 4.73 (EC50 values: hM5 EC50 of ACh + vehicle = 539 pM, hM5 
EC50 of ACh + 4.73 = 70.0 pM, hM5 fold shift = 7.7; rM5 EC50 of ACh + vehicle = 1.11 nM, rM5 EC50 of 
ACh + 4.73 = 159 pM, rM5 fold shift = 7.0). Data represent the mean ± S.E.M. of at least 3 independent 
experiments with similar results. 
 
 
Combination of benzylic methyl and sulfonamide substituent SAR 
At this stage we acknowledged the importance of the multidimensional nature of 
our optimization strategy by combining the two regions of SAR explored thus far. A 
small library of analogs was constructed that combined the (R)-oriented benzylic methyl 
with the optimal sulfonamide substituents from our previous library. 1H-indazol-5-yl, 
1H-indazol-6-yl, and benzofuran-5-yl were recognized as the optimal sulfonamide 
substituents to be utilized, while 4 novel sulfonamide substituents were also selected to 
further explore and expand on the SAR of the sulfonamide region in the context of the 
benzylic methyl. From intermediate 4.71, the secondary amine was sulfonylated with the 
selected sulfonyl chlorides under standard acyl chloride amide coupling conditions 
(Scheme 4.4).  
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Scheme 4.4. Synthetic scheme for sulfonamide library analogs 4.75-4.81 from intermediate 4.71. Syntheses 
performed jointly with M. Kokubo. 
 
 
 
Table 4.3. Potencies at hM5 for 7 sulfonamide analogs, 4.75-4.81, in the context of the (R)-oriented 
benzylic methyl. Ca2+ mobilization assays with hM5 cells were used to obtain CRCs of compounds in the 
presence of a fixed submaximal (~EC20) concentration of ACh. VU number denotes the compound 
identifier assigned by Vanderbilt University. Data represent the mean of at least 3 independent experiments 
with similar results. 
 
 
 
 
Potency data gathered via CRC Ca
2+
 mobilization assays at hM5 revealed that the 
potency seen in 4.73 was maintained in the benzofuran-5-yl analog 4.77, while 
substantial gains in potency were seen in 1H-indazolyl analogs 4.75 and 4.76 as well as 
in the novel sulfonamide analogs 4.79 and 4.81 (Table 4.3). Further selectivity data 
obtained for 4.75 (VU0476212) against rM5 and the remaining human mAChR subtypes 
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revealed that 4.75 possessed comparable potency at rM5 (rM5 EC50 = 0.64 μM, %AChMax 
= 89) and was completely selective versus hM2 and hM4 (hM2, hM4 EC50 >30 μM). Slight 
activity was noted at hM1 and hM3, albeit with poor efficacy (hM1 EC50 = 4.8 μM, 
%AChMax = 61; hM3 EC50 = 1.7 μM, %AChMax = 59; Figure 4.9). Along with the 
increased potency seen at hM5 and rM5 with 4.75, fold shift data revealed that 4.75 
displayed an increased fold shift, shifting the ACh EC50 12- and 17-fold at hM5 and rM5, 
respectively (Figure 4.10).  
 
 
Figure 4.9. Structure, potency, and selectivity of analog 4.75 (VU0476212). Ca2+ mobilization assays with 
hM1-hM5 (M2 and M4 co-expressing Gαqi5) and rM5 cells were used to obtain CRCs of resynthesized 
compound 4.75 in the presence of a fixed submaximal (~EC20) concentration of ACh (EC50 values: hM5 
EC50 = 0.74 μM, %AChMax = 86; hM3 EC50 = 1.7 μM, %AChMax = 59; hM1 EC50 = 4.8 μM, %AChMax = 61; 
hM2, hM4 EC50 >30 μM; rM5 EC50 = 0.64 μM, %AChMax = 89). Data represent the mean ± S.E.M. of at 
least 3 independent experiments with similar results. 
 
 
124 
 
 
Figure 4.10. ACh CRC fold shifts of compound 4.75 (VU0476212) at hM5 (left panel) and rM5 (right 
panel). Ca2+ mobilization assays with hM5 cells and rM5 cells were used to obtain ACh CRCs in the 
presence of vehicle or 10 μM compound 4.75 (EC50 values: hM5 EC50 of ACh + vehicle = 1.10 nM, hM5 
EC50 of ACh + 4.75 = 95.2 pM, hM5 fold shift = 11.6; rM5 EC50 of ACh + vehicle = 4.54 nM, rM5 EC50 of 
ACh + 4.75 = 266 pM, rM5 fold shift = 17.1). Data represent the mean ± S.E.M. of at least 3 independent 
experiments with similar results. 
 
 
 
In vitro DMPK characterization of non-isatin M5 PAM VU0476212 
 
In vitro DMPK characterization of VU0476212 
 Considering that 4.75 (VU0476212) represented a ~13-fold improvement in 
potency over the HTS lead 4.1 and possessed a high degree of M5-selectivity in both 
human and rat, we elected to characterize the in vitro DMPK profile of 4.75 in order to 
ascertain if the compound might be a candidate for in vivo studies of M5 in the CNS. The 
compound was assayed in several in vitro DMPK assays, including plasma protein 
binding, rat and human microsomal stability, and a CYP inhibition panel. The results 
from these assays are summarized in Table 4.4. 
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Table 4.4. In vitro DMPK data for 4.75 (VU0476212) in multiple species. Studies performed by T. 
Bridges. ---, not determined. 
 
 
 
 
 
 Compound 4.75 displayed a moderate CYP inhibition profile, with 3A4 
representing the primary liability. In both rat and human 4.75 displayed a low-to-
moderate fraction unbound in plasma. In microsomal stability studies 4.75 exhibited high 
intrinsic clearance, with predicted hepatic clearance values near the hepatic blood flow 
rate in each species tested. 
 In addition to the standard DMPK profile studies, a bidirectional Caco-2 transwell 
assay was also carried out to assess efflux liabilities. When dosed at 5 μM, 4.75 exhibited 
a Papp of 16.6 x 10
-6
 cm/sec, indicating moderate-high permeability, and an ER of 0.7, 
suggesting an absence of P-gp-mediated active efflux liabilities at the BBB. 
 
VU0476212 metabolite identification  
 From the results of the microsomal stability assay it was clear that we needed to 
bolster the unstable structural elements of analog 4.75 that were leading to the 
compound’s rapid metabolism and clearance. Thus we sought to determine the relevant 
biotransformation pathway(s) occurring within the hepatic microsomes via metabolite 
identification studies (Figure 4.11).  
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Figure 4.11. Results of metabolite identification following incubation of 4.75 with rat hepatic microsomes 
and NADPH. The primary metabolite identified, 4.82, is the product of oxidative (NADPH-dependent) N-
dealkylation. Studies performed by T. Bridges. 
 
 
 
These analyses revealed the oxidative N-dealkylation of the amide to be the 
primary pathway of biotransformation in both plasma and microsomes. To explore the 
possibility that the primary metabolite may itself be an M5 PAM we synthesized 
metabolite 4.82 from intermediate 4.67 (Scheme 4.5). Unfortunately, upon testing 4.82 in 
a full CRC Ca
2+
 mobilization assay at hM5, and found the primary metabolite to be 
inactive (hM5 EC50 >>30 μM). 
 
 
 
Scheme 4.5. Synthesis of 4.82 (VU0485582), the primary metabolite of 4.75 (VU0476212), from 
intermediate 4.67. Syntheses performed jointly with M. Kokubo 
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Since the primary metabolite 4.82 was an inactive species, we attempted to reduce 
metabolism via deuteration of the methylene position of the amide N-ethyl. Through the 
deuteration of the N-alkyl substituent we sought to take advantage of the kinetic isotope 
effect and thereby perturb the rate of the oxidation by the CYP proteins
86,87
. The 
deuterium analog 4.86 was synthesized from intermediate 4.67 with the previously 
described procedure (Scheme 4.6). Upon testing in a CRC Ca
2+
 mobilization assay at 
hM5, we were pleased to see that 4.86 maintained sub-micromolar activity at hM5 (hM5 
EC50 = 0.56 μM, %AChMax = 93; Scheme 4.6). In order to determine if improved 
metabolic stability accompanied the improved potency, deuterated analog 4.86 was tested 
in plasma protein binding and microsomal stability assays at rat and human (Table 4.5). 
Although deuteration of the N-ethyl methylene position slightly reduced the intrinsic 
clearance values at rat and human relative to the values seen for 4.75 in Table 4.4, the 
intrinsic clearance values were still exceedingly high and the predicted hepatic clearance 
values remained near the hepatic blood flow rate. 
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Scheme 4.6. Synthesis and activity of deuterated analog 4.86 (VU0477898) from intermediate 4.67. Ca2+ 
mobilization assays in hM5 cells were used to obtain CRCs of compound 4.86 in the presence of a fixed 
submaximal (~EC20) concentration of ACh. Data represent the mean of at least 3 independent experiments 
with similar results. 
 
 
 
Table 4.5. In vitro DMPK data for 4.86 (VU0477898) in multiple species. Studies performed by T. 
Bridges.  
 
 
 
 
 
Although we were unsuccessful in our initial attempts to directly address the 
oxidative dealkylation of 4.75, the SAR of many regions of the chemical scaffold had yet 
to have been explored. Thus, we returned to optimizing unexplored chemical space with 
the confidence that further discoveries found in the course of potency optimization might 
present a solution to shunt or block the oxidative dealkylation of the amide. 
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Optimization of VU0476212 to obtain non-isatin M5 PAM VU0481443 
 
Exploration of amide and sulfonamide SAR 
 Since it was evident that the DMPK liabilities of compound 4.75 centered on the 
oxidative dealkylation of the tertiary amide, we next explored the SAR in this area with 
the goal of altering or masking the amide to the point that it would retard or halt oxidative 
dealkylation. It should be noted that this particular effort was not concerted, but was 
carried out over time as a side project to the larger SAR exploration efforts, hence the 
smattering of different elements of SAR.  
Initial studies exploring the SAR around the amide consisted of several 
standalone compounds and small libraries designed to examine the tractability and 
necessity of the amide itself. Scheme 4.7 depicts the synthesis of a bis-amide analog 4.87 
from intermediate 4.5, while Scheme 4.8 depicts the complete synthesis of bis-
sulfonamides 4.92-4.94. Upon testing these compounds in Ca
2+
 mobilization assays at 
hM5, they were shown to be inactive (hM5 EC50 >>30 μM). 
 
 
Scheme 4.7. Synthesis of bisamide analog 4.87 (VU0475726) from intermediate 4.5. 
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Scheme 4.8. Synthesis of bissulfonamide analogs 4.92-4.94. Synthesized jointly with M. Kokubo. 
 
 
 Scheme 4.9 depicts the synthesis of the reverse amide, analog 4.99. This 
compound was also found to be inactive at hM5 upon testing in Ca
2+
 mobilization assays 
(hM5 EC50 >>30 μM). 
 
 
Scheme 4.9. Synthesis of reverse amide analog 4.99 (VU0473996). 
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Lastly, we synthesized two libraries that examined the migration of the amide 
carbonyl to form either benzamide analogs (4.104-4.109) or acetamide analogs (4.113-
4.118) in the context of multiple sulfonamide substituents. Scheme 4.10 and Scheme 
4.11 depict the syntheses of these libraries. As with all other attempts to manipulate the 
amide carbonyl, these analogs proved to be devoid of activity at hM5 upon testing in Ca
2+
 
mobilization assays. Thus, despite probing multiple variations of amide positioning and 
composition, persistent inactivity in the resulting analogs suggests that the original amide 
is a necessary structural element for PAM activity. 
 
 
Scheme 4.10. Synthesis of benzamide analogs 4.104-4.109. Syntheses performed by M. Kokubo. 
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Scheme 4.11. Synthesis of acetamide analogs 4.113-4.118. Syntheses performed by M. Kokubo. 
 
 
Attempts to constrain the N-alkyl moiety 
 After finding it challenging to modify the amide without losing PAM activity, we 
investigated other strategies to prevent the oxidative dealkylation of the N-ethyl. One 
intriguing possibility was to constrain the N-alkyl by bonding the alkyl chain to either the 
benzyl ring or the benzylic position. We constructed a small library that examined the 
effects of tying back the N-alkyl to the benzyl ring with varying chain lengths (analogs 
4.119-4.121), tying back the N-alkyl to the benzyl ring in the context of a benzylic methyl 
(analog 4.122-4.124), and tying back the N-ethyl to the benzylic methyl (analog 4.125; 
Scheme 4.12, Figure 4.12). Unfortunately, all of the constrained N-alkyl library analogs 
were devoid of PAM activity in Ca
2+
 mobilization assays at hM5 (Figure 4.12). 
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Scheme 4.12. General synthesis of libraries constraining N-alkyl to benzyl moiety, analogs 4.119-4.125. 
Synthesized jointly with M. Kokubo. 
 
 
 
 
Figure 4.12. Structures of inactive analogs from the constrained N-alkyl library, analogs 4.119-4.125. 
 
 
 
Optimization of western benzamide ring substituent SAR 
 Disappointed by our unsuccessful attempts to directly address the oxidative 
dealkylation of the N-alkyl substituent, we elected to further explore the general SAR of 
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the chemical scaffold with the expectation that further potency optimization may also 
result in increased stability to metabolic processes. We next turned our attention to the 
SAR of the western benzamide region, recalling the marked improvement in potency 
observed after the introduction of the benzylic methyl during our previous exploration of 
this region. Up until this point an unadorned benzyl ring was present all of our analogs; 
therefore, we aimed to construct a library exploring diverse substitutions of the western 
benzyl ring in order to assess the general SAR of the region.  
While planning the library we took great care in deciding which features of 
existing SAR to include and which to omit. We ultimately decided to use 1H-indazol-6-yl 
to serve as the model sulfonamide substituent to be used throughout the library. We also 
elected to construct the benzyl library analogs in the absence of the benzylic methyl. This 
latter decision was due to the estimation that omitting the benzylic methyl allowed us to 
avoid confusing constructive or destructive SAR interactions between benzyl ring 
substituents and the benzylic methyl, thus making for a more systematic examination of 
the benzyl ring SAR.  
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Scheme 4.13. General synthesis of benzyl bromide library compounds 4.127-4.151. Synthesized jointly 
with M. Kokubo. 
 
 
Beginning from N-Boc protected carboxylic acid core 4.2, a HATU-mediated 
peptide coupling with ethanamine furnished the secondary amide 4.126. The amide was 
deprotonated and alkylated with a library of 25 benzyl bromides and 
bromomethylpyridines to form the tertiary amides. Removal of the Boc protecting group 
for each analog intermediate was accomplished under standard anhydrous HCl conditions 
to provide the HCl salts. Finally, the secondary amines were sulfonylated with 1H-
indazol-6-sulfonyl chloride to form the final library analogs 4.127-4.151 (Scheme 4.13). 
 The benzyl ring library analogs were tested in single point (10 μM) Ca2+ 
mobilization assays to assess their general PAM activity. The results of this primary 
assay are summarized in Figure 4.13 and Table 4.6. The single point library revealed 
that a number of the benzyl ring modifications were productive. The activity of the 
benzyl ring substitution followed a general pattern of ortho > meta > para, with halide, 
methyl, trifluoromethyl, methoxy, and trifluoromethoxy substitutions all exhibiting 
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strong potentiation of the EC20. Contrastingly, nitrile substitutions and methylpyridyl 
replacements displayed weak or no PAM activity.  
 
Figure 4.13. Comparison of single point (10 μM) screen results of the benzyl library, analogs 4.127-4.151. 
Ca2+ mobilization was used to obtain % AChMax values for each compound in the presence of a fixed 
submaximal (~EC20) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 replicate 
experiments with similar results. 
 
 
 
Table 4.6. Structures for benzyl analogs 4.127-4.151 and associated PAM activity data from the single 
point (10 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported as a percentage 
of the maximum ACh response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # 
hM5 
%AChMax 
 
4.127 VU0479095 69.9 
 
4.128 VU0477974 84.8 
 
4.129 VU0477945 52.1 
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4.130 VU0487292 63.7 
 
4.131 VU0477948 57.2 
 
4.132 VU0481717 90.7 
 
4.133 VU0479028 73.9 
 
4.134 VU0481762 85.1 
 
4.135 VU0481910 85.8 
 
4.136 VU0479111 84.2 
 
4.137 VU0482003 35.4 
 
4.138 VU0479129 24.2 
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4.139 VU0477935 40.8 
 
4.140 VU0481788 36.8 
 
4.141 VU0480112 46.3 
 
4.142 VU0479112 8.4 
 
4.143 VU0480113 24.8 
 
4.144 VU0477880 39.6 
 
4.145 VU0487191 84.5 
 
4.146 VU0479011 74.2 
 
4.147 VU0480124 32.0 
139 
 
 
4.148 VU0479128 14.0 
 
4.149 VU0480186 35.1 
 
4.150 VU0480161 19.8 
 
4.151 VU0481420 22.4 
    
 
To further corroborate these SAR results we obtained potency data on selected 
analogs in full CRC Ca
2+
 mobilization assays at hM5 (Table 4.7). As we observed in the 
single-point screen, the ortho-substituted analogs generally provided the greatest 
improvements in potency, with the ortho-CF3 of compound 4.136 (VU0479111) 
demonstrating the greatest potency that we had yet observed in a non-isatin M5 PAM 
(hM5 EC50 = 480 nM, %AChMax = 92).  
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Table 4.7. Potencies at hM5 for substituted benzyl ring analogs selected from the single point (10 μM) 
screen. Ca2+ mobilization assays with hM5 cells were used to obtain CRCs of compounds in the presence of 
a fixed submaximal (~EC20) concentration of ACh. Data represent the mean of at least 3 independent 
experiments with similar results. 
 
 
With our earlier lead analog, 4.75, we had witnessed increased off-target mAChR 
activity accompanying the compound’s sub-micromolar potency at M5, thus we were 
interested to further characterize the activity of 4.136 in selectivity assays at the 
remaining human mAChRs and rM5, and at fold shift assays at hM5. The results of these 
studies are shown in Figure 4.14 and Figure 4.15. 
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Figure 4.14. Structure, potency, and selectivity of analog 4.136 (VU0479111). Ca2+ mobilization assays 
with hM1-hM5 (M2 and M4 co-expressing Gαqi5) and rM5 cells were used to obtain CRCs of compound 
4.136 in the presence of a fixed submaximal (~EC20) concentration of ACh (EC50 values: hM5 EC50 = 0.48 
μM, %AChMax = 92; hM3 EC50 = 4.4 μM, %AChMax = 65; hM1, hM2, hM4 EC50 >30 μM; rM5 EC50 = 1.3 
μM, %AChMax = 96). Data represent the mean ± S.E.M. of at least 3 independent experiments with similar 
results. 
 
 
Figure 4.15. ACh CRC fold shifts of compound 4.136 (VU0479111) at hM5 (left panel) and rM5 (right 
panel). Ca2+ mobilization assays with hM5 cells and rM5 cells were used to obtain ACh CRCs in the 
presence of vehicle or 10 μM compound 4.136 (EC50 values: hM5 EC50 of ACh + vehicle = 1.20 nM, hM5 
EC50 of ACh + 4.136 = 174 pM, hM5 fold shift = 6.9; rM5 EC50 of ACh + vehicle = 1.84 nM, rM5 EC50 of 
ACh + 4.136 = 241 pM, rM5 fold shift = 7.6). Data represent the mean ± S.E.M. of at least 3 independent 
experiments with similar results. 
 
 
These data revealed that 4.136 suffers some species difference, being ~3-fold less 
potent at rM5 than at hM5 (rM5 EC50 = 1.3 μM, %AChMax = 92). The compound is, 
however highly M5-preferring (hM1, hM2, hM4 EC50 > 30 μM). M3 remains the primary 
off-target mAChR activity (hM3 EC50 = 4.4 μM, %AChMax = 65), yet it displayed ~2.5-
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fold less potency than in compound 4.75. This factor, in combination with the increased 
potency at M5, indicates that the ortho-CF3 benzyl modification of 4.136 considerably 
increased the selectivity window for the non-isatin M5 PAMs. Despite the increased 
potency and selectivity window of 4.136, fold shift assays revealed the compound is less 
proficient at shifting an ACh CRC (hM5 fold shift = 6.9, rM5 fold shift = 7.6) compared 
to 4.75 (hM5 fold shift = 11.6, rM5 fold shift = 17.1). 
 
 
Combination of benzyl region SAR 
Pleased with the gain in potency offered by the ortho-CF3 benzyl substituent, we 
once again combined elements of SAR by synthesizing analogs possessing both the 
ortho-CF3 as well as the (R)-oriented benzylic methyl. In order to maximize the diversity 
of SAR explored, this combination of SAR was attempted in the context of multiple 
sulfonamide substituents previously observed to be potent in their own respect. 
 
 
Scheme 4.14. Synthesis of combined benzyl region SAR compounds 4.155-4.157. Synthesis performed by 
M. Kokubo. 
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Table 4.8. Potencies at hM5 for combined benzyl region SAR analogs 4.155-4.157. Ca
2+ mobilization 
assays with hM5 cells were used to obtain CRCs of compounds in the presence of a fixed submaximal 
(~EC20) concentration of ACh. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean of at least 3 independent experiments with similar results. ---, not 
determined. 
 
 
 
 From the N-Boc protected carboxylic acid core 4.2, a HATU-mediated peptide 
coupling with (R)-1-(2-(trifluoromethyl)phenyl)ethanamine furnished the secondary 
amide 4.152. The amide was then deprotonated and treated with iodoethane to furnish 
intermediate 4.153. Removal of the Boc protecting group was accomplished under 
standard anhydrous HCl conditions to provide HCl salt 4.154. Finally, the secondary 
amine was sulfonylated with 1H-indazol-5-, benzofuran-5-, or 4-(1H-pyrazol-1-
yl)benzene-1-sulfonyl chloride to form analogs 4.155-4.157 (Scheme 4.14). 
Disappointingly, CRC Ca
2+
 mobilization assays at hM5 revealed that the SAR of the 
benzylic methyl group and the ortho-CF3 substituent was not cooperative. Instead, 
combination of these structural elements resulted in inactive or dramatically weakened 
compounds (Table 4.8). 
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Discovery of VU0481443  
After finding it unfavorable to combine the SAR of the benzylic methyl group 
with the ortho-CF3 benzyl ring substituent, we sought alternate means to directly 
compare these two elements of benzamide SAR. Thus, we synthesized an analog 
possessing the ortho-CF3 in the context of the 1H-indazol-5-sulfonamide substituent, 
which we previously observed to be slightly more potent than the 1H-indazol-6-yl 
congener in our initial library. This analog would serve as a direct comparator to 
compound 4.75 (VU0476212), which possessed the benzylic methyl in the context of the 
1H-indazol-5-sulfonamide substituent. 
From the N-Boc protected carboxylic acid core 4.2, a HATU-mediated peptide 
coupling with 2-(trifluoromethyl)benzylamine furnished the secondary amide 4.158. The 
amide was then deprotonated and treated with iodoethane to furnish intermediate 4.159. 
Removal of the Boc protecting group was accomplished under standard anhydrous HCl 
conditions to provide HCl salt 4.160. Finally, the secondary amine was sulfonylated with 
1H-indazol-5-sulfonyl chloride to form analog 4.161 (VU0481443) (Scheme 4.15). 
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Scheme 4.15. Synthesis of compound 4.161 (VU0481443). Synthesized jointly with M. Kokubo 
 
 
Upon testing in a full CRC Ca
2+
 mobilization assay at hM5, we were pleased to 
see that the 1H-indazol-5-yl analog 4.161 was extremely potent (hM5 EC50 = 190 nM, 
%AChMax = 96). Analog 4.161 was thus ~2.5-fold more potent than the 1H-indazol-6-
sulfonamide analog 4.136, ~4-fold more potent than its benzylic methyl congener 4.75 
(VU0476212), and the most potent M5 PAM that we had observed to date. 
 
In vitro pharmacological characterization of non-isatin M5 PAM VU0481443 
 
Characterization of VU0481443 mAChR selectivity and fold shift 
 Impressed by the hM5 potency of 4.161 (VU0481443), we desired to obtain a 
more extensive in vitro pharmacologic profile. This characterization effort began with a 
full mAChR subtype-selectivity profile for the compound. Counterscreening was carried 
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out against human mAChR subtypes as well as for all rat mAChR subtypes (Figure 
4.16). 
 
 
Figure 4.16. Potency and selectivity of compound 4.161 (VU0481443) at all human and rat mAChR 
subtypes. Ca2+ mobilization assays with hM1-hM5 cells and with rM1-rM5 cells (M2 and M4 co-expressing 
Gαqi5) were used to obtain CRCs of 4.161 in the presence of a fixed submaximal (~EC20) concentration of 
ACh (EC50 values: hM5 EC50 = 0.19 μM, %AChMax = 96; hM3 EC50 = 2.1 μM, %AChMax = 68; hM1 EC50 = 
5.4 μM, %AChMax = 52; hM2, hM4 EC50 >30 μM; rM5 EC50 = 0.48 μM, %AChMax = 89; rM3 EC50 = 3.1 
μM, %AChMax = 48; rM1 EC50 = 3.6 μM, %AChMax = 81; rM2, rM4 EC50 >30 μM). Data represent the mean 
± S.E.M. of at least 3 independent experiments with similar results. 
 
 
The mAChR selectivity panel revealed that 4.161 possesses a high degree of 
preference for hM5 and ~10-fold selectivity for hM5 over hM1 and hM3 (hM3 EC50 = 2.1 
μM, %AChMax = 68; hM1 EC50 = 5.4 μM, %AChMax = 52). Across rat mAChR subtypes, 
we again observed rM5 to be ~2.5-fold less potent than the human isoform (rM5 EC50 = 
0.48 μM, %AChMax = 89). Interestingly, the rat mAChR subtypes displayed different 
subtype selectivity than the human isoforms, with M3 activity diminished and M1 activity 
becoming the prevalent off target mAChR subtype (rM3 EC50 = 3.1 μM, %AChMax = 48; 
rM1 EC50 = 3.6 μM, %AChMax = 81). 
Further characterization of the compound’s efficacy was probed in fold shift 
assays. In these assays 4.161 induced a 9.3-fold leftward shift of the ACh CRC in hM5 
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and 13.8-fold shift in rM5 (Figure 4.17). Although the fold shifts of 4.161 are greater 
than most of the previous analogs, the fold shifts of the benzylic methyl congener 4.75 
(hM5: 11.6-fold, rM5: 17.1 fold) remain the highest values yet observed with this 
chemical series. Thus, although our exploration of the SAR around the benzyl ring 
resulted in the greatest potency of this chemical series, the SAR around the benzylic 
methyl position appears to have a greater ability to shift the CRC of ACh. Nevertheless, 
the submicromolar potency, M5-selectivity, and ACh fold shift exhibited by compound 
4.161 earned it lead compound status and it was subsequently approved as an MLPCN 
probe and given the identifier ML380. 
 
 
Figure 4.17. ACh CRC fold shifts of compound 4.161 (VU0481443) at hM5 (left panel) and rM5 (right 
panel). Ca2+ mobilization assays with hM5 cells and rM5 cells were used to obtain ACh CRCs in the 
presence of vehicle or 10 μM compound 4.161 (EC50 values: hM5 EC50 of ACh + vehicle = 1.20 nM, hM5 
EC50 of ACh + 4.161 = 129 pM, hM5 fold shift = 9.3; rM5 EC50 of ACh + vehicle = 1.84 nM, rM5 EC50 of 
ACh + 4.161 = 133 pM, rM5 fold shift = 13.8). Data represent the mean ± S.E.M. of at least 3 independent 
experiments with similar results. 
 
 
Ancillary pharmacology of VU0481443 
 To more broadly characterize the off-target pharmacology of 4.161, we assayed 
the compound in a commercial radioligand competition binding screen of 67 GPCRs, ion 
channels, and transporters (Table 4.9). Pleasingly, 4.161 showed significant inhibition of 
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binding (≥50% radioligand displacement) at only two of the targets tested: cannabinoid 
CB1 (50% displ acement) and sigma σ1 (53% displacement).  
 
Table 4.9. Ancillary/off-target competition binding screen results for 4.161 (VU0481443, ML380). 4.161 
was dosed at 10 μM for single point competition binding assays. Targets displaying significant binding 
(≥50% at 10 μM) are outlined. Data represent the mean of 2 independent experiments with similar results. 
Studies performed by Eurofins Panlabs, Inc. 
 
Target/Protein Species % Inhibition 
Adenosine A1 Human -3 
Adenosine A2A Human 3 
Adenosine A3 Human 14 
Adrenergic α1A Rat 12 
Adrenergic α1B Rat -10 
Adrenergic α1D Human 5 
Adrenergic α2A Human 37 
Adrenergic β1 Human 3 
Adrenergic β2 Human -8 
Androgen (Testosterone) AR Rat 11 
Bradykinin B1 Human 8 
Bradykinin B2 Human 11 
Calcium Channel L-Type, Benzothiazepine Rat 37 
Calcium Channel L-Type, Dihydropyridine Rat 17 
Calcium Channel N-Type Rat 2 
Cannabinoid CB1 Human 50 
Dopamine D1 Human 7 
Dopamine D2S Human 6 
Dopamine D3 Human 23 
Dopamine D4.2 Human -2 
Endothelin ETA Human 1 
Endothelin ETB Human 8 
Epidermal Growth Factor (EGF) Human 9 
Estrogen ERα Human 8 
GABAA, Flunitrazepam, Central Rat 1 
GABAA, Muscimol, Central Rat -2 
GABAB1A Human -2 
Glucocorticoid Human 1 
Glutamate, Kainate Rat -6 
Glutamate, NMDA, Agonism Rat 1 
Glutamate, NMDA, Glycine Rat -2 
Glutamate, NMDA, Phencyclidine Rat 8 
Histamine H1 Human 26 
Histamine H2 Human 5 
Histamine H3 Human 6 
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Imidazoline I2, Central Rat 15 
Interleukin IL-1 Mouse -9 
Leukotriene, Cysteinyl CysLT1 Human 38 
Melatonin MT1 Human 34 
Muscarinic M1 Human 1 
Muscarinic M2 Human 1 
Muscarinic M3 Human 14 
Neuropeptide Y Y1 Human -4 
Neuropeptide Y Y2 Human 3 
Nicotinic Acetylcholine Human 8 
Nicotinic Acetylcholine α1, Bungarotoxin Human 1 
Opiate δ1 (OP1, DOP) Human 6 
Opiate κ (OP2, KOP) Human 5 
Opiate μ (OP3, MOP) Human 5 
Phorbol Ester Mouse 2 
Platelet Activating Factor (PAF) Human 7 
Potassium Channel [KATP] Human 5 
Potassium Channel hERG Human 18 
Prostanoid EP4 Human 33 
Purinergic P2X Rabbit 31 
Purinergic P2Y Rat 4 
Rolipram Rat 4 
Serotonin (5-HT1A) Human 0 
Serotonin (5-HT2B) Human 32 
Serotonin (5-HT3) Human -4 
Sigma σ1 Human 53 
Sodium Channel, Site 2 Rat 49 
Tachykinin NK1 Human 18 
Thyroid Hormone Rat 5 
Transporter, Dopamine (DAT) Human 39 
Transporter, GABA Rat -1 
Transporter, Norepinephrine (NET) Human 20 
Transporter, Serotonin (SERT) Human 2 
 
 
Confirmation of the allosteric mechanism of VU0481443 
Although the allosteric mechanism of 4.161 was strongly supported by its 
behavior in double-add Ca
2+
 mobilization assays (i.e. – 4.161 possesses no inherent 
activity, yet potentiates an ACh EC20), we desired to confirm the allosteric mechanism 
via [
3
H]-NMS competition binding with 4.161 (Figure 4.18). As anticipated, when 
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competing with [
3
H]-NMS in hM5 membrane preparations, 4.161 does not compete for 
the orthosteric site. These competition binding data, when taken into account with the 
aforementioned evidence of an allosteric mechanism, strongly suggests that 4.161 is 
indeed an allosteric modulator. 
 
 
Figure 4.18. [3H]-NMS competition binding assay with 4.161 (VU0481443, ML380) in an hM5 membrane 
preparation. [3H]-NMS and a CRC of either atropine (control) or 4.161 were allowed to equilibrate for 3 
hours in the hM5 membrane preparation before filtration and scintillation counting (Ki values: atropine Ki = 
1.5 nM, 4.161 Ki >> 10 μM). Data represent the mean ± S.E.M. of at least 3 independent experiments with 
similar results. 
 
 
In vitro and in vivo DMPK characterization of non-isatin M5 PAM VU0481443 
Encouraged by the compound’s potent and M5-preferring in vitro 
pharmacological profile, we began investigating the DMPK profile of 4.161 
(VU0481443, ML380). 4.161 was entered into multiple studies, including plasma protein 
binding, rat brain homogenate binding, and rat and human microsomal stability. The 
results from these assays are summarized in Table 4.10. As with compound 4.75, 4.161 
displayed very low metabolic stability, with high intrinsic clearance values and 
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correspondingly high predicted hepatic clearance values near hepatic blood flow in both 
rat and human.  
 
Table 4.10. In vitro and in vivo IV PK/PBL DMPK data for 4.161 (VU0481443, ML380) in multiple 
species. Studies performed by T. Bridges. ---, not determined. 
 
 
 
 
The instability of 4.161 was reconfirmed in an in vivo IV PK/PBL assay where 
compound was dosed to male Sprague-Dawley rats at 1 mg/kg (n = 3). The compound 
displayed high plasma clearance and a short half-life. A modest Kp of 0.36 was 
determined at 15 minutes post-administration which translates to a Kp,uu of 0.28, 
indicating that the compound is weakly CNS penetrant, or a substrate for active efflux 
across the BBB. 
To examine this latter hypothesis we tested the compound in an in vitro, 
bidirectional transwell assay employing MDCK-MDR1 cells to assess efflux liabilities at 
the BBB. When dosed at 5 μM, 4.161 exhibited an efflux ratio of 16, suggesting that it is 
a strong substrate for P-gp-mediated active efflux. This high efflux ratio, along with the 
restricted CNS penetrance demonstrated in the IV PK/PBL study, indicates that 4.161 is 
impractical as a chemical probe for M5 within the CNS. Nevertheless, if the stability of 
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the compound could be improved, its restriction to the periphery may prove to make 
4.161 an ideal probe for studying M5 in the endothelium of the cerebral vasculature. 
 Given that the tertiary amide of 4.161 was virtually unchanged from that of 4.75, 
it appeared probable that the compound was undergoing an identical or similar oxidative 
dealkylation process. Thus we again turned our synthetic efforts back to exploring novel 
SAR that could bolster the stability of the chemical scaffold while maintaining its potent 
M5 PAM activity. 
 
 
Continued SAR exploration of non-isatin M5 PAM VU0481443 
 
Exploration of piperidine core modifications 
 We investigated multiple modifications to the heretofore unexplored piperidine 
core, hypothesizing that changes to the structure or orientation of the core and its 
connectivity to the tertiary amide may block the instabilities around this region. As with 
our earlier exploration of the amide carbonyl composition and orientation, it should be 
noted that this effort was not concerted, but was compiled from several standalone 
syntheses performed alongside larger library synthetic efforts, hence the assortment of 
elements of SAR. 
 The earliest modification of the core involved simply shifting the connectivity of 
the amide one carbon over, thus kinking the structure and introducing a chiral center. 
From the enantiopure starting materials (S)- or (R)-1-Boc-piperidine-3-carboxylic acid, 
analogs (R)-4.170 and (S)-4.171 were synthesized in the context of 4-
methoxybenzenesulfonamide in the previously detailed fashion (Scheme 4.16). Both 
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analogs were found to be inactive in CRC Ca
2+
 mobilization assays at hM5 (hM5 EC50 
>>30 μM). 
 
 
 
Scheme 4.16. Synthesis of shifted piperidine core analogs 4.170 (VU0475663) and 4.171 (VU0475676). 
  
Echoing our attempts at constraining the N-alkyl moiety to the benzyl ring, we 
synthesized two analogs that constrain the N-alkyl to the piperidine core itself in a 
spirocyclic fashion. In both cases an N-Boc-protected spirocyclic amide was alkylated 
with a benzyl bromide, deprotected, and subsequently sulfonylated in the previously 
detailed fashion to provide analogs 4.178 and 4.179 (Scheme 4.17). Once again, both 
analogs proved to be inactive in CRC Ca
2+
 mobilization assays at hM5 (hM5 EC50 >>30 
μM). 
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Scheme 4.17. Synthesis of spirocyclic core compounds 4.178 (VU0473644) and 4.179 (VU0482981). 
Synthesized jointly with M. Kokubo. 
 
 
 Our final attempt at SAR exploration in this region was the alteration of the core 
structure itself. In the case of analog 4.188 we substituted an azetidine core, whereas in 
the case of analog 4.189 we substituted a 3-azabicyclo[3.1.0]hexane core. For both 
analogs, the synthesis began from the respective N-Boc protected acid cores and 
proceeded in the previously detailed fashion (Scheme 4.18). SAR of the core yet again 
proved to be intractable as both analogs were devoid of activity in CRC Ca
2+
 
mobilization assays at hM5 (hM5 EC50 >>30 μM). 
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Scheme 4.18. Synthesis of central core substitutions, analogs 4.188 (VU0481897) and 4.199 (VU0482092). 
Syntheses performed by M. Kokubo. 
 
 
Substitution of the amide N-alkyl substituent 
 As we were thwarted in all attempts to dramatically change the structure or 
conformation of the sensitive amide region of the chemical scaffold, we opted to take a 
new approach by substituting the N-alkyl substituent. Employing a variety of small 
alkylamines we were able to construct a library of novel N-alkyl analogs in the context of 
both the ortho-CF3 benzyl substitution and the 1H-indazol-5-sulfonamide. 
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Scheme 4.19. General synthesis of N-alkyl library analogs 4.190-4.201. Syntheses performed by M. 
Kokubo. 
 
 
From the N-Boc protected carboxylic acid core 4.2, an EDC-mediated peptide 
coupling with one of a library of 12 alkyl halides furnished the secondary amide 
intermediates. The amides were next deprotonated with tert-butoxide followed by 
treatment with 1-(bromomethyl)-2-(trifluoromethyl)benzene to form the tertiary amide 
intermediates. Removal of the Boc protecting group was accomplished under standard 
anhydrous HCl conditions to provide the HCl salts. Finally, the secondary amines were 
sulfonylated with 1H-indazol-5-sulfonyl chloride to produce compounds 4.190-4.201 
(Scheme 4.19). 
When the analogs were tested in full CRC Ca
2+
 mobilization assays at hM5, we 
were pleased to see that the SAR surrounding the N-alkyl substituent was diverse and 
rich. Multiple N-alkyl substitutions resulted in highly potent M5 PAMs. Aliphatic 
substitutions were highly productive, with EC50 values as low as 120 nM in the case of 
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the N-neopentyl analog 4.196 (Table 4.11). Many of the N-alkyl analogs were submitted 
to human and rat hepatic microsome stability studies in order to ascertain if these changes 
in any way affected the scaffold’s metabolic instability. Unfortunately, despite the variety 
of substitutions, all analogs tested were rapidly cleared, with predicted hepatic clearance 
values at parity with hepatic blood flow in each species. The N-cyclopropyl analog 4.197 
was cleared at relatively slower rate; however, it was inactive in Ca
2+
 mobilization assays 
at hM5 (Table 4.11). 
 
Table 4.11. Potencies at hM5 for N-alkyl library analogs 4.190-4.201 and corresponding microsomal 
clearance data in rat and human for selected analogs. Ca2+ mobilization assays with hM5 cells were used to 
obtain CRCs of compounds in the presence of a fixed submaximal (~EC20) concentration of ACh. VU 
number denotes the compound identifier assigned by Vanderbilt University. Data represent the mean of at 
least 3 independent experiments with similar results. Microsomal clearance studies performed by T. 
Bridges. ---, not determined. 
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 Our previous metabolite identification study that identified oxidative dealkylation 
as the primary mode of clearance was carried out on the less potency optimized analog 
4.75. In order to investigate if the current series of N-alkyl substituted analogs was 
cleared via the same biotransformation pathways we initiated a second metabolite 
identification study on the highly potent N-neopentyl analog 4.196.  
 
 
Figure 4.19. Results of metabolite identification following incubation of analog 4.196 (VU0549968) with 
rat hepatic microsomes and NADPH. Studies performed by A. Rajapakse. 
 
 
 This study revealed a pathway similar to what we had previously observed, but it 
gave more detailed insight into the clearance pathway (Figure 4.19). The primary 
metabolites detected indicated keto-reduction of the amide (4.203) as well as methylene 
hydroxylation (4.202). This latter metabolite could potentially be involved in the 
dealkylation pathway we previously observed by forming an unstable hemiaminal which 
subsequently collapses, dealkylating the amide.  
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Summary and future directions 
 
The first non-isatin M5 PAM, 4.1 (VU0472882), was discovered in an HTS of the 
MLPCN screening deck, presenting weak potency at M5. The HTS lead was subsequently 
subjected to a multidimensional iterative parallel synthesis optimization effort to explore 
SAR and improve potency. This effort produced over 170 analogs, culminating in the 
lead compound, 4.161 (VU0481443, ML380), an M5-preferring PAM which possessed 
over 50-fold greater potency at M5 relative to the HTS lead (Figure 4.20). 
 
 
Figure 4.20. Summary and comparison of the structure, potency, and SAR found around the non-isatin M5 
PAM HTS lead 4.1 (VU0472882) that led to the discovery of the novel, sub-micromolar, non-isatin M5-
preferring PAM 4.161 (VU0481443, ML380).  
 
In exploring the SAR of the compound it was found that the sulfonamide region 
possessed a high degree of flexibility in what substituents were tolerated. Nearly all aryl 
sulfonamides produced active analogs; however it was found that 6-5 heterocyclic 
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systems such as 1H-indazol-5-, 1H-indazol-6-, and benzofuran-5-sulfonamide produced 
the most potent results (analogs 4.47, 4.50, and 4.53, respectively). 
The benzyl region of the molecule was found to have more nuanced SAR. The 
introduction of a methyl to the benzylic position revealed enantiospecific activity, with 
the (R)-oriented methyl producing sub-micromolar activity in the context of a 1H-
indazol-5-sulfonamide (analog 4.75). Sub-micromolar EC50s could also be obtained via 
the substitution of benzyl ring, with the ortho position being highly favored. It was in this 
region that the introduction of an ortho-CF3 on the benzyl ring in the context of a 1H-
indazol-5-sulfonamide led to our current lead compound, the highly potent 4.161. In 
further characterization, 4.161 was found to be highly M5-preferring (Figure 4.20).  
From a DMPK standpoint, 4.161 possessed moderate-to-low plasma protein 
binding values in rat and human (rat fu = 0.014; human fu = 0.015); however, the intrinsic 
clearance of the compound was found to be high, with the predicted hepatic clearance 
values equivalent to hepatic blood flow in rat and human (rat CLint = 2639 mL/min/kg, 
predicted rat CLhep = 68 mL/min/kg; human CLint = 538, predicted human CLhep = 20 
mL/min/kg). Metabolite identification studies indicated that the primary metabolic 
product was a result of oxidative dealkylation of the N-ethyl group. In reaction to these 
data, all further SAR exploration was aimed at bolstering this metabolic lability. A 
multitude of analogs were synthesized exploring the migration and substitution of the 
amide, the cyclization of the N-alkyl to either the benzyl ring or core piperidine ring, and 
the substitution of the piperidine core. Unfortunately, in all cases these our efforts 
resulted in inactive or weakly potent compounds. 
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The only further region of tractable SAR that was discovered was the substitution 
of the N-alkyl substituent. A library constructed around this region revealed that bulky 
aliphatic substituents were highly favored, producing potencies as low as 120 nM. 
Regrettably, these compounds also suffered from rapid clearance. 
At present, compound 4.161 remains our lead non-isatin M5 PAM. Although 
4.161 is not a highly CNS penetrant M5 PAM, its potency and preference for M5 make it 
a potential candidate for pharmacodynamic studies of the relationship between M5 
potentiation and the dilation of rat cerebral vasculature. Currently, 4.161 is entered into 
such a study that is using functional MRI to monitor changes in cerebral blood volume in 
response to the presence of an M5 PAM. The outcome of these experiments hold the 
potential to answer fundamental questions put forth in studies of the constitutively 
constricted cerebral vasculature of M5
-/-
 mice (Chapter I).  
Regardless of the outcome of the pharmacodynamic studies, the high rate of 
hepatic microsome clearance and off-target M3/M1 activity of 4.161 leave open the 
possibility for further optimization of this chemical series. A future optimization effort 
might begin by reexamining existing analogs that did not undergo full selectivity screens. 
By counterscreening these analogs against M3 and M1, elements of SAR that dial-in or 
dial-out M3 and/or M1 activity may become apparent. Similarly, a counterscreen of all 
analogs against rM5 may reveal the elements of SAR that are the basis for the slight 
species difference in potency between hM5 and rM5. 
Beyond further scrutiny of existing analogs, many possibilities remain for 
synthesizing new non-isatin M5 PAM analogs focusing on the lightly explored regions of 
the chemical scaffold. For instance, our library of N-alkyl substituents revealed that many 
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substituents produce active compounds, but the majority of these library members were 
entirely aliphatic. Incorporating N-aryl or N-heteroaryl groups in this region could reveal 
new dimensions of SAR while also helping to block oxidative metabolism. Similarly, the 
series could benefit from searching for new SAR surrounding the barely explored 
piperidine core. The sulfonamide linkage is another structural element that emerged from 
this campaign virtually unexplored. Analog 4.87 demonstrated that an amide is an 
untenable substitution for this linkage, but many other options for alternative linkers 
remain to be studied. 
There are many possibilities available to a campaign aiming to further optimize 
the non-isatin M5 PAM chemical series. The optimization of the highly potent and M5-
preferring 4.161 has successfully laid the groundwork for such future campaigns, 
demonstrating that this chemical series possesses highly flexible SAR and the potential to 
produce highly potent and M5-selective compounds. The depth of SAR that still remains 
to be explored within this chemical series promises to generate many more analogs that 
will be indispensable in the study of M5. 
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Chapter V 
 
IDENTIFICATION, OPTIMIZATION, AND CHARACTERIZATION OF THE 
FIRST HIGHLY SELECTIVE M5 NEGATIVE ALLOSTERIC MODULATOR 
 
 
HTS identification of a novel, M5-selective ligand with antagonist activity 
 
 
 As discussed in the opening of Chapter IV, the 2012 HTS campaign of the 
MLPCN screening deck identified a number of novel M5-selective ligands. In addition to 
the identification of nine confirmed M5 PAMs (of which VU0472882 and its analogs 
were discussed in Chapter IV) the screen also identified nine novel M5 antagonists 
(discussed here and in Chapter VI). The HTS assay protocol could not determine whether 
the compounds possessing inhibitory activity were M5 orthosteric antagonists or NAMs; 
nevertheless, we proceeded to explore the SAR around these molecules since an M5-
selective ligand of either mode of pharmacology would be highly useful in the study of 
M5 in the CNS.  
 
 
Scheme 5.1. Structure and synthetic pathway for the synthesis of HTS lead 5.1 (VU0352221). 
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Of the antagonist hits highlighted in the HTS, we focused on compound 5.1 
(VU0352221) due to its unique 2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one-
based scaffold which, in the HTS screen, was inactive at hM1 and hM4 isoforms, but 
displayed weak inhibition of hM5 (IC50 >10 μM, data not shown; Scheme 5.1). The 
compound was resynthesized in-house via a two-step synthetic pathway consisting of the 
condensation of ethylene diamine and 2-benzoylbenzoic acid 5.2 to provide amine 5.3 
Subsequent acylation with 4-fluorobenzoyl chloride provided HTS hit compound 5.1 
(Scheme 5.1). Full CRCs were obtained in double-add functional Ca
2+
 mobilization 
assays against all the human mAChR subtypes (M2 and M4 co-expressing Gαqi5) as well 
as rat M5. Upon retesting compound 5.1 we were pleased to observe that the 
resynthesized powder reconfirmed its activity and selectivity with enhanced potency 
(hM5 IC50 = 3.5 μM, rM5 IC50 = 5.7 μM, hM1-hM4 IC50 >> 30 μM) (Figure 5.1). 
Reconfirmation of the potency and selectivity of compound 5.1 reinforced our confidence 
in exploring and optimizing the SAR surrounding the chemical scaffold with the goal of 
increasing potency while maintaining the high degree of M5 selectivity exhibited my 
compound 5.1 (Figure 5.1)
73
. 
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Figure 5.1. Structure, planned SAR exploration, potency, and selectivity of HTS hit compound 5.1 
(VU0352221). Ca2+ mobilization assays with hM1-hM5 (M2 and M4 co-expressing Gαqi5) and rM5 cells were 
used to obtain CRCs of resynthesized compound 5.1 in the presence of a fixed submaximal (~EC80) 
concentration of ACh (IC50 values: hM5 IC50 = 3.5 μM, hM1-hM4 IC50 >>30 μM, rM5 IC50 = 5.7 μM). Data 
represent the mean ± S.E.M. of at least 3 independent experiments with similar results. 
 
 
 
Optimization of VU0352221 to obtain the first M5 NAM, VU0483253 
 
Optimization of benzamide region SAR 
To begin the optimization of compound 5.1 we turned our attention to the 
benzamide moiety. We constructed an amide library combining amine 5.3 with a library 
of 38 acid chlorides (aryl, heteroaryl, and aliphatic) under standard acylation conditions 
to furnish compounds 5.4-5.41 in yields of 20-95% (Scheme 5.2).  
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Scheme 5.2. Synthesis of benzamide analogs 5.4-5.41 from intermediate 5.3. Syntheses performed jointly 
with M. Kokubo. 
 
 
 
These library analogs, as well as HTS hit 5.1, were next screened in single point 
(10 μM) Ca2+ mobilization assays in the presence of an ACh ~EC80 in CHO cells stably 
expressing hM5. The results of this single point screen are shown in Figure 5.2 and 
Table 5.1.  
 
 
 
Figure 5.2. Comparison of single point (10 μM) screen results of the benzamide library, analogs 5.3-5.41. 
Also included is the single point Ca2+ mobilization response of the initial hit, compound 5.1. Ca2+ 
mobilization was used to obtain %AChMax values for each compound in the presence of a fixed submaximal 
(~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 replicate experiments with 
similar results. 
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Table 5.1. Structures for benzamide analogs 5.3-5.41 and associated inhibitory activity data from the single 
point (10 μM) screen at hM5. Also included is the structure and single point Ca
2+ mobilization response of 
the HTS hit, compound 5.1. Ca2+ mobilization responses for each compound are reported as a percentage of 
the maximum ACh response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
5.1 VU0352221 7.0 
 
5.3 VU0026940 89.3 
 
5.4 VU0477969 74.8 
 
5.5 VU0478013 50.5 
 
5.6 VU0478015 52.7 
 
5.7 VU0333569 70.2 
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5.8 VU0477901 85.8 
 
5.9 VU0477902 86.0 
 
5.10 VU0478080 84.1 
 
5.11 VU0478231 76.0 
 
5.12 VU0478230 69.1 
 
5.13 VU0478232 4.2 
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5.14 VU0478141 0.9 
 
5.15 VU0478223 64.1 
 
5.16 VU0477637 89.9 
 
5.17 VU0477674 5.4 
 
5.18 VU0478073 30.5 
 
5.19 VU0478180 82.4 
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5.20 VU0478244 6.8 
 
5.21 VU0478119 1.1 
 
5.22 VU0478027 62.7 
 
5.23 VU0478224 64.1 
 
5.24 VU0477938 77.7 
 
5.25 VU0477830 61.1 
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5.26 VU0478005 1.8 
 
5.27 VU0477900 75.1 
 
5.28 VU0477903 75.1 
 
5.29 VU0478002 58.0 
 
5.30 VU0478052 1.1 
 
5.31 VU0477934 88.0 
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5.32 VU0477975 100 
 
5.33 VU0478033 74.8 
 
5.34 VU0477944 98.6 
 
5.35 VU0477936 81.3 
 
5.36 VU0477631 79.5 
 
5.37 VU0477831 97.8 
 
5.38 VU0477779 86.4 
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5.39 VU0478021 75.3 
 
5.40 VU0477879 83.6 
 
5.41 VU0477662 55.1 
 
 
The majority of the analogs assayed demonstrated little or no ability to inhibit the 
ACh EC80. Out of the 40 novel analogs tested, only seven antagonized the EC80 to near 
baseline. Of the active compounds, all were substituted benzamides; all heterocycles and 
aliphatic analogs were inactive. The seven active compounds were subsequently tested in 
full CRC in Ca
2+
 mobilization assays at hM5 to obtain IC50 potencies (Table 5.2).  
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Table 5.2. Potencies at hM5 for active benzamide analogs selected from the single point (10 μM) screen. 
Ca2+ mobilization assays with hM5 cells were used to obtain CRCs of compounds in the presence of a fixed 
submaximal (~EC80) concentration of ACh. Data represent the mean of at least 3 independent experiments 
with similar results. 
 
 
 
 
Figure 5.3. Structure, potency, and selectivity of benzamide analog 5.14 (VU0478141). Ca2+ mobilization 
assays with hM1-hM5 (M2 and M4 co-expressing Gαqi5) and rM5 cells were used to obtain CRCs of 
compound 5.14 in the presence of a fixed submaximal (~EC80) concentration of ACh (IC50 values: hM5 IC50 
= 1.0 μM, hM1-hM4 IC50 >> 30 μM, rM5 IC50 = 2.1 μM). Data represent the mean ± S.E.M. of at least 3 
independent experiments with similar results. 
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We were pleased to see that the majority of these analogs displayed improvement 
in potency over the HTS hit. Compound 5.14 was the most potent analog, with an hM5 
IC50 = 1.0 μM (Table 5.2). Encouraged by this 3-fold jump in potency over the HTS hit, 
we subjected compound 5.14 to a counterscreen against all human mAChR subtypes as 
well as rM5 to insure that M5-selectivity was maintained with the increased potency 
(Figure 5.3). Compound 5.14 displayed complete selectivity for M5, with slightly 
decreased potency at rM5 (hM5 IC50 = 1.0 μM, rM5 IC50 = 2.1 μM, hM1-hM4 IC50 >> 30 
μM). Based on its ability to maintain selectivity with a 3-fold increase in potency over the 
HTS lead compound 5.1, we provisionally declared the 3,4-difluoro substitution pattern 
to be the optimal benzamide analog.  
 Concurrent with our efforts to optimize the benzamide ring substituent, we 
explored the necessity and structural flexibility of the SAR around the amide itself. To 
begin with, we synthesized the N-4-fluorobenzyl analog of compound 5.1 via a reductive 
amination of 4-fluorobenzaldehyde with compound 5.3 under standard conditions to 
obtain compound 5.42 (Scheme 5.3).  
 
 
Scheme 5.3. Synthesis of des-carbonyl analog 5.42 (VU0478004). Synthesis performed by M. Kokubo. 
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In addition to the N-4-fluorobenzyl analog 5.42, a small library of 10 
commercially available compounds possessing interesting variations around the amide 
was acquired to aid in exploring the SAR of this region. This library included analogs 
that substituted the amide moiety with urea, thiourea, and sulfonamide. The structures 
and commercial suppliers of these compounds are noted in Table 5.3. These compounds 
were screened along with 5.42 in single point (10 μM) Ca2+ mobilization assays against 
hM5 to assess the general inhibitory activity of each analog (Figure 5.4, Table 5.3). 
 
 
Figure 5.4. Comparison of single point (10 μM) screen results of the amide library, analogs 5.42-5.52. Ca2+ 
mobilization was used to obtain %AChMax values for each compound in the presence of a fixed submaximal 
(~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 replicate experiments with 
similar results. 
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Table 5.3. Structures for amide analogs 5.42-5.52 and associated inhibitory activity data from the single 
point (10 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported as a percentage 
of the maximum ACh response. VU number denotes the compound identifier assigned by Vanderbilt 
University. The name of the commercial supplier and the commercial stock number are also provided. Data 
represent the mean of at least 3 replicate experiments with similar results. 
 
 
Structure Cmpd # VU # 
Commercial 
Supplier 
hM5 
%AChMax 
 
5.42 VU0478004 n/a 80.8 
 
5.43 VU0217057 
Vitas M. 
Laboratories, 
Ltd. 
(STK777060) 
80.4 
 
5.44 VU0477823 
Butt Park, 
Ltd. 
(42\07-24) 
78.2 
 
5.45 VU0202910 
Vitas M. 
Laboratories, 
Ltd. 
(STK836668) 
83.0 
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5.46 VU0170704 
Vitas M. 
Laboratories, 
Ltd. 
(STK837554) 
84.3 
 
5.47 VU0477746 
Butt Park, 
Ltd. 
(39\07-92) 
76.4 
 
5.48 VU0099964 
Enamine 
(Z56798121) 
86.6 
 
5.49 VU0477682 
Maybridge, 
Ltd. 
(DSHS01083) 
77.7 
 
5.50 VU0477813 
Maybridge, 
Ltd. 
(DSHS01080) 
83.0 
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5.51 VU0477810 
Vitas M. 
Laboratories, 
Ltd. 
(STK724323) 
73.4 
 
5.52 VU0477619 
Maybridge, 
Ltd. 
(DSHS01055) 
80.0 
 
 
The single point screen against hM5 revealed that none of the amide analogs 
displayed any inhibitory activity, suggesting that the amide moiety is necessary for 
activity in this chemical scaffold. Satisfied with our initial exploration of the benzamide 
region of the chemical scaffold, we moved on to assess the tractability of SAR in the 
tricyclic core region. 
 
Exploration of tricyclic core region SAR 
As the tricyclic core was the feature of this chemical scaffold that originally 
attracted our attention, we were interested to test modifications of the core to gauge the 
flexibility of the SAR in this region. A number of commercially available molecules 
possessing unique variations on the tricyclic core arrangement of lead compound 5.1 
were obtained to serve as a library exploring the SAR of this region. Analogs selected 
featured disconnections of one or more of the core tricycles, expansions of the aminal 
ring, and both additions and deletions of rings from the core. In selecting these analogs 
our goal was to discover if the tricycle is a necessary element for the scaffold’s activity, if 
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only certain constitutive elements are required, or if the core scaffold may be expanded. 
The structures and commercial suppliers of these core analogs 5.53-5.64 are noted in 
Table 5.4. As with other early libraries, these compounds were assayed in single point 
(10 μM) Ca2+ mobilization assays against hM5 to assess the general inhibitory activity of 
each analog (Figure 5.5, Table 5.4). 
 
 
Figure 5.5. Comparison of single point (10 μM) screen results of the core library, analogs 5.53-5.64. Ca2+ 
mobilization was used to obtain %AChMax values for each compound in the presence of a fixed submaximal 
(~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 replicate experiments with 
similar results. 
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Table 5.4. Structures for core analogs 5.53-5.64 and associated inhibitory activity data from the single 
point (10 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported as a percentage 
of the maximum ACh response. VU number denotes the compound identifier assigned by Vanderbilt 
University. The name of the commercial supplier and the commercial stock number are also provided. Data 
represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # 
Commercial 
Supplier 
hM5 
%AChMax 
 
5.53 VU0477642 
UkrOrgSyn, 
Ltd. 
(PB231861070) 
88.8 
 
5.54 VU0477751 
UkrOrgSyn, 
Ltd. 
(PB281653944) 
87.0 
 
5.55 VU0099964 
InterBioScreen, 
Ltd. 
(2S-29658) 
86.6 
 
5.56 VU0477660 
Enamine 
(Z29317183) 
84.3 
 
5.57 VU0477650 
Enamine 
(Z29317241) 
81.6 
 
5.58 VU0104716 
Vitas M. 
Laboratories, 
Ltd. 
(STK212693) 
85.3 
 
5.59 VU0477745 
Labotest 
(LT00008901) 
78.1 
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5.60 VU0477780 
Vitas M. 
Laboratories, 
Ltd. 
(STK044900) 
86.1 
 
5.61 VU0477778 
Vitas M. 
Laboratories, 
Ltd. 
(STK871398) 
81.8 
 
5.62 VU0477652 
Vitas M. 
Laboratories, 
Ltd. 
(STK526400) 
81.8 
 
5.63 VU0477680 
Butt Park, Ltd. 
(39\07-93) 
54.0 
 
5.64 VU0477654 
Butt Park, Ltd. 
(39\07-94) 
51.9 
 
 
The results of the screen of core analogs demonstrated that most modifications of 
the tricyclic core produced no inhibitory effects at the 10 μM concentration used in the 
single point assay. The exceptions to this inactivity were compounds 5.63 and 5.64, 
which feature an expanded, 6-membered aminal ring; however, even these compounds 
showed a relatively weak response. At this point we accepted that dramatic 
disconnections, expansions, or contractions of the tricyclic core rings were unproductive 
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pathways for moving forward in our optimization efforts. Thus, we left the core in its 
original state and moved on to another unexplored region of the molecule, the 9b-phenyl 
ring. 
 
Optimization of 9b-phenyl ring SAR 
Having established the 3,4-difluorobenzamide moiety as the optimal substitution 
for the benzamide ring system, we next proposed to test substitutions for the 9b-phenyl 
ring and their impact on activity at M5. Ideally, when optimizing a chemical lead with 
multidimensional iterative parallel synthesis, it is simplest for the library step to be the 
final step of the synthesis, as with the optimization of the benzamide region. In this case, 
however, the 9b-phenyl library step is the first step in a two-step synthesis, limiting the 
ease of library preparation (Scheme 5.4). Thus, we prepared analogs of the 9b-phenyl 
ring in a matrix library format (3 x 9) with three functionalized congeners of compound 
5.2 (5.68-5.70) that were acylated with nine benzoyl chlorides possessing the most potent 
substitution patterns discovered during the optimization of the benzamide region 
(compounds 5.71-5.79) to provide analogs 5.80-5.109 (Scheme 5.4). This strategy of 
constructing a matrix library not only provides us with SAR information on a sampling of 
9b-phenyl analogs, but also gives us SAR data on how the 9b-phenyl substitution 
interacts, if at all, with benzamide ring system. The library analogs were assayed in 
parallel in single point (10 μM) Ca2+ mobilization assays against hM5 to assess the 
general inhibitory activity of each analog. These results of are shown in Figure 5.6 and 
Table 5.5. 
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Scheme 5.4. Synthesis of matrix library exploring substituents in the 9b-phenyl regions, analogs 5.70-5.96. 
Three different 9b-phenyl-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-ones (5.66-5.68) were acylated 
under standard conditions with 9 different benzoyl chlorides (5.69a-5.69i) to produce a 27 member library 
(5.70-5.96). Syntheses performed by M. Kokubo.  
 
 
 
 
Figure 5.6. Comparison of single point (10 μM) screen results of the 9b-phenyl matrix library, analogs 
5.70-5.96. Also included in the assay were the unacylated 9b-phenyl-2,3-dihydro-1H-imidazo[2,1-
a]isoindol-5(9bH)-ones, 5.66-5.68. Ca2+ mobilization was used to obtain %AChMax values for each 
compound in the presence of a fixed submaximal (~EC80) concentration of ACh. Data represent the mean ± 
S.E.M. of at least 3 replicate experiments with similar results. 
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Table 5.5. Structures for 9b-phenyl matrix library analogs 5.70-5.96 and associated inhibitory activity data 
from the single point (10 μM) screen at hM5. Also included are the structures and single point Ca
2+ 
mobilization response of the unacylated 9b-phenyl-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-ones, 
5.66-5.68. Ca2+ mobilization responses for each compound are reported as a percentage of the maximum 
ACh response. VU number denotes the compound identifier assigned by Vanderbilt University. Data 
represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
5.66 VU0066006 78.7 
 
5.67 VU0331642 77.6 
 
5.68 VU0478193 77.4 
 
5.70 VU0156675 1.2 
 
5.71 VU0156706 3.3 
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5.72 VU0478358 4.4 
 
5.73 VU0478345 1.2 
 
5.74 VU0478319 1.9 
 
5.75 VU0478351 2.0 
 
5.76 VU0326724 78.8 
 
5.77 VU0478357 3.5 
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5.78 VU0478333 0.9 
 
5.79 VU0478355 67.6 
 
5.80 VU0478360 67.9 
 
5.81 VU0478302 -0.7 
 
5.82 VU0478346 69.4 
 
5.83 VU0478301 0.2 
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5.84 VU0478336 70.3 
 
5.85 VU0478300 69.7 
 
5.86 VU0478359 69.3 
 
5.87 VU0478354 64.5 
 
5.88 VU0478270 53.3 
 
5.89 VU0478271 49.1 
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5.90 VU0478264 10.9 
 
5.91 VU0478269 6.6 
 
5.92 VU0478327 28.8 
 
5.93 VU0478297 28.6 
 
5.94 VU0478340 14.1 
 
5.95 VU0478341 2.4 
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5.96 VU0478268 0.5 
 
  
The single point assay of the matrix library reveals that the substituent at the 4-
position of the 9b-phenyl has a profound effect on analog activity. In general, compounds 
possessing a 9b-4-fluorophenyl showed the lowest occurrence of activity, although with 
some highly active exceptions (compounds 5.81 and 5.83). Compounds with a 9b-4-
methylphenyl moiety showed middling results in activity. Compounds with the 9b-4-
chlorophenyl moiety were typically active regardless of the substitution on the benzamide 
moiety; however, a notable exception to this observation is the 9b-4-chlorophenyl analog 
of the HTS hit compound 5.1, compound 5.76. The failure of compound 5.76 to display 
inhibitory activity at 10 μM hints at a complex relationship between substituents on the 
9b-phenyl and those on the benzamide ring. 
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Table 5.6. Potencies at hM5 for 9b-phenyl matrix library analogs 5.70-5.96. Ca
2+ mobilization assays with 
hM5 cells were used to obtain CRCs of compounds in the presence of a fixed submaximal (~EC80) 
concentration of ACh. Data represent the mean ± S.E.M. of at least 3 independent experiments with similar 
results. ---, not determined. 
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We aimed to explore this relationship in more detail by testing selected matrix 
analogs in full CRC Ca
2+ 
mobilization assays at M5 (Table 5.6). As with the single point 
data, the CRC data strongly suggests the presence of a complex and cooperative 
relationship between the benzamide and 9b-phenyl substituents. Excitingly, one analog, 
compound 5.78, possessing the 3,4-difluorobenzamide and a 9b-4-chlorophenyl moiety, 
afforded submicromolar potency (hM5 IC50 = 0.48 μM). As this was the first 
submicromolar antagonist witnessed from this chemical series, compound 5.78 was 
counterscreened in full CRC Ca
2+ 
mobilization assays at the remaining human mAChR 
subtypes and rM5 in order to determine if this highly potent compound maintained the 
M5-selectivity previously seen in this chemical series (Figure 5.7). 
 
 
Figure 5.7. Structure, potency, and selectivity of benzamide analog compound 5.78 (VU0478333). Ca2+ 
mobilization assays with hM1-hM5 (M2 and M4 co-expressing Gαqi5) and rM5 cells were used to obtain 
CRCs of compound 5.78 in the presence of a fixed submaximal (~EC80) concentration of ACh (IC50 values: 
hM5 IC50 = 0.47 μM, hM1-hM4 IC50 >>30 μM, rM5 IC50 = 1.1 μM). Data represent the mean ± S.E.M. of at 
least 3 independent experiments with similar results. 
 
 
The results of the counterscreen demonstrated that compound 5.78 maintained 
complete M5-selectivity, although we again observed attenuated potency at the rat 
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isoform (hM1-hM4 IC50 >> 30 μM, hM5 IC50 = 0.48 μM, rM5 IC50 = 1.1 μM). With such 
encouraging results in potency and selectivity with the racemic 5.78 we were anxious to 
resolve the enantiomers in order to investigate the potential for enantioselective inhibition 
of M5.  
Using a supercritical fluid chromatography purification system we developed 
conditions to separate the pure enantiomers of 5.78 to furnish 5.97 (VU0483253) and 
5.98 (VU0483252) in >99% ee. Optical rotations were recorded, and the two enantiomers 
were compared in a full CRC Ca
2+
 mobilization assay in hM5 cells. The (–)-enantiomer 
5.97 was found to be the active enantiomer (hM5 IC50 = 0.30 μM), while the (+)-
enantiomer 5.98 was devoid of activity at M5 (hM5 IC50 >>30 μM; Figure 5.8A). Single 
crystal X-ray crystallography ultimately revealed that the active (–)-enantiomer 5.97 
possessed (S)-stereochemistry (Figure 5.8B, C). 
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Figure 5.8. A) CRCs comparing activities of 5.78 (VU0478333), 5.97 (VU0483253), and 5.98 
(VU0483252). Ca2+ mobilization assays with hM5 cells were used to obtain CRCs of compounds 5.76 (hM5 
IC50 = 0.47 μM), 5.97 (hM5 IC50 = 0.30 μM), and 5.98 (hM5 IC50 >> 30 μM) in the presence of a fixed 
submaximal (~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 independent 
experiments with similar results. B) Crystal structure of the isolated active (–)-enantiomer of 5.97, 
revealing its (S)-stereochemistry. Note that the fluorine in the meta-position of the benzamide (F1A/B) 
appears doubled because, when crystallized, this fluorine exhibits 50% occupancy in both the upper and 
lower position. Single crystal X-ray crystallography performed by J. Harp. C) Structures of 5.78, 5.97, and 
5.98. 
 
 
In vitro pharmacological characterization of M5 NAM VU0483253 
 
 
 
Characterization of mAChR subtype selectivity of VU0483253 
In light of the enantiospecific, submicromolar activity of compound 5.97 
(VU0483253), we next obtained a full mAChR subtype-selectivity profile of 5.97. 
Counterscreening was carried out against the remaining human mAChR subtypes to 
insure that M5-selectivity had been maintained by the pure enantiomer; furthermore, since 
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we ultimately desired an in vivo tool compound with which to study M5, we also 
evaluated 5.97 against all rat mAChR subtypes to similarly insure that the compound 
possessed no species-specific activity outside of M5 (Figure 5.9).  
 
 
Figure 5.9. Potency and selectivity of compound 5.97 (VU0483253) at all human and rat mAChR 
subtypes. Ca2+ mobilization assays with hM1-hM5 cells and with rM1-rM5 (M2 and M4 co-expressing Gαqi5) 
cells were used to obtain CRCs of 5.97 in the presence of a fixed submaximal (~EC80) concentration of 
ACh (IC50 values: hM5 IC50 = 0.30 μM, hM1-hM4 IC50 >> 30 μM, rM5 IC50 = 0.79 μM, rM1-rM4 IC50 >> 30 
μM). Data represent the mean ± S.E.M. of at least 3 independent experiments with similar results. 
 
 
 Gratifyingly, we observed no off-target mAChR activity in rat or human isoforms. 
Although we observed a slight species difference in potency between human and rat M5 
(hM5 IC50 = 0.30 μM, rM5 IC50 = 0.79 μM), 5.97 was inactive at hM1-hM4 and rM1-rM4, 
thus making it the first M5-selective small molecule inhibitor with submicromolar 
potency. 
 
Investigation of allosteric mechanism of VU0483253 
At this point in our optimization and characterization of this chemical series it 
was still unknown whether 5.97 and its related analogs were orthosteric antagonists or 
NAMs. Because both a NAM and an orthosteric antagonist are functionally capable of 
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inhibiting an ACh EC80 response, the Ca
2+
 mobilization assays that have driven the 
project to this point are unable distinguish between the two. In order to probe the 
mechanism of action by which compound 5.97 exerts its inhibitory effect, we performed 
radioligand competition binding experiments in hM5 membrane preparations with the 
orthosteric mAChR antagonist [
3
H]-NMS (Figure 5.10A). We observed that compound 
5.97 exhibited no competition with [
3
H]-NMS, suggesting an allosteric mode of receptor 
inhibition. However, this outcome represented a lack of an observable response; 
therefore, additional experiments were needed to conclusively declare compound 5.97 a 
NAM.  
To further substantiate the allosteric mechanism, we performed [
3
H]-NMS 
dissociation kinetics experiments in hM5 membrane preparations (Figure 5.10B). In these 
experiments, [
3
H]-NMS was allowed to bind to the hM5 membrane preparation before a 
fixed concentration (10 μM) of the orthosteric antagonist atropine and 5.97 were added at 
multiple time points to observe any perturbation of the dissociation rate of [
3
H]-NMS 
when compared to the dissociation rate of [
3
H]-NMS in the presence atropine (and 
vehicle) alone. These experiments revealed that, in the presence of 5.97, the dissociation 
rate of [
3
H]-NMS is retarded (Atropine + vehicle t1/2 = 49.9 min, Atropine + 5.97 t1/2 = 
68.8 min). Together, these binding experiments demonstrated that 5.97 exerts an 
allosteric effect on the orthosteric site, which led us to conclude that 5.97 is the first M5-
selective NAM. Based on the unprecedented submicromolar potency, M5-selectivity, and 
NAM mode of action displayed by compound 5.97, it was declared an MLPCN probe and 
given the identifier ML375. 
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Figure 5.10. A) [3H]-NMS competition binding assay with 5.97 (VU0483253, ML375) in an hM5 
membrane preparation. [3H]-NMS and a CRC of either Atropine (control) or 5.97 were allowed to 
equilibrate for 3 hours in the hM5 membrane preparation before filtration and scintillation counting (Ki 
values: Atropine Ki = 2.5 nM, 5.97 Ki >> 10 μM). B) [
3H]-NMS dissociation kinetics assay with 5.97 in an 
hM5 membrane preparation. [
3H]-NMS was allowed to label the hM5 membrane preparation for 3 hours 
before the application of a fixed concentration (10 μM) of either Atropine + vehicle (control) or Atropine + 
5.97 at various time points (t1/2 values: Atropine + vehicle t1/2 = 49.9 min, Atropine + 5.97 t1/2 = 68.8 min). 
Data represent the mean ± S.E.M. of at least 3 independent experiments with similar results. 
 
 
Ancillary pharmacology of the VU0483253 
Having optimized several major regions of SAR around the 5.97 chemical 
scaffold, we paused our chemical optimization and pharmacological characterization 
efforts to determine what, if any, wider ancillary pharmacology 5.97 may possess. In 
order to do this we employed a commercial radioligand competition binding screen of 68 
GPCRs, ion channels, and transporters (Table 5.7).  
 
Table 5.7. Ancillary/off-target competition binding screen results for compound 5.97 (VU0483253, 
ML375). Compound 5.97 was dosed at 10 μM for single point competition binding assays. Targets 
displaying significant binding (≥50% at 10 μM) are outlined. Data represent the mean of 2 independent 
experiments with similar results. Studies performed by Eurofins Panlabs, Inc. 
 
Target/Protein Species % Inhibition 
Adenosine A1 Human 10 
Adenosine A2A Human 20 
Adenosine A3 Human 42 
Adrenergic α1A Rat 16 
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Adrenergic α1B Rat 10 
Adrenergic α1D Human 7 
Adrenergic α2A Human 7 
Adrenergic β1 Human -12 
Adrenergic β2 Human 13 
Androgen (Testosterone) AR Rat 42 
Bradykinin B1 Human 21 
Bradykinin B2 Human 3 
Calcium Channel L-Type, Benzothiazepine Rat 33 
Calcium Channel L-Type, Dihydropyridine Rat 18 
Calcium Channel N-Type Rat -2 
Cannabinoid CB1 Human 66 
Dopamine D1 Human 27 
Dopamine D2S Human 1 
Dopamine D3 Human 28 
Dopamine D4.2 Human 1 
Endothelin ETA Human 10 
Endothelin ETB Human 15 
Epidermal Growth Factor (EGF) Human 4 
Estrogen ERα Human -20 
GABAA, Flunitrazepam, Central Rat -3 
GABAA, Muscimol, Central Rat 2 
GABAB1A Human 13 
Glucocorticoid Human 27 
Glutamate, Kainate Rat 31 
Glutamate, NMDA, Agonism Rat 27 
Glutamate, NMDA, Glycine Rat 15 
Glutamate, NMDA, Phencyclidine Rat 6 
Histamine H1 Human 23 
Histamine H2 Human -7 
Histamine H3 Human 12 
Imidazoline I2, Central Rat 13 
Interleukin IL-1 Mouse 3 
Leukotriene, Cysteinyl CysLT1 Human 4 
Melatonin MT1 Human 32 
Muscarinic M1 Human 9 
Muscarinic M2 Human 14 
Muscarinic M3 Human 11 
Neuropeptide Y Y1 Human 14 
Neuropeptide Y Y2 Human 14 
Nicotinic Acetylcholine Human -21 
Nicotinic Acetylcholine α1, Bungarotoxin Human 12 
Opiate δ1 (OP1, DOP) Human 9 
Opiate κ (OP2, KOP) Human 7 
Opiate μ (OP3, MOP) Human 3 
Phorbol Ester Mouse 3 
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Platelet Activating Factor (PAF) Human 19 
Potassium Channel [KATP] Human 9 
Potassium Channel hERG Human 39 
Prostanoid EP4 Human 1 
Purinergic P2X Rabbit -6 
Purinergic P2Y Rat 7 
Rolipram Rat 20 
Serotonin (5-HT1A) Human 8 
Serotonin (5-HT2B) Human 13 
Serotonin (5-HT3) Human -4 
Sigma σ1 Human 42 
Sodium Channel, Site 2 Rat 49 
Tachykinin NK1 Human 7 
Thyroid Hormone Rat 3 
Transporter, Dopamine (DAT) Human 28 
Transporter, GABA Rat 45 
Transporter, Norepinephrine (NET) Human 21 
Transporter, Serotonin (SERT) Human 0 
 
 
Pleasingly, among all 68 targets tested, compound 5.97 displayed significant 
binding (>50% at 10 μM) at only one target, the cannabinoid CB1 receptor (66% 
inhibition). Compound 5.97 was subsequently tested in a functional assay at CB1, but no 
functional activity was found at this target (data not shown, experiment performed by 
Eurofins Panlabs, Inc.). 
 
In vitro & in vivo DMPK characterization of M5 NAM VU0483253 
 
Now that we possessed a highly selective M5 NAM with submicromolar potency, 
we sought to determine the in vitro DMPK profile of compound 5.97 (VU0483253, 
ML375) in order to evaluate its potential to serve as a future in vivo tool compound with 
which so study M5 in the CNS. The compound was assayed in several in vitro DMPK 
assays, including plasma protein binding, rat and human microsomal stability, and a CYP 
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inhibition panel. These studies revealed 5.97 to have a very robust DMPK profile with 
strong microsomal stability and low predicted hepatic clearance in human, rat, and 
cynomolgus monkey (Table 5.8). 
 
Table 5.8. In vitro and in vivo DMPK data for 5.97 (VU0483253) in multiple species. Human and rat 
studies performed by T. Bridges. Non-human primate cynomolgus monkey studies performed by Frontage 
Laboratories, Inc. 
 
 
 
Given its promising in vitro profile, we moved on to testing the in vivo DMPK 
properties of 5.97 in rat. In a rat IV/PO PK study the parameters of plasma clearance 
(CLp), elimination half-life (t1/2), volume of distribution at steady state (Vss), 
bioavailability through oral dosing (%F), and the brain:plasma partition coefficient (Kp) 
were determined (Table 5.8). We were pleased to observe low plasma clearance rates 
that correlated well with the low hepatic clearance predicted by the in vitro microsomal 
intrinsic clearance data. Furthermore, with an oral bioavailability of 80%, the compound 
appears to be readily available systemically when dosed orally. Most excitingly, a Kp of 
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1.8 indicates the compound is CNS penetrant; however, when combined with the fu,plasma 
and fu,brain, a Kp of 1.8 translates to an unbound brain:plasma partition coefficient (Kp,uu) 
of 0.20, indicating that the compound is either highly bound to protein and lipids in the 
brain or possibly subject to active efflux. Unfortunately, bidirectional efflux experiments 
with Caco-2 and MDCK-P-gp cells were confounded by the poor solubility of 5.97 in the 
assay buffer, so the potential involvement of active transporter activity at the BBB is 
presently unknown. 
Altogether, these DMPK data demonstrate that compound 5.97 possesses a robust 
metabolic profile and is CNS penetrant. Unfortunately, the free fraction of compound 
within the brain was extremely low and hence, the amount of compound free at the site of 
action would be extremely low as well, for a free fraction-driven effect. In light of this 
data, the optimization effort now turned towards focusing on means by which to increase 
either the free fraction or overall potency of the chemical series.  
  
Continued SAR exploration and physicochemical optimization of M5 NAM 
VU0483253 
 
Having gained knowledge of the DMPK properties of compound 5.97 
(VU0483253, ML375) we returned to further optimization efforts. As previously 
mentioned, 5.97 possesses an excellent potency and selectivity profile, the primary 
hindrance to employing compound 5.97 as an in vivo probe is its low Kp,uu. Given the 
compound’s excellent Kp value, it is clear that the compound is CNS penetrant; however, 
once within the brain the compound is likely highly protein and lipid bound. The low free 
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fraction within the brain may be due to the compounds highly bound nature alone, or it 
may be further exacerbated by the active transport of unbound compound out of the CNS 
(a factor which we have thus far been unable to test, vide supra). In either scenario, the 
notably high lipophilicity of compound 5.97 (CLogP = 5.0, as calculated by 
ChemBioDraw Ultra, version 12.0.2.1076) is very likely contributing to the high level of 
protein and lipid binding in the brain. As a result, the goals of our continued optimization 
efforts were twofold: (1) Decrease the scaffold’s lipophilicity in order to increase the 
CNS free fraction of compound and/or (2) explore untapped SAR in order to increase the 
potency to a level that the observed low concentration of free compound will be sufficient 
to exert an effect.  
Historically, the manner in which medicinal chemists have decreased lipophilicity 
is by introducing hydrogen bond donors and acceptors and by increasing the molecule’s 
total polar surface area through the introduction of heteroatoms
88,89
. Since compound 
5.97 currently contains few of either of these features, we envisioned many opportunities 
to improve the molecule’s physicochemical properties. In addition to these efforts, we 
also planned to continue generally exploring the chemical scaffold’s SAR in the event 
that such efforts may yield even more potent analogs. 
 
Continued exploration of tricyclic core region SAR 
 In searching for areas of the chemical scaffold to experiment with our revised 
optimization strategy, we returned to the tricyclic core. Although we had previously 
found little tractable SAR around this region (vide supra), we felt that the structural 
composition of the previous library, consisting of relatively radical variations on the 
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tricyclic core, warranted a more nuanced approach that examined more targeted changes 
to the core that may improve the physical properties of the chemical scaffold. Thus we 
sought to make analogs of compounds 5.63 and 5.64, which contained an expanded, 6-
membered aminal ring and showed weak activity in the previous screen of the core 
library (Figure 5.5, Table 5.4). The added conformational freedom allowed by a 6-
membered aminal ring lessens the planarity of the chemical scaffold and marginally 
improves the ClogP of the scaffold when compared to the 5-membered version (CLogP = 
4.8). We hypothesized that, by combining this new core with the potent 9b-4-
chlorophenyl moiety, we might improve the potency of the 6-membered aminal scaffold 
while also improving the physicochemical properties of the overall scaffold 
 
 
Scheme 5.5. Synthesis of 6-membered aminal core library analogs 5.100-5.109. Syntheses performed by 
M. Kokubo.  
 
 
6-membered aminal analogs were easily accessed by modifying the general 
synthesis of the NAM scaffold with the substitution of 1,3-diaminopropane for ethylene 
diamine. The resulting 6-membered aminal analog 5.99 was subsequently acylated with 
10 benzoyl chlorides selected for their strong activity in earlier libraries (Scheme 5.5). 
The library analogs as well as the unacylated 5.99 were assayed in parallel in single point 
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(10 μM) Ca2+ mobilization assays against hM5 to assess the activity of each analog 
(Figure 5.11, Table 5.9). 
 
 
Figure 5.11. Comparison of single point (10 μM) screen results of the 6-membered aminal core library, 
analogs 5.99-5.109. Ca2+ mobilization was used to obtain %AChMax values for each compound in the 
presence of a fixed submaximal (~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 
3 replicate experiments with similar results. 
 
 
Table 5.9. Structures for 6-membered aminal core analogs 5.99-5.109 and associated inhibitory activity 
data from the single point (10 μM) screen at hM5. Ca
2+ mobilization responses for each compound are 
reported as a percentage of the maximum ACh response. VU number denotes the compound identifier 
assigned by Vanderbilt University. Data represent the mean of at least 3 replicate experiments with similar 
results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
5.99 VU0485459 70.4 
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5.100 VU0478978 82.5 
 
5.101 VU0478903 72.9 
 
5.102 VU0478886 74.8 
 
5.103 VU0478910 76.0 
 
5.104 VU0478911 76.8 
 
5.105 VU0478914 80.4 
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5.106 VU0478894 78.6 
 
5.107 VU0478906 75.7 
 
5.108 VU0478996 76.4 
 
5.109 VU0478862 78.5 
 
 
Unfortunately, all 6-membered aminal ring analogs were devoid of activity in the 
Ca
2+
 mobilization assays at hM5. That a seemingly minor ring expansion should cause 
such a dramatic loss in potency further underscores the paucity of SAR surrounding the 
NAM chemical scaffold.  
Discouraged from further manipulation of the size and orientation of the core, we 
next attempted the strategy of increasing the molecule’s total polar surface area via the 
introduction of heteroatoms to the core benzo ring. Specifically, we aimed to replace the 
core benzo ring with a pyridyl version. From 3-(4-chlorobenzoyl)picolinic acid, 
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condensation with ethylene diamine furnished amine intermediate 5.111. The amine was 
subsequently acylated with 11 benzoyl chlorides to furnish library analogs 5.112-5.122 
(Scheme 5.6). The library analogs as well as the unacylated 5.111 were assayed in 
parallel in single point (10 μM) Ca2+ mobilization assays against hM5 to assess the 
activity of each analog (Figure 5.12, Table 5.10). 
 
 
Scheme 5.6. Synthesis of pyridyl core library analogs 5.112-5.122. Syntheses performed by M. Kokubo.  
 
 
 
Figure 5.12. Comparison of single point (10 μM) screen results of the pyridyl core library, analogs 5.112-
5.122. Ca2+ mobilization was used to obtain %AChMax values for each compound in the presence of a fixed 
submaximal (~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 replicate 
experiments with similar results. 
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Table 5.10. Structures for pyridyl core analogs 5.112-5.122 and associated inhibitory activity data from the 
single point (10 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported as a 
percentage of the maximum ACh response. VU number denotes the compound identifier assigned by 
Vanderbilt University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
5.111 VU0481528 67.2 
 
5.112 VU0481905 76.7 
 
5.113 VU0481890 68.9 
 
5.114 VU0481888 63.1 
 
5.115 VU0482002 65.2 
 
5.116 VU0481787 75.2 
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5.117 VU0481760 66.4 
 
5.118 VU0481886 76.6 
 
5.119 VU0481887 72.2 
 
5.120 VU00481969 73.1 
 
5.121 VU0481970 62.1 
 
5.122 VU0481909 73.8 
 
 
As with the aminal library, all core pyridyl library analogs failed to display 
activity in the Ca
2+
 mobilization assays at hM5. Thwarted by the delicate SAR of the core 
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tricycle, we again were forced to leave the core in its original state as we shifted our 
renewed optimization efforts to a different region of the chemical scaffold.  
 
Continued optimization of benzamide region SAR 
Disheartened by the lack of productive SAR in the core region, we returned to the 
relatively diverse SAR of the benzamide region in order to try our strategy of introducing 
heteroatoms and proton donors/acceptors to improve the physicochemical profile of the 
chemical scaffold. Beginning from amine intermediate 5.66, we synthesized a small 
library of benzamide analogs by acylating the amine with 10 acyl chlorides possessing 
heteroatoms and proton donors/acceptors (Scheme 5.7). The new benzamide library 
analogs were subsequently assayed in single point (10 μM) Ca2+ mobilization assays 
against hM5 to assess the activity of each analog (Figure 5.13, Table 5.11). 
 
 
Scheme 5.7. Synthesis of benzamide library analogs 5.123-5.132. Syntheses performed by M. Kokubo. 
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Figure 5.13. Comparison of single point (10 μM) screen results of the benzamide library, analogs 5.123-
5.132. Ca2+ mobilization was used to obtain %AChMax values for each compound in the presence of a fixed 
submaximal (~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 replicate 
experiments with similar results. 
 
 
Table 5.11. Structures for benzamide analogs 5.123-5.132 and associated inhibitory activity data from the 
single point (10 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported as a 
percentage of the maximum ACh response. VU number denotes the compound identifier assigned by 
Vanderbilt University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
5.123 VU0480132 88.9 
 
5.124 VU0480152 82.6 
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5.125 VU0480187 72.4 
 
5.126 VU0480125 82.9 
 
5.127 VU0486204 74.0 
 
5.128 VU0486268 63.4 
 
5.129 VU0486240 -1.4 
 
5.130 VU0486205 13.3 
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5.131 VU0486177 8.7 
 
5.132 VU0486162 71.1 
 
 
 We were interested to see a range of SAR displayed in the results of the single 
point screen. All three regioisomers of the pyridyl analogs proved to be inactive. The 
three active analogs, 5.129, 5.130, and 5.131, all share the feature an oxygen stemming 
from the 4-position of the benzamide. Nevertheless, this trait obviously is not a guarantee 
of activity as other analogs such as 5.127, 5.128, and 5.132 share this structural element, 
but are inactive. The three active compounds were subsequently tested in full CRC Ca
2+
 
mobilization assays at hM5 (Table 5.12). 
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Table 5.12. Potencies at hM5 for selected benzamide analogs 5.129-5.131. Ca
2+ mobilization assays with 
hM5 cells were used to obtain CRCs of compounds in the presence of a fixed submaximal (~EC80) 
concentration of ACh. Data represent the mean of at least 3 independent experiments with similar results. 
 
 
 
 Although none of the active benzamide analogs proved as potent as the lead M5 
NAM 5.97 or its racemic precursor, 5.76, the 4-isopropoxyphenyl analog 5.129 
demonstrated submicromolar potency while also possessing the added physicochemical 
benefit of a proton acceptor. Despite this, its CLogP was increased relative to 5.97 
(CLogP = 5.7). Nevertheless, this small benzamide library demonstrates that it is possible 
to incorporate substituents containing proton donors/acceptors into the relatively diverse 
SAR of the benzamide region. Moving forward in the optimization of this series, such 
groups will be necessary to tweak and refine the physicochemical properties of the 
chemical series in order to obtain an M5 NAM analog with a DMPK profile suitable for 
the in vivo study of M5. 
 
 
 
215 
 
Continued exploration of 9b-phenyl region SAR 
 Having revisited the core and the benzamide with our mandate to decrease 
lipophilicity and explore SAR we continued on to the 9b-phenyl region to test its 
response to the incorporation of a proton-accepting substituent. In this case we tested the 
effect of a 4-methoxy on the potency and DMPK profile of the chemical series. 
Beginning from 2-(4-methoxybenzoyl)benzoic acid, condensation with ethylene diamine 
furnished amine 5.134. Subsequent acylation with a library of 12 acid chlorides provided 
analogs 5.135-5.146 (Scheme 5.8). The 9b-4-methoxyphenyl library analogs were 
subsequently tested in in single point (10 μM) Ca2+ mobilization assays against hM5 to 
assess the activity of each analog (Figure 5.14, Table 5.13). 
 
 
Scheme 5.8. Synthesis of 9b-phenyl library analogs 5.135-5.146. Syntheses performed by M. Kokubo. 
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Figure 5.14. Comparison of single point (10 μM) screen results of the 9b-4-methoxyphenyl library, analogs 
5.134-5.146. Ca2+ mobilization was used to obtain %AChMax values for each compound in the presence of a 
fixed submaximal (~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 replicate 
experiments with similar results. 
 
 
 
Table 5.13. Structures for 9b-4-methoxyphenyl analogs 5.134-5.146 and associated inhibitory activity data 
from the single point (10 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported 
as a percentage of the maximum ACh response. VU number denotes the compound identifier assigned by 
Vanderbilt University. Data represent the mean of at least 3 replicate experiments with similar results.. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
5.134 VU0487631 72.7 
 
5.135 VU0515835 73.0 
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5.136 VU0515833 49.9 
 
5.137 VU0515834 61.1 
 
5.138 VU0515979 68.4 
 
5.139 VU0515980 57.4 
 
5.140 VU0515981 62.4 
 
5.141 VU0487632 2.9 
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5.142 VU0515827 47.9 
 
5.143 VU0515982 48.0 
 
5.144 VU0515828 26.7 
 
5.145 VU0515829 30.7 
 
5.146 VU0515830 66.1 
 
 
In general, the 9b-4-methoxyphenyl library produced weak or inactive 
compounds, with the one exception of the 3,4-difluorobenzamide analog 5.141 
(VU0487632). The fact that many of the observed benzamide substituents were formerly 
active in the presence of different 9b-phenyl substituents and were now inactive in the 
presence of the 9b-4-methoxyphenyl once again underscored the complex interaction 
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between the 9b-phenyl moiety and the benzamide moiety. To ascertain IC50 potencies, 
analog 5.141 as well as the relatively active analogs 5.144 and 5.145 were tested in full 
CRC Ca
2+
 assays (Table 5.14)  
 
Table 5.14. Potencies at hM5 for selected 9b-4-methoxyphenyl analogs 5.141, 5.144, and 5.145. Ca
2+ 
mobilization assays with hM5 cells were used to obtain CRCs of compounds in the presence of a fixed 
submaximal (~EC80) concentration of ACh. Data represent the mean of at least 3 independent experiments 
with similar results. 
 
 
 Although analogs 5.144 and 5.145 were relatively weak, we were pleased to see a 
higher degree of potency from analog 5.141. Despite the fact that this analog was 
nowhere near as potent as the lead M5 NAM 5.97 or its racemic precursor 5.76, its 
CLogP was markedly decreased (CLogP = 4.2) and we rationalized that a slightly weaker 
compound with a higher free fraction may still have the potential to be useful in an in 
vivo study. Thus we submitted 5.141 to a plasma protein binding studies to assess its free 
fractions in human and rat. Gratifyingly, 5.141 displayed a >2-fold increase in free 
fraction compared to 5.97 (5.97 human fu,plasma = 0.013, rat fu,plasma = 0.029; 5.141 human 
fu,plasma = 0.037, rat fu,plasma = 0.064), demonstrating that the incorporation of even a single 
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proton acceptor can improve the physicochemical properties of the chemical series. 
Despite this, the low-micromolar potency of 5.141 leaves much to be desired. Although 
its exhibition of an improved plasma free fraction is a positive advance, more 
optimization will be necessary to increase the potency and/or physicochemical properties 
to a level that will be suitable for in vivo studies of M5 in the CNS 
 
Summary and Future Directions 
 
The HTS of the MLPCN screening deck that interrogated the chemical landscape 
surrounding M5 selective ligands revealed a weakly active M5-selective inhibitor, 5.1 
(VU0352221). The SAR of each region of the lead compound was subsequently analyzed 
and optimized with a multidimensional iterative parallel synthesis strategy. This effort 
produced over 130 analogs, including the highly potent and M5-selective lead compound 
5.97 (VU0483253, ML375). Moreover, analysis of the mechanism of action of 5.97 
revealed that the compound acts as a NAM, making it the first M5-selective NAM ever 
reported (Figure 5.15). 
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Figure 5.15. Summary and comparison of the structure, potency, and SAR surrounding the M5 antagonist 
HTS lead 5.1 (VU0352221) that led to the discovery of the first sub-micromolar, M5-selective NAM 5.97 
(VU0483253, ML375).  
 
Optimization efforts up to this point have given us a general understanding of the 
SAR surrounding the novel M5 NAM chemical series. Although the unique tricyclic core 
was what originally drew our attention to this chemical series, SAR around this region 
was found to be extremely delicate, and any disturbance to the original tricyclic 
arrangement resulted in inactive compounds. Contrastingly, the benzamide region 
exhibited far more flexible SAR. In this region we found that the amide connectivity is 
required for activity, but the benzyl ring itself tolerates a multitude of substituents and 
substitution patterns. Out of the 40+ benzamide analogs we analyzed, 3,4-
difluorobenzamide was the most optimal benzamide found. It was also discovered that 
the benzamide substituents are not independent from the 9b-phenyl in their influence on 
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activity. Depending on the substituents of the 9b-phenyl region, formerly active 
benzamide substituents may be rendered inactive, or vice versa. A stark example of this 
interesting relationship was found between the original HTS hit 5.1 (hM5 IC50 = 3.5 μM) 
and its 9b-4-chlorophenyl analog 5.76 (hM5 IC50 >> 10 μM). Despite this example, the 
9b-4-chlorophenyl moiety was generally found to increase potency in the presence of 
most benzamide substituents. It was the combination of this 9b-4-chlorophenyl and the 
3,4-difluorobenzamide which produced the highly potent analog 5.76. By resolving the 
enantiomers of 5.76 we discovered that the chemical scaffold exhibits enantiospecific 
inhibition, with the (S)-enantiomer, our lead M5 NAM 5.97 (VU0483253, ML375), being 
the active arrangement (Figure 5.15). 
In vitro DMPK studies revealed that 5.97 possesses a robust metabolic and 
pharmacokinetic profile with strong microsomal stability and low predicted hepatic 
clearance in human, rat, and cynomolgus monkey (rat CLint = 24 mL/min/kg, predicted 
rat CLhep = 18 mL/min/kg; human CLint = 2.6 mL/min/kg, predicted human CLhep = 2.3 
mL/min/kg; cyno CLint = 20 mL/min/kg, predicted cyno CLhep = 14 mL/min/kg). Based 
on this profile 5.97 was entered into in vivo rat pharmacokinetic studies. These studies 
corroborated that the compound was highly stable. Furthermore, 5.97 exhibited high oral 
bioavailability and CNS penetrance (%F = 80, Kp = 1.8). Unfortunately these studies, 
along with plasma protein/rat brain homogenate binding studies, also revealed that 5.97 is 
highly protein and lipid bound in the brain (fu,brain = 0.003), likely precluding its ability to 
reach an effective concentration in the CNS.  
In response to this DMPK profile, our optimization efforts shifted towards 
revisiting regions of the chemical scaffold with the goal of improving the 
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physicochemical properties of the chemical series. Although the majority of these newer 
analogs have been inactive or far less potent than 5.97, several analogs, including the 4-
isopropoxybenzamide analog 5.129 and the 9b-4-methoxy analog 5.141 are promising 
leads for future campaigns seeking to improve the in vivo potential for this scaffold.  
Indeed, there are many options for further exploration and optimization of the 
SAR and physicochemical properties of the M5 NAM chemical series. The 9b-phenyl 
remains an underexplored region. Thus far only 4-substituted phenyl rings have been 
tested. Any number of substituents, substitution patterns, and/or heterocycles in the 9b-
position could lead to entirely new dimensions of SAR. Similarly, further study of the 
synergy between the 9b-phenyl ring and the benzamide is warranted. At this point the 
phenomenon of fluctuations in potency resulting from the interaction of these regions is 
poorly understood. A large matrix library comparing these two regions may be able to 
provide a deeper understanding of this interaction. Conveniently, such an effort could be 
accomplished alongside the aforementioned expanded study of SAR in the 9b-phenyl 
region. Finally, this chemical series could benefit from a counterscreen of all analogs 
against rM5 with the goal of discovering the elements of SAR that are the basis for the 
species difference in potency between hM5 and rM5. 
Although the M5 NAM 5.97 may not be optimal for systemic dosing in in vivo 
studies due to its highly protein-bound nature, its M5-selectivity, potency, and unique 
NAM pharmacology make it an invaluable probe for a number of studies into M5 receptor 
structure and function. For instance, insight into the role of M5 in regulating dopamine 
release in neurons of the VTA or SNc could be accomplished using the M5 NAM in 
electrophysiological studies of ex vivo brain slices. Alternatively, 5.97 could be utilized 
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in X-ray crystallography studies of M5 to gain greater insight into the structural biology 
of negative allosteric modulation of M5. Such a study may also provide insight into the 
binding orientation of 5.97 and its interaction with amino acid residues, possibly 
explaining the basis of the aforementioned relationship between the 9b-phenyl and 
benzamide regions. Finally, direct perfusion via an intracerebral cannula could represent 
a viable method by which to administer a high concentration of 5.97 to the site of action 
in a pharmacodynamic study. However 5.97 is used in the future, this first series of M5 
NAMs represents a landmark achievement and has greatly expanded the tools available to 
pharmacologists for the study of the neurobiology of M5.  
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Chapter VI 
 
DISCOVERY, OPTIMIZATION, AND CHARACTERIZATION OF A HIGHLY 
SELECTIVE M5 ORTHOSTERIC ANTAGONST 
 
HTS Identification of a novel, M5-selective ligand with antagonist activity 
 
 As discussed in the opening of Chapter IV, the 2012 HTS campaign of the 
MLPCN screening deck identified a number of novel M5-selective ligands. In addition to 
the identification of nine confirmed M5 PAMs (discussed in Chapter IV) the screen also 
identified nine novel M5 antagonists (discussed here and in Chapter V). At the time of the 
project’s initiation it was not clear whether the compounds possessing inhibitory activity 
were M5 orthosteric antagonists or NAMs; nevertheless, we proceeded to explore the 
SAR around these molecules as an M5-selective ligand of either mode of pharmacology 
would be highly useful in the study of M5 in the CNS. Where Chapter V discussed a 
ligand that was ultimately characterized as the first highly M5-selective NAM, this 
chapter will examine another HTS hit with inhibitory activity which was ultimately 
revealed to be an M5-selective orthosteric antagonist. 
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Scheme 6.1. Structure and synthetic pathway for the synthesis of compound 6.1 (VU0480131). Synthesis 
performed by M. Kokubo. 
 
   
 During examination of the HTS results the weak, yet M5-selective, isoxazole-
based amide 6.1 drew our attention. The HTS reported 6.1 as having an IC50 = 9.3 μM at 
hM5 and selectivity against hM1 and hM4 (hM1 IC50 >30 μM, hM4 IC50 >30 μM). 
Compound 6.1 (VU0480131) was synthesized in-house via the amide coupling of the 
commercially available acid 6.2 and the secondary amine 6.3 under HATU-mediated 
conditions (Scheme 6.1). Upon retesting the freshly prepared compound in full CRC Ca
2+
 
mobilization assays against all mAChR subtypes, we were pleased to see that 6.1 
displayed increased potency at human and rat M5 (hM5 IC50 = 1.1 μM, rM5 IC50 = 3.5 
μM) and high selectivity versus hM1-hM4 (hM1- hM4 IC50 >30 μM) (Figure 6.1).Given 
the innate high potency and M5-selectivity of 6.1, we were confident that, by exploring 
and optimizing the SAR around the multiple dimensions of the chemical scaffold, we 
could further increase the compound’s potency and maintain its selectivity for M5 
(Figure 6.1)
90
.  
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Figure 6.1. Structure, planned SAR exploration, potency, and selectivity of HTS hit compound 6.1 
(VU0480131). Ca2+ mobilization assays with hM1-hM5 and rM5 cells were used to obtain CRCs of 
resynthesized compound 6.1 in the presence of a fixed submaximal (~EC80) concentration of ACh (EC50 
values: hM5 IC50 = 1.1 μM; hM1-hM4 EC50 >30 μM; rM5 EC50 > 3.5 μM). Data represent the mean ± 
S.E.M. of at least 3 independent experiments with similar results. 
 
Before initiating our campaign of multidimensional iterative parallel synthesis, we 
first desired to analyze the mechanism of action of 6.1. Thus, we performed competition 
binding experiments against the pan-mAChR antagonist radioligand [
3
H]-NMS. 
Interestingly, these experiments demonstrated that 6.1 displaces [
3
H]-NMS in a 
concentration-dependent manner (6.1 Ki = 1.3 μM; Figure 6.2). Such behavior suggests 
that 6.1 competes with [
3
H]-NMS for the orthosteric site. As discussed in Chapter 1, the 
residues of the orthosteric site are highly conserved across mAChR subtypes. So the 
revelation that 6.1 possesses an orthosteric mechanism of action while also being M5-
selective was particularly unexpected and stressed the need for an extensive exploration 
of the compound’s SAR. 
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Figure 6.2. [3H]-NMS competition binding assay with 6.1 (VU0480131) in an hM5 membrane preparation. 
[3H]-NMS and a CRC of either atropine (control) or 6.1 were allowed to equilibrate for 3 hours in the hM5 
membrane preparation before filtration and scintillation counting (Ki values: atropine Ki = 2.5 nM, 6.1 Ki = 
1.3 μM). Data represent the mean ± S.E.M. of at least 3 independent experiments with similar results. 
 
 
 
Optimization of VU0480131 to obtain M5 orthosteric antagonist VU0488130 
 
Exploration of eastern amide region SAR 
 As we already possessed the acid starting material 6.2, we initially focused our 
synthetic efforts on constructing an amide library to explore the easternmost amide region 
of compound 6.1. Specifically we desired to explore the effects of the deletion or 
expansion of the amide N-methyl, including joining the N-alkyl to the pyridine ring 
system to create a bicyclic system. We also used the amide library as an opportunity to 
explore the deletion or regioisomers of the pyridyl ring and the deletion or substitution of 
the chiral methyl. To construct the library, a library of commercial primary and 
secondary amines were coupled with acid 6.2 under HATU-mediated conditions to 
furnish analogs 6.4-6.16 (Scheme 6.2, Table 6.1). Upon testing the library in our single 
point (10 μM) Ca2+ mobilization assay at hM5 it became readily apparent that SAR was 
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very delicate in this region as the majority of amide region analogs proved to be inactive 
(Figure 6.3, Table 6.1). The exception to this inactivity was found in the N-ethyl 
homolog 6.16; however, the compound was later found to be only weakly potent in a full 
CRC Ca
2+
 mobilization assays at human and rat M5 (hM5 IC50 = 5.6 μM, rM5 IC50 >10 
μM ). 
 
 
Scheme 6.2. Synthesis of amide region library analogs 6.4-6.16. Syntheses performed by M. Kokubo. 
 
 
Figure 6.3. Comparison of single point (10 μM) screen results of the amide region library, analogs 6.4-
6.16. Also included is the single point Ca2+ mobilization response of the initial hit, compound 6.1. Ca2+ 
mobilization was used to obtain %AChMax values for each compound in the presence of a fixed submaximal 
(~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 replicate experiments with 
similar results. 
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Table 6.1. Structures for amide analogs 6.4-6.16 and associated inhibitory activity data from the single 
point (10 μM) screen at hM5. Also included are the structure and single point Ca
2+ mobilization response of 
the HTS hit, compound 6.1. Ca2+ mobilization responses for each compound are reported as a percentage of 
the maximum ACh response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
6.1 VU0480131 5.3 
 
6.4 VU0480164 76.6 
 
6.5 VU0481440 52.9 
 
6.6 VU0481381 72.6 
 
6.7 VU0481906 76.0 
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6.8 VU0481408 88.7 
 
6.9 VU0481344 78.2 
 
6.10 VU0481377 80.9 
 
6.11 VU0481422 86.8 
 
6.12 VU0481348 81.5 
 
6.13 VU0485707 74.2 
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6.14 VU0481349 77.1 
 
6.15 VU0481529 77.8 
 
6.16 VU0481461 14.2 
 
 
Exploration of the western aryl ether SAR 
 With the amide region of 6.1 seemingly resistant to modification, we next turned 
our attention to optimizing the aryl ether moiety at the opposite end of the chemical 
scaffold. We aimed to explore the SAR of this region utilizing the Mitsunobu reaction 
and a library of phenols. Beginning from acid 6.17, a HATU-mediated amide coupling 
with secondary amine 6.3 furnished intermediate 6.18. The subsequent Mitsunobu 
reactions furnished analogs 6.19-6.41 (Scheme 6.4, Table 6.2). Despite surveying nitro, 
halogen, alkoxy, and alkyl moieties around the pendant phenyl ring, as well as reduced 
variations of the 3-acetyl group, no analogs in this library displayed any notable activity 
at hM5 in single point (10 μM) Ca
2+
 mobilization assays at hM5 (Figure 6.4, Table 6.2).  
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Scheme 6.3. Synthesis of aryl ether library analogs 6.19-6.41. Syntheses performed by M. Kokubo. 
 
 
Figure 6.4. Comparison of single point (10 μM) screen results of the aryl ether library, compounds 6.19-
6.41. Ca2+ mobilization was used to obtain %AChMax values for each compound in the presence of a fixed 
submaximal (~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 replicate 
experiments with similar results. 
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Table 6.2. Structures for aryl ether analogs 6.19-6.41 and associated inhibitory activity data from the single 
point (10 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported as a percentage 
of the maximum ACh response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
6.19 VU0483374 80.4 
 
6.20 VU0484029 75.0 
 
6.21 VU0483913 69.3 
 
6.22 VU0485567 83.1 
 
6.23 VU0485666 75.5 
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6.24 VU0483387 67.3 
 
6.25 VU0485568 76.1 
 
6.26 VU0483513 83.7 
 
6.27 VU0483517 77.1 
 
6.28 VU0483510 82.2 
 
6.29 VU0483482 85.3 
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6.30 VU0483421 77.2 
 
6.31 VU0483432 84.2 
 
6.32 VU0483509 71.7 
 
6.33 VU0483467 79.9 
 
6.34 VU0483385 78.5 
 
6.35 VU0483375 84.1 
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6.36 VU0483481 73.7 
 
6.37 VU0483438 79.8 
 
6.38 VU0483386 82.8 
 
6.39 VU0483429 79.2 
 
6.40 VU0483376 83.1 
 
6.41 VU0483430 79.0 
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 Concurrent with the aryl ether library, we constructed a similar library in which 
the ether linker was replaced with a secondary amine, or tertiary amide congeners. 
Beginning from the aniline 6.42, nosyl protection of the amine and a subsequent 
Mitsunobu reaction with alcohol 6.44 furnished ester 6.45. The ester was saponified to 
acid 6.46 and a HATU-mediated amide coupling with secondary amine 6.3 furnished the 
nosyl-protected amine linker analog 6.47. Deprotection of the amine with 3-
chlorothiophenol provided the amine linker analog 6.48. Finally, acylation with a library 
of 11 acyl chlorides furnished analogs 6.49-6.59 (Scheme 6.4). 
Disappointingly, all tertiary amide congeners as well as the nosyl protected 
intermediate 6.47 led to complete loss of hM5 inhibitory activity in single point (10 μM) 
Ca
2+
 mobilization assays at hM5 (Figure 6.5, Table 6.3). The secondary amine linker 
analog 6.48 displayed promising activity in the single point assay (%AChMin at 10 μM = 
21.4); however, further investigation in a full CRC Ca
2+
 mobilization assays at human 
and rat M5 revealed it to be only weakly active (hM5 IC50 >10 μM, rM5 IC50 >10 μM).  
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Scheme 6.4. Synthesis of amine and amide linker library analogs 6.47-6.59. Syntheses performed by M. 
Kokubo 
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Figure 6.5. Comparison of single point (10 μM) screen results of the amine and amide linker library, 
analogs 6.47-6.59. Ca2+ mobilization was used to obtain %AChMax values for each compound in the 
presence of a fixed submaximal (~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 
3 replicate experiments with similar results. 
 
 
 
Table 6.3. Structures for amine and amide linker analogs 6.47-6.59 and associated inhibitory activity data 
from the single point (10 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported 
as a percentage of the maximum ACh response. VU number denotes the compound identifier assigned by 
Vanderbilt University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
6.47 VU0486654 60.6 
 
6.48 VU0486512 21.4 
241 
 
 
6.49 VU0486435 69.6 
 
6.50 VU0486433 74.8 
 
6.51 VU0486598 70.0 
 
6.52 VU0486653 69.3 
 
6.53 VU0486539 67.3 
 
6.54 VU0486514 65.5 
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6.55 VU0486572 63.5 
 
6.56 VU0486599 73.8 
 
6.57 VU0486624 66.0 
 
6.58 VU0486597 73.9 
 
6.59 VU0486434 70.4 
 
 
The final library exploring the SAR in the western aryl ether region tested the 
replacement of the ether linker with a secondary amide moiety. Alcohol 6.44 was 
protected with mesyl chloride to provide the mesylate 6.60. Treatment with NaN3 
furnished azide 6.61 which was reduced to the amine under modified Staudinger 
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conditions. The amine was subsequently protected with Boc anhydride to furnish ester 
6.62. The ester was saponified and the resulting acid 6.63 was coupled to secondary 
amine 6.3 under HATU-mediated conditions to provide 6.64. Removal of the Boc 
protecting group was accomplished under anhydrous HCl conditions to provide HCl salt 
6.65. Finally, 6.65 was acylated with a library of 12 acyl chlorides to furnish analogs 
6.66-6.77 (Scheme 6.5, Table 6.4). Once again, when tested in single point (10 μM) Ca2+ 
mobilization assays at hM5, the library revealed itself to be completely devoid of 
inhibitory activity (Figure 6.6, Table 6.4). 
 
 
Scheme 6.5. Synthesis of secondary amide linker library analogs 6.66-6.77. Syntheses performed by M. 
Kokubo 
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Figure 6.6. Comparison of single point (10 μM) screen results of the secondary amide linker library, 
analogs 6.66-6.77. Ca2+ mobilization was used to obtain %AChMax values for each compound in the 
presence of a fixed submaximal (~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 
3 replicate experiments with similar results. 
 
 
 
Table 6.4. Structures for secondary amide linker analogs 6.66-6.77 and associated inhibitory activity data 
from the single point (10 μM) screen at hM5. Ca
2+ mobilization responses for each compound are reported 
as a percentage of the maximum ACh response. VU number denotes the compound identifier assigned by 
Vanderbilt University. Data represent the mean of at least 3 replicate experiments with similar results. 
 
Structure Cmpd # VU # hM5 %AChMax 
 
6.66 VU0486671 76.7 
 
6.67 VU0486884 71.8 
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6.68 VU0486747 78.2 
 
6.69 VU0486811 77.0 
 
6.70 VU0486948 73.8 
 
6.71 VU0486735 71.5 
 
6.72 VU0486808 75.1 
 
6.73 VU0486810 76.4 
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6.74 VU0486681 77.7 
 
6.75 VU0486857 77.8 
 
6.76 VU0486736 76.8 
 
6.77 VU0486675 80.4 
 
 
Exploration of isoxazole core region SAR 
 Faced with intractable SAR in both the amide and aryl ether regions of the 
chemical scaffold, we turned our focus to the remaining unexplored region, the isoxazole 
core. Discouraged by failure of our larger libraries to reveal tractable SAR, we chose to 
synthesize only a couple of test analogs for the core region. Scheme 6.6 details the 
synthesis of benzyl ring replacements for the isoxazole core, with regioisomers in the 
meta- (6.85) and para- (6.86) positions. Upon testing in full CRC Ca
2+
 mobilization 
assays at hM5, both analogs proved to be inactive (hM5 IC50 >30 μM). 
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Scheme 6.6. Synthesis of core substitution analogs 6.85 (VU0483210) and 6.86 (VU0483109). Ca2+ 
mobilization assays in hM5 cells were used to obtain CRCs of compounds 6.85 and 6.86 in the presence of 
a fixed submaximal (~EC80) concentration of ACh. Data represent the mean of at least 3 independent 
experiments with similar results. Syntheses performed by M. Kokubo. 
 
 
Synthesis of VU0480131 enantiomers 
 Having studied a diverse range of analogs designed to test structural 
modifications throughout the orthosteric antagonist chemical scaffold, we found no 
tractable SAR. All analogs tested in single point or CRC Ca
2+
 mobilization assays 
demonstrated little or no inhibitory activity at M5, and none showed activity remotely 
equal to HTS lead 6.1. Thus, we elected to proceed by synthesizing the pure enantiomers 
of 6.1 in search of the active enantiomer. 
 Beginning from the commercial (S)- or (R)-1-(pyridine-2-yl)ethanamine (R)-6.87 
and (S)-6.88, treatment with NsCl provided protected amines (R)-6.89 and (S)-6.90. The 
N-methyl moiety was installed via a Mitsunobu reaction with methanol to furnish the 
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tertiary sulfonamides (R)-6.91 and (S)-6.92. Next, nosyl deprotection with 3-
chlorothiophenol resulted in the chiral secondary amines (R)-6.93 and (S)-6.94. Finally, 
the amines were coupled to acid 6.2 under HATU conditions to afford the single 
enantiomers of 6.1, (R)-6.95 (VU0487996) and (S)-6.96 (VU0488130; Scheme 6.7). 
 
 
Scheme 6.7. Synthesis of single enantiomers of HTS lead 6.1, analogs (R) - 6.95 (VU0487996) and (S) - 
6.96 (VU0488130). Syntheses performed by M. Kokubo 
 
 
When screened in full CRC Ca
2+
 mobilization assays at hM5, enantiospecific 
inhibition was observed, with (S)-6.96 (VU0488130) exhibiting sub-micromolar potency 
(hM5 IC50 = 450 nM) while (R)-6.95 (VU0487996) displayed no activity (hM5 IC50 >10 
μM; Figure 6.7). 
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Figure 6.7. A) CRCs comparing activities of HTS lead 6.1 (VU0480131), 6.95 (VU0487996), and 6.96 
(VU0488130). Ca2+ mobilization assays with hM5 cells were used to obtain CRCs of compounds 6.1 (hM5 
IC50 = 1.1 μM), 6.95 (hM5 IC50 > 30 μM), and 6.96 (hM5 IC50 = 0.45 μM) in the presence of a fixed 
submaximal (~EC80) concentration of ACh. Data represent the mean ± S.E.M. of at least 3 independent 
experiments with similar results. B) Structures of 6.1, 6.95, and 6.96. 
 
 
In vitro pharmacological characterization of M5 orthosteric antagonist VU0488130 
 
Characterization of mAChR subtype selectivity of VU0488130 
 Having finally arrived at a compound with greater potency than the original HTS 
hit 6.1, we were interested to see if 6.96 (VU0488130) maintained selectivity for human 
M5. Furthermore, because an M5-selective orthosteric antagonist would be a unique 
chemical tool in the study of M5 in in vivo studies, we also surveyed the compound’s 
selectivity in rat mAChR isoforms. Thus a full rat and human mAChR subtype selectivity 
panel was run in CRC Ca
2+
 mobilization assays (Figure 6.8). The selectivity panel 
showed that 6.96 possesses exceptional selectivity for M5 in both human and rat mAChR 
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isoforms; however, a ~4-fold reduction in potency was noted at rat M5 (hM5 IC50 = 0.45 
μM, hM1-hM4 IC50 >30 μM; rM5 IC50 = 1.7 μM, rM1-rM4 IC50 >30 μM). Based on the 
potency and M5-selectivity of 6.96, it was approved as an MLPCN probe and given the 
identifier ML381. 
 
 
Figure 6.8. Potency and selectivity of compound 6.96 (VU0488130, ML381) at all human and rat mAChR 
subtypes. Ca2+ mobilization assays with hM1-hM5 cells and with rM1-rM5 (M2 and M4 co-expressing Gαqi5) 
cells were used to obtain CRCs of 6.96 in the presence of a fixed submaximal (~EC80) concentration of 
ACh (IC50 values: hM5 IC50 = 0.45 μM, hM1-hM4 IC50 >30 μM, rM5 IC50 = 1.7 μM, rM1-rM4 IC50 >30 μM). 
Data represent the mean ± S.E.M. of at least 3 independent experiments with similar results. 
 
 
Confirmation of the orthosteric mechanism of VU0488130 
 As with the original HTS lead 6.1, we desired to confirm the mechanism of action 
of 6.96 via competition binding with the radioligand [
3
H]-NMS in hM5 membrane 
preparations. As with the parent 6.1, 6.96 appeared to act with an orthosteric mode of 
action, displacing [
3
H]-NMS in a concentration-dependent manner (Ki = 0.34 μM; Figure 
6.9).  
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Figure 6.9. [3H]-NMS competition binding assay with 6.96 (VU0488130, ML381) in an hM5 membrane 
preparation. [3H]-NMS and a CRC of either atropine (control) or 6.96 were allowed to equilibrate for 3 
hours in the hM5 membrane preparation before filtration and scintillation counting (Ki values: atropine Ki = 
1.5 nM, 6.96 Ki = 0.34 μM). Data represent the mean ± S.E.M. of at least 3 independent experiments with 
similar results. 
 
 
 
Ancillary pharmacology of VU0488130 
To gain a general impression of off-target binding outside of the mAChRs, 6.96 
was entered into a commercial radioligand competition binding screen of 67 GPCRs, ion 
channels, and transporters (Table 6.5). Significant binding was seen only at the 5-HT2B 
receptor (50% inhibition). Thus, in addition to selectivity versus the mAChR subtypes, 
6.96 also displays relatively clean ancillary pharmacology with respect to binding against 
a diverse array of discrete molecular targets.  
 
Table 6.5. Ancillary/off-target competition binding screen results for 6.96 (VU0488130, ML381). 6.96 was 
dosed at 10 μM for single point competition binding assays. Targets displaying significant binding (≥50% 
at 10 μM) are highlighted. Data represent the mean of 2 independent experiments with similar results. 
Studies performed by Eurofins Panlabs, Inc. 
 
Target/Protein Species % Inhibition 
Adenosine A1 Human -4 
Adenosine A2A Human -2 
Adenosine A3 Human 12 
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Adrenergic α1A Rat -10 
Adrenergic α1B Rat -18 
Adrenergic α1D Human 12 
Adrenergic α2A Human 5 
Adrenergic β1 Human -3 
Adrenergic β2 Human -16 
Androgen (Testosterone) AR Rat 2 
Bradykinin B1 Human -1 
Bradykinin B2 Human -1 
Calcium Channel L-Type, Benzothiazepine Rat 11 
Calcium Channel L-Type, Dihydropyridine Rat -9 
Calcium Channel N-Type Rat -4 
Cannabinoid CB1 Human 21 
Dopamine D1 Human 13 
Dopamine D2S Human 2 
Dopamine D3 Human 6 
Dopamine D4.2 Human 3 
Endothelin ETA Human 14 
Endothelin ETB Human -1 
Epidermal Growth Factor (EGF) Human 3 
Estrogen ERα Human -9 
GABAA, Flunitrazepam, Central Rat 30 
GABAA, Muscimol, Central Rat 2 
GABAB1A Human 13 
Glucocorticoid Human -6 
Glutamate, Kainate Rat 11 
Glutamate, NMDA, Agonism Rat -9 
Glutamate, NMDA, Glycine Rat -2 
Glutamate, NMDA, Phencyclidine Rat 4 
Histamine H1 Human -5 
Histamine H2 Human 6 
Histamine H3 Human 2 
Imidazoline I2, Central Rat 4 
Interleukin IL-1 Mouse 8 
Leukotriene, Cysteinyl CysLT1 Human 2 
Melatonin MT1 Human 3 
Muscarinic M1 Human 0 
Muscarinic M2 Human 12 
Muscarinic M3 Human 13 
Neuropeptide Y Y1 Human -2 
Neuropeptide Y Y2 Human -2 
Nicotinic Acetylcholine Human 11 
Nicotinic Acetylcholine α1, Bungarotoxin Human 1 
Opiate δ1 (OP1, DOP) Human 1 
Opiate κ (OP2, KOP) Human 8 
Opiate μ (OP3, MOP) Human 1 
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Phorbol Ester Mouse -20 
Platelet Activating Factor (PAF) Human 43 
Potassium Channel [KATP] Human 4 
Potassium Channel hERG Human 6 
Prostanoid EP4 Human 28 
Purinergic P2X Rabbit 16 
Purinergic P2Y Rat 18 
Rolipram Rat -3 
Serotonin (5-HT1A) Human 13 
Serotonin (5-HT2B) Human 50 
Serotonin (5-HT3) Human -6 
Sigma σ1 Human 6 
Sodium Channel, Site 2 Rat 6 
Tachykinin NK1 Human 4 
Thyroid Hormone Rat -1 
Transporter, Dopamine (DAT) Human 2 
Transporter, GABA Rat -2 
Transporter, Norepinephrine (NET) Human -2 
Transporter, Serotonin (SERT) Human 6 
 
 
In vitro and in vivo DMPK characterization of  
M5 orthosteric antagonist VU0488130 
 
In vitro DMPK characterization of VU0488130 
 Enthused by the excellent potency and selectivity profile of the M5 orthosteric 
antagonist 6.96 (VU0488130, ML381), we were eager to characterize the compound’s 
DMPK profile in order to assess its fitness for future in vivo studies of M5 in the CNS. 
We entered 6.96 into an in-house in vitro DMPK panel which included plasma protein 
binding, rat brain homogenate binding, rat and human microsomal stability, and CYP 
inhibition. The results of these studies are summarized in Table 6.6. 
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Table 6.6. In vitro DMPK data for 6.96 (VU0488130) in multiple species. Studies performed by T. 
Bridges.  
 
 
 
 Compound 6.96 displayed a relatively clean CYP inhibition profile, with 2C9 
representing the primary liability. In microsomal stability studies 6.96 exhibited high 
intrinsic clearance, with predicted hepatic clearance values near the hepatic blood flow 
rate in each species tested. Curiously, the results of the protein binding studies showed 
that 6.96 exhibits high fu,brain in rat and exceptionally high fu,plasma values in rat and 
human. These unusually high fu,plasma values forced us to question if the compound might 
be unstable in the plasma of the species tested. To test the plasma stability of the 
compound we monitored the percent of parent remaining after the compound was 
incubated at 37 °C in rat and human plasma for a total of four hours. This experiment 
revealed 6.96 is markedly unstable in rat plasma and a moderately unstable in human 
plasma, ultimately precluding our ability to acquire an accurate value of fu,plasma. 
 In addition to our standard in vitro DMPK profile studies, we also submitted 6.96 
to an in vitro, bidirectional transwell assay employing MDCK-MDR1 cells in order to 
assess efflux liabilities of 6.96 at the BBB. When dosed at 5 μM, 6.96 exhibited an ER of 
1.6, suggesting an absence of P-gp-mediated active efflux liabilities at the BBB. 
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M5 antagonist VU0488140 metabolite identification  
 Given the pronounced instability of 6.96 in both microsomes and plasma, we 
sought to determine the relevant biotransformation pathway(s) at work in hopes that 
further medicinal chemistry optimization efforts may improve the stability of the 
compound. Metabolite identification experiments were carried out using rat and human 
hepatic microsomes and plasma (Figure 6.10). These analyses revealed hydrolytic 
cleavage of the amide to (6.97) be a primary pathway of biotransformation in both 
plasma and microsomes. Additionally, an array of NADPH-dependent mono-oxidation 
pathways were also identified in rat and human microsomes, including O-dearylation 
(6.98), phenyl hydroxylation (6.99), keto-reduction (6.100), and N-dealkylations at the 
amide (6.101, 6.102; Figure 6.10). 
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Figure 6.10. Metabolite identification results for 6.96 (VU0488130, ML381) in rat and human. Multiple 
metabolites were identified (M1-M6), stemming from six major routes of metabolism. Metabolite 
identification studies performed by T. Bridges. 
 
In vivo DMPK characterization of VU0488130  
 Although 6.96 had demonstrated itself to be extremely unstable to both plasma 
and microsomes, we desired to gauge how well the compound might distribute to the 
CNS in an in vivo administration. Thus 6.96 was dosed in a single IV injection (0.2 
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mg/kg) to male Sprague-Dawley rats (n = 2). Whole brains and plasma were collected at 
a single time point 15 minutes later and compound distribution was quantitated. The 
study revealed a Kp = 0.58, suggesting moderate distribution to the CNS. Calculation of 
Kp,uu was precluded by our aforementioned inability to obtain accurate fu,plasma values. 
 
Summary and Future Directions 
 
 This project began with the goals of exploring the SAR and improving the 
potency of the M5-selective orthosteric antagonist HTS lead 6.1 (VU0480131). In the 
course of exploring the chemical space of this series we synthesized over 60 novel 
analogs that focused on structural variation of the amide, pyridyl, isoxazole, and aryl 
ether regions of the molecule. Unfortunately we found SAR to be extremely delicate, 
with even the most subtle modifications leading to complete loss of inhibitory activity at 
M5. HTS lead 6.1 was ultimately found to possess enantiospecific inhibition, with all 
activity being found in the (S)-enantiomer, compound 6.96 (VU0488130, ML381). 6.96 
was subsequently shown to be the most potent and selective M5 orthosteric antagonist 
reported to date (Figure 6.11). Moreover, 6.96 possesses an overall favorable DMPK 
profile with moderate CNS penetrance; however, the compound’s extreme instability in 
hepatic microsomes and plasma limit its in vivo utility. 
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Figure 6.11. Summary and comparison of the structure, potency, and SAR surrounding the M5 antagonist 
HTS lead 6.1 (VU0480131) that led to the discovery of the first sub-micromolar, M5-selective orthosteric 
antagonist 6.96 (VU0488130, ML381). 
 
Through metabolite identification studies we traced the instability of 6.96 to 
multiple metabolically labile spots on the chemical scaffold. Due to the combination of 
compound 6.96’s delicate SAR and the wide-ranging nature of its metabolic instability, 
further chemical optimization with the goal of bolstering metabolically labile regions 
while maintaining potency is an extremely challenging task. Out of all of the chemical 
regions of this scaffold, the core isoxazole remains the least explored and may present the 
best opportunity for beneficial modifications. 
Although unsuited for in vivo systemic dosing, 6.96 is an extremely interesting 
chemical probe for the study of M5. That 6.96 possesses an orthosteric mechanism of 
action while still maintaining M5-selectivity makes it an interesting tool for structural 
biology studies with M5 probing the source of its selectivity. That is, structural biology 
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studies could reveal if the selectivity of 6.96 for M5 is purely orthosteric or if 6.96 
interacts with both the allosteric and orthosteric sites in a bitopic fashion. From a 
pharmacological standpoint, inhibitors of M5 are desirable tool compounds for the study 
of M5 on the dopaminergic neurons of the midbrain (Chapter I) and orthosteric antagonist 
6.96 could be extremely valuable in in vitro pharmacology and electrophysiology 
experiments aiming to study the effect of M5 inhibition in the CNS.  
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